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This thesis focuses on the efforts made in improving quality and patient safety of breast 
cancer care and breast implant surgery in the Netherlands.
In the last decades, transparency in the quality of health care has received considerable 
attention. Rapid innovations, growing medical costs, and patients’ increasing expecta-
tions require insight into what represents ‘quality of care’. Before registry of quality 
of health care can begin we must decide how the quality of care is to be defined. 
There are multiple conceptualizations of ‘quality of care’, based on agreed standards 
(norms and values) and components (the possibilities). As proposed by the Institute of 
Medicine (IOM): “Quality of care is the degree to which health services for individuals 
and populations increase the likelihood of desired health outcomes and are consistent 
with current professional knowledge. The identified components of quality care are: 
quality care is safe, effective, patient-centered, timely, efficient, and equitable”.1
Aiming at measuring quality, Donabedian described health care as a function of 
three components which are closely related to each other: structure, process, and 
outcome.2,3 Ideally, a standardized process makes the quality of care more measurable, 
enhances the quality of care and improves patient safety, and may eventually reduce 
costs. To gain insight into the quality of care, collecting data from different sources is 
fundamental.
Multiple national and international initiatives on quality improvement have been devel-
oped to identify a set of priority conditions upon which to focus efforts; to re-evaluate 
clinical practice, to facilitate benchmarking between hospitals and to ensure patients’ 
safety. With Sweden as a pioneer, several nation-wide clinical quality registries have 
been initiated in the Western world, leading to demonstrable improvement in clinical 
outcomes and reduced variation between providers.4,5 In the current time frame of 
shared-decision making, patient advocacy groups encourage the professionals to use 
this data in daily clinical practice. Moreover, clinical quality registries are increasingly 
appreciated as a source of information for research on evidence-based medicine as 
they provide ‘real world’ data on patients often not eligible for clinical trials.6
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However, funding and sustainability of registries are highly dependent on a collabora-
tive working relationship and culture of transparency between payers, providers, patient 
advocacy groups and professional medical societies. Where Sweden has succeeded, 
many others have found it difficult to cultivate an environment in which stakeholders 
join forces in such harmony. In 2011, the Dutch Institute of Clinical Auditing (DICA) was 
founded, with the objective to facilitate and organize the start-up of new nation-wide 
audits in the Netherlands.7 One of the key factors of success of DICA is the leading role 
of clinicians and professional medical societies in defining and agreeing on outcome 
data sets. This approach guarantees clinician commitment and ownership, resulting 
in high participation rates, high-quality data in the registry, and the completion of 
quality improvement loops. Funding is achieved by several large stakeholders, aiming 
for independence, consisting of the Dutch Ministry of Health and Health Insurance 
Companies.8
DICA’s primary aim is to drive positive results in both health care outcome and costs. 
The results of the Dutch Surgical Colorectal Audit (DSCA) showed that substantial clini-
cal improvements can be realized within a short period of time.4 For example, there 
was a reduction in surgical complications from 33% to 30% for colon cancer, and 40% 
to 37% for rectal cancer from 2009 to 2011 (and further continued). Subsequent to the 
success of the DSCA, at present twenty-two national registries covering a wide range 
of medical conditions have been established in the Netherlands, including the National 
Breast Cancer Audit (NBCA) and the Dutch breast implant registration (DBIR).
With the foundation of the NBCA and the DBIR, interesting data became available on 
breast cancer diagnosis and therapy (NBCA), and on breast implant surgery (DBIR). 
In part 1 of this thesis, we discuss some important trends in breast cancer treatment 
in the Netherlands, e.g. the actual use of neoadjuvant chemotherapy (NAC), breast-
conserving therapy and axillary lymph-node management. In part 2 of this thesis, we 
illustrate key elements of the DBIR and the first results of two years of registration.
I. Quality assurance in breast cancer care
Breast cancer is the most common female affecting cancer type worldwide.9 In the 
Netherlands over 15.000 women get diagnosed with breast cancer every year.10 Until 







Cancer Organisation Netherlands (NABON) that defined and distributed guidelines 
that contained multidisciplinary criteria for providing good breast cancer care.11 In 
2008, the Dutch Health Care Institute published a report regarding the large differ-
ences between what is considered standard of care and what people actually received 
in different hospitals in the Netherlands. For example, there was a large difference be-
tween hospitals in their rate of tumor involved margins after breast-conserving therapy. 
With the purpose to monitor and improve the quality of breast cancer care in the 
Netherlands, the NABON Breast Cancer Audit (NBCA) was instituted as a nation-wide 
audit in 2011. All patients who are surgically treated for newly diagnosed breast cancer 
in the Netherlands are registered (since 2011), and information on diagnostic and 
treatment modalities are structured. The main purpose of the NBCA was to provide 
health care providers with reliable, benchmarked information on structure, process and 
outcome parameters that can be used to improve quality of care and can be used for 
shared-decision making in clinical practice. A multidisciplinary set of quality indicators 
was defined as a means of quality assurance.
In one of the first reports based on NBCA data, van Bommel et al. described the 
results of 4 years of auditing.12 The use of quality indicators, embedded in a national 
audit providing benchmark information, has led to significant improvements on hos-
pital level. Hospitals recognized themselves as being an ‘outlier’ on certain indicators, 
evaluated their processes and found keystones for improvement (e.g. adjustments in 
reporting results, other ways of organizing Multidisciplinary Team Meetings (MDTs) and 
new partnerships between hospitals were initiated). Apart from the actions of the indi-
vidual hospitals, work has been established to synthesize, implement and monitor ‘best 
practice’. The comprehensive audit outcomes enabled research into hospital variation 
associated with the adoption of several monitor and treatment modalities.13,14,15,16
Neoadjuvant chemotherapy
Breast cancer (BC) care consists of a multidisciplinary approach of surgery, radiation, 
and systemic therapy including chemotherapy.11 Chemotherapy can be timed either 
prior to or following surgery; so-called neoadjuvant (NAC) or adjuvant (AC) chemother-
apy. Initially, NAC was used exclusively in the treatment of inoperable breast cancer 
in order to reduce the tumor burden and allow resection with mastectomy.17 The role 
of preoperative therapy broadened when the National Surgical Adjuvant Breast and 
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Bowel (NSABP) project B-18 trial demonstrated that patients who underwent NAC were 
significantly more likely to receive breast-conservation therapy than patients who were 
treated with AC.18,19,20 Other potential advantages of NAC include the opportunity to 
investigate tumor biology, to monitor response to systemic therapy and to adapt to 
suboptimal response.21 Moreover, NAC may improve survival in triple-negative and 
HER2 positive BC subtypes when a pathologic complete response (pCR) is achieved.22
In chapter 2, we examine the use of NAC in patients with stage III breast cancer in the 
Netherlands and assessed which patient, tumor and hospital-related factors influenced 
clinical practice. Locally advanced (or stage III breast cancer) is defined as a bulky 
tumor of the breast and/or extensive nodal disease. The prognosis of stage III breast 
cancer is still poor with a ten-year overall survival of only 56%.10 The Dutch national 
breast cancer guideline recommends NAC for all patients with stage III breast cancer 
aged <70 years, in accordance with international guidelines.23,24
Because patient and disease characteristics determine possible treatment options for a 
specific condition, demand factors contribute to variation in care on an individual level. 
However, several national and international studies have shown that after case-mix 
adjustment considerable unexplained variation in the use of NAC remains between 
hospitals13,16,25,26,27, as was indeed shown in results from chapter 2.
The preferences of both patient and clinician and the level of shared decision-making 
may be important factors in the decision for certain use of health care. Moreover, 
‘physician supply-side factors’, such as clinicians’ preferences, style of practice and 
incentives, may be even more important factors in explaining inter-hospital variations 
than patient demand.28
To gain insight in the reasons for the observed considerable variation in the use of NAC 
in patients with breast cancer, we have deployed further research to examine the role of 
patient- and specialist preferences in shared-decision making on NAC in patients with 
breast cancer. In chapter 3, we evaluate the current opinion of surgical and medical 
oncologists in the Netherlands on the use of NAC and their decisions towards NAC 
in early breast cancer. Chapter 4 displays patients’ experiences with decisions on the 








As systemic therapy becomes more effective, the use of NAC has increased, enabling 
more patients to potentially undergo breast-conserving therapy (BCT). There are many 
questions, however, that remain unanswered. While NAC has been shown to increase 
the rate of BCT in clinical trials29, it is unknown how NAC is being used to improve the 
use of BCT in general community practice and what the surgical outcomes (including 
margins and re-excision rates) are for BCS after NAC compared to primary BCS. In 
chapter 5 we, therefore, analyzed national trends in the use of BCS after NAC in early 
breast cancer and the surgical outcomes after NAC in the Netherlands.
Axillary lymph-node management
In chapter 6, we investigate the implementation process in the Netherlands of omitting 
ALND in cT1-2N0M0 sentinel node-positive breast cancer patients after the publication 
of the ACOSOG-Z0011 and AMAROS trial. Previously, performing an axillary lymph 
node dissection (ALND) was the standard of care for all non-metastatic breast cancer 
patients. However, this treatment is associated with significant long-term problems 
such as pain, arm swelling (lymphedema), restricted shoulder movement, and sensory 
changes in the arm and hand.30,31 In the early nineties, sentinel lymph node biopsy 
(SLNB) was introduced as an accurate and less invasive axillary staging procedure, 
omitting the need for an axillary lymph node dissection in cT1-2N0M0 sentinel node-
negative breast cancer patients.32,33 The additional value of ALND in cT1-2N0M0 breast 
cancer patients with 1-2 detected positive sentinel lymph nodes was further ques-
tioned in two important randomized controlled trials; the ACOSOG-Z0011 trial and the 
AMAROS trial. The main objective of ACOSOG Z0011 was to compare locoregional 
recurrence-free survival for these patient population managed with or without ALND 
and no axillary irradiation.34 The AMAROS trial evaluated whether regional control was 
comparable between ALND and axillary radiation therapy in cT1-2N0M0 breast cancer 
patients with a positive sentinel lymph node.35 The results of these trials indicate that in 
case of a positive sentinel node, both ALND and axillary radiotherapy provide excellent 
and comparable axillary control in terms of disease-free and overall survival. This is 
illustrated by the 2012 Dutch breast cancer guideline, suggesting omission of ALND in 
cT1-2N0 breast cancer patients with a maximum of two positive sentinel nodes treated 
with breast-conserving treatment and adjuvant systemic therapy.
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II. Quality assurance in breast implant surgery
Breast implants are used routinely for purposes of breast reconstruction and breast 
augmentation. Since the introduction five decades ago, problems with a variety of 
breast implants have emerged with direct consequences for the patients’ health. 
Plastic surgeons worldwide reacted through campaigning for auditing on long-term 
implant quality, surgeon performance and institutional outcomes in implant registries. 
Especially, the Poly Implant Prothèse (PIP) crisis36,37 and more recent reports on breast 
implant-associated anaplastic large cell lymphoma38,39 have raised awareness of the 
need for long-term follow-up and clinical registries for long-term safety reasons. 
Various reports e.g. by the European Union, the FDA and other stakeholders, stress 
the importance of a well-organized clinical registry including epidemiological data to 
assess the appropriateness and effectiveness of a specified clinical issue, whether it is 
an implantable device or care pathway.40
The Dutch Breast Implant Registry (DBIR)
In the Netherlands, an estimated 30.000 implants are inserted annually. As an initiative 
of the Association of Plastic Surgeons of the Netherlands (NVPC), the Dutch Breast 
Implants Registry (DBIR) was instituted in April 2015, as a nation-wide audit to monitor 
breast implant quality and complications, independently from the industry. The main 
purpose of the DBIR is to enable benchmarking between hospitals and surgeons and 
to develop a ‘track-and-trace system’ with the implants and patients. Since the start 
of the DBIR in April 2015, all board-certified plastic surgeons are required to register 
their implants in the system and thousands of implants have been registered. Since 
2016 registry of all sorts of medical implants is being required by the Dutch Health 
Inspectorate.
The dataset of the DBIR is based on the dataset constructed by the international Col-
laboration of Breast Registry Activities (ICOBRA).41 Patient data including indication 
for surgery, unique and descriptional implant data, operation details and data regard-
ing surgical technique. Also, the reasons for revision or explantations are collected. 
Chapter 7 gives an overview of which numbers and types of implants, patients and 







The International Collaboration of Breast Registry Activities (ICOBRA)
In 2012, the International Collaboration of Breast Registry Activities (ICOBRA) was 
founded by the Australian Society of Plastic Surgeons to improve breast device 
registries by sharing datasets and connecting organizations from various countries all 
over the world.41 The members of ICOBRA include national plastic surgery societies 
or multidisciplinary breast implant registries of several countries, including Australia, 
Austria, Canada, France, Germany, Ireland, Italy, the Netherlands, New Zealand, South 
Africa, the United Kingdom, and the United States. Each country has an independent 
registry, but all are using largely similar datasets. Harmonization of data points and 
data definitions is key in order to compare and pool data from registries. Pooling is 
crucial to amplify the data and reduce the time needed to identify implants perform-
ing well and those associated with higher rates of adverse events, such as anaplastic 
lymphoma or capsular contraction. We, therefore, set out to identify and define an 
internationally agreed minimum core set of data points to be used by all breast device 
registries globally (chapter 8).
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Variation in use of neoadjuvant chemotherapy in patients with stage 










Objective: Neoadjuvant chemotherapy (NAC) is important in the optimal treatment 
of patients with locally advanced (stage III) breast cancer (BC). The objective of this 
study was to examine the clinical practice of NAC for stage III BC patients in all Dutch 
hospitals participating in BC care.
Materials and methods: All patients aged 18-70 years who received surgery for stage 
III BC from January 2011 to September 2015 were selected from the national multi-
disciplinary NABON Breast Cancer Audit. Multivariable logistic regression was used to 
assess independent predictors of NAC use, focusing on hospital factors.
Results: A total of 1230 out of 1556 patients with stage III BC (79%) received NAC prior 
to surgery. The use of NAC did not change over time. We observed a large variation 
of NAC use between hospitals (0-100%). Age <50 years, breast MRI, large tumour size, 
advanced nodal disease, negative hormone receptor status and hospital participation 
in neoadjuvant clinical studies were significant independent predictors of NAC use (all 
P<0.001). NAC use in stage III BC was not influenced by hospital type and hospital 
surgical volume. After adjustment for all independent predictors, variation in NAC use 
between hospitals remained (0% to 97%).
Conclusion: NAC was used in 79% of patients with stage III BC, which represent a high 
quality of care in the NL. Patient, tumour, clinical management and hospital factors 
could not explain considerable variation in its use between hospitals. Hospital partici-











Locally advanced or stage III breast cancer (BC) is defined as a bulky tumour of the breast 
and/or extensive nodal disease. The prognosis of stage III BC is worse than early stage 
disease showing a ten-year overall survival in only 56% of patients1. As multimodality 
treatment improves the outcome of Stage III BC, neoadjuvant chemotherapy (NAC) 
has become an important initial treatment strategy. NAC aims to downsize the tumour 
to improve the possibility of a radical resection or even to enable breast conserving 
surgery2-4. Other potential advantages of NAC include the opportunity to investigate 
tumour biology, to monitor response and adapt to suboptimal response. Several stud-
ies have demonstrated that NAC, when compared to adjuvant chemotherapy, leads 
to similar overall and disease-free survival and may even improve survival in triple-
negative and HER2 positive BC subtypes when pCR is achieved5-8. In accordance with 
international guidelines10-11, the Dutch national breast cancer guideline recommends 
NAC for patients with stage III BC aged <70 years12.
The NABON Breast Cancer Audit (NBCA) is a multidisciplinary nationwide registry of 
all diagnostic and treatment modalities of patients who are surgically treated for BC 
in the Netherlands since 2011. This audit provides the opportunity to gain insight into 
patterns of practice in different hospitals by creating a national benchmark. Knowledge 
of variation in the use of NAC for stage III BC and the reasons for this variation may 
help in bringing down barriers to use upfront chemotherapy and to improve outcome 
in these patients. The objective of the present study was therefore to examine the use 
of NAC in patients with stage III BC in the Netherlands and to assess which patient, 
tumour and hospital related factors influence clinical practice.
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METHODS
The NBCA is a nationwide registry that captures 100% of all newly diagnosed and 
surgically treated breast cancer patients in the Netherlands. We selected data from the 
NBCA database on all patients aged 18-70 years diagnosed with stage III BC (clinical 
cT1-4N2, cT3N1-3, cT4N0, M0) from January 2011 to September 2015. In the given 
time frame, 63.315 patients with invasive breast cancer are registered in the NBCA, 
which means a proportion of 2,46% stage III patients aged 18-70 years. Tumour stage 
was defined according to the 7th edition of the International Union Against Cancer tu-
mour node metastasis (TNM) classification13. We excluded patients with a prior cancer 
diagnosis or unknown sequence of chemotherapy and surgery. Patients aged 70 years 
and older were also excluded, because the use of NAC is not considered standard 
treatment in the elderly12. Patients who received both neoadjuvant- and adjuvant 
chemotherapy were not excluded from this study.
Construction of variables
The primary outcome of the study was the use of NAC, defined as chemotherapy 
given within four weeks prior to surgery, for stage III BC in the different hospitals in 
the Netherlands. The hospital of treatment was defined as the hospital where the 
first therapeutic surgical intervention was conducted. Available data from the NBCA 
dataset regarding the use of NAC includes factors of the patient (year of incidence, 
age), the tumour (histologic subtype, clinical tumour stage, clinical nodal stage and 
hormone receptor status), clinical management and various hospital related factors. 
The surgical volume of a hospital was defined as the mean annual number of breast 
cancer surgeries during the period 2011-2015; divided into low-volume (<150), mid-
range (150-300) and high-volume (>300) categories. Type of hospital was described as 
academic, teaching and general hospitals. Academic hospitals are part of a university, 
and both academic and teaching hospitals provide medical training to surgical resi-
dents. Between 2011 and 2015, there were three clinical trials regarding neoadjuvant 
therapy in which participation was possible: NEO-ZOTAC, TRAIN-2 and TEAM IIa14. 











The Pearson’s Chi-square test was applied to test associations of the use of NAC and 
the covariates in the entire study population. A multivariable logistic regression model 
was used to determine whether patient, tumour, clinical management and hospital 
factors were independent predictors associated with the odds of receiving NAC in 
comparison with patients who were treated only surgically with or without adjuvant 
therapy. The multivariable logistic regression model was used to quantify the percent-
age of NAC in daily practice and to reveal the variation among the 89 Dutch hospitals 
adjusted for the predictors15. Statistical significance was defined as a two-sided p value 
< 0.05. All analyses were performed in PASW Statistics version 20 (SPSS inc Chicago, 
IL, USA).
RESULTS
We identified 1556 surgically treated patients with stage III BC aged 18-70 between 
2011 and 2015 in the Netherlands. A total of 1230 patients (79%) with stage III BC 
received NAC. The rate of NAC did not significantly change over time.
Table 1a shows the patient, tumour and clinical management factors according to the 
use of NAC. The median age of patients with stage III disease was 51 years (range 
19-70 years). The median age of treated patients in general hospitals was 53.0 years 
compared to 51.4 years in teaching hospitals and 49.1 years in academic hospitals (p 
< 0.001). In case a breast MRI was performed or when the patient had been discussed 
in a preoperative MDT, a significantly higher rate of NAC use was observed (84% 
versus 57%, p<0.001; 79% versus 68%, p=0.038). Of notice, a total of 227 patients 
(87%) in which breast conserving surgery was performed, received NAC compared to 
1003 patients (77%) in which a mastectomy was performed (p<0.001). Hospital factors 
regarding NAC use are depicted in Table 1b. The median number of surgically treated 
patients with stage III BC per hospital was 15 (range 2-99). Significant more patients in 
academic hospitals received NAC (88%) as compared to patients in teaching hospitals 
(79%) or in general hospitals (75%) (p<0.001). The use of NAC in hospitals participating 
in neoadjuvant clinical studies was significantly higher (83%) than in hospital not doing 
so (73%) (p<0.001).
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To determine the independent predictors of NAC use, a multivariable logistic regres-
sion analysis was conducted (Table 2). Age <50 years, breast MRI, large tumour size, 
advanced nodal disease, negative HR status and hospital participation in neoadjuvant 
clinical studies remained significant (all p<0.001). Hospital type and hospital surgical 
volume were not independently associated with the use of NAC.
Table 1A. Factors of patient, tumour and clinical management regarding the use of neoadjuvant chemotherapy 





Year of incidence 2011 204 158 77% 0,283
2012 306 244 80%
2013 357 271 76%
2014 377 299 79%
2015 312 258 83%
Age <40 162 137 85% 0,000
40-50 547 462 84%
50-60 470 362 77%
60-70 377 269 71%
Histologic subtype ductal 1293 1044 81% 0,000
lobular 263 186 71%
Clinical tumor stage cT1 20 7 35% 0,000
cT2 48 31 65%
cT3 995 768 77%
cT4 493 424 86%
Clinical nodal status cNx/N0 116 85 73% 0,000
cN1 1250 992 79%
cN2 95 64 67%
cN3 95 89 94%
Hormone receptorstatus triple - 235 200 85% 0,000
HR- HER2+ 171 152 89%
HR+ HER2+ 214 165 77%
HR+ HER2- 936 713 76%
Preoperative MDT No 60 41 68% 0,038
Yes 1496 1189 79%
Breast MRI No 284 162 57% 0,000
Yes 1272 1068 84%
Type of surgery BCS 260 227 87% 0,000
Mastectomy 1296 1003 77%
MDT= multidisciplinary team










The variation between hospitals in the Netherlands in the percentage of patients with 
stage III BC receiving NAC during 2011-2015 is depicted in Fig. 1. The median is 
48,3% and a large variation in its use was observed (0-100%). After adjusting for inde-
pendent predictors according to our multivariable model, the rate of NAC per hospital 
over the period 2011-2015 were modified from minus 8,9% to plus 22%. One hospital 
with only two patients with stage III BC, neither of whom received NAC, accounted for 
the number of 0%. According to the 95% confidence interval (CI), three hospitals were 
negative outliers (significant lower rates than average).








Type of hospital General 37 390 291 75% 0,001
Teaching 43 957 755 79%
Academic 9 209 184 88%
Hospital surgical <150 44 455 348 76% 0,148
volume 150-300 34 692 547 79%
>300 11 409 335 82%
PET-CT available No 56 700 538 77% 0,055
Yes 33 856 692 81%
Hospital study participation No 48 604 440 73% 0,000






























Hospital surgical volume of stage III BC patients
median
Figure 1. Variation between hospitals in the use of neoadjuvant chemotherapy (NAC) in patients with stage III breast 
cancer (n=1556) in the Netherlands in 2011-2015.
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Table 2. Multivariable logistic regression of the use of neoadjuvant chemotherapy (NAC) in patients with stage III 
breast cancer (N=1556)
OR 95% C.I. Sig.
Lower Upper
Age <40 ref. 0,000
40-50 1,12 0,679 1,849
50-60 0,677 0,41 1,118
60-70 0,458 0,275 0,762
Histologic subtype ductal ref. 0,021
lobular 0,674 0,482 0,942
Clinical tumor stage cT1 0,091 0,025 0,337 0,000
cT2 0,228 0,078 0,664
cT3 ref.
cT4 2,46 1,653 3,662
Clinical nodal status cN0 0,398 0,227 0,698 0,000
cN1 ref. 1,195 4,19
cN2 1,671 0,671 4,158
cN3 5,13 1,734 15,178
Hormone receptorstatus triple - ref. 0,004
HR -, HER2+ 1,502 0,8 2,821
HR+, HER2- 0,675 0,445 1,025
HR+, HER2+ 0,567 0,342 0,94
Preoperative MDT No ref. 0,495
Yes 1,927 1,043 3,559
Type of hospital General- ref. 0,058
Teaching- 1,04 0,708 1,527
Academic- 1,824 1,042 3,194
Hospital surgical <150 ref. 0,999
volume 150-300 1,01 0,674 1,515
>300 1,013 0,596 1,721
PET-CT available No ref. 0,517
Yes 0,881 0,6 1,293
Study participation No ref. 0,000












In this nationwide population-based study from 2011 to 2015 in the Netherlands, we 
observed that 1230 out of 1556 of women aged 18-70 years with stage III BC (79%) 
were treated with NAC prior to surgery. Various recent studies reveal an international 
trend on the increasing implementation for NAC in patients with BC. The high rate of 
NAC in The Netherlands did not significantly change over time. Our data compare 
favourably with those reported from cancer registries in other countries. For stage III 
BC, Mougalian et al. used data from the National Cancer Data Base of America and 
reported a mean use of NAC in 41.6% of 71,433 patients during 2003-2011, while 
they observed an increase to 59.3% in 201116. Recent studies from the United States 
on patients with all stages of BC showed a major increase in the use of NAC during 
the last decade, with a proportion of 10-20% of BC patients treated with NAC2,17. A 
similar increase was seen in a population study of 10 Dutch hospitals in which the use 
of NAC for BC increased from 2.5% in 2003 to 13% in 201218. During this time span, 
the use of NAC for cT3 BC increased from 30.6% to 70.9%. A French survey reported 
the use of NAC in 16.3% of patients with BC in 2010, but data on stage of disease were 
incomplete19.
In line with other studies16,17,20, we found the following predictive patient and tumour 
factors for the use of NAC in patients with BC: young age, large tumour size, advanced 
nodal disease and a negative hormone receptor status. Going beyond the scope of 
prior studies, we also assessed factors at hospital level and observed that the surgical 
volume and type of hospital was not independently associated with the use of NAC 
in the Netherlands. This has been previously observed by a study in the Netherlands 
on variation in adjuvant chemotherapy19 and is presumably due to the consultancy 
of experts in oncology meetings between academic, teaching and general hospitals. 
Of notice, we observed a significantly higher use of NAC in hospitals participating in 
neoadjuvant clinical studies (83% versus 73%). Study participation is an instrument of 
cultural change. It creates more awareness among physicians and it narrows the gap 
between the best available evidence and current practice. Moreover, it also requires 
an adjustment of the current pattern of care and may facilitate the implementation of 
new therapeutic concepts.
32
Variation in the use of NAC between hospitals is in line with international literature, 
except that these studies did not adjust for hospital related factors and did not exclude 
patients >70 years of age with possible contraindications2,16,20. After adjustment ac-
cording to our multivariable model, we observed a constant proportion of 77% and 
considerable variation between 89 hospitals remained.
The preferences of both patient and clinician and the level of shared decision-making 
may be important factors in the decision to use or to refrain from NAC. It may be 
possible that many women prefer to undergo surgery first because of an incorrect idea 
of delayed surgery or because of a preference for mastectomy (in combination with a 
reconstruction). Patients may not realise that neoadjuvant treatment is a viable choice. 
It has been demonstrated that clinicians’ treatment recommendations and preferences 
exert one of the most powerful influences over patients’ decisions21,22.
Valid options to refrain from NAC may be a contraindication for chemotherapy such 
as poor performance status or severe comorbidity, or the choice for neoadjuvant hor-
monal therapy in lowgrade highly endocrine-sensitive BC. Other factors such as under 
capacity or financial incentives could negatively affect the implementation of NAC. 
In-hospital factors such as the level of training of physicians, the composition of MDT 
meetings and an integrated oncological care pathway for BC may also account for 
discrepancies between hospitals23,24. Confirmed by our univariate analyses, preopera-
tive MDT is significantly associated with NAC use.
The main strength of the present study is the multivariable adjustment for hospital case 
mix, including factors regarding patient, tumour, clinical management and hospital 
level. Additionally, because our data covers all surgically treated BC patients in the 
Netherlands we can more reliable understand clinical practice. Unfortunately, we had 
no data available regarding the reason why NAC was omitted, such as patient perfor-
mance status, comorbidities, genetic risk factors and other treatment decision-making 
factors.
In conclusion, our study shows that NAC is being used in 79% of patients with stage 
III BC, which stands for high quality of care compared to the international percentages 










adjustment for all independent predictors of NAC, a considerable variation remained 
between hospitals. Hospital participation in neoadjuvant clinical studies may be a major 
factor contributing to a more rapid implementation of NAC in daily practice. We have 
deployed further research to examine the role of patient- and specialist preferences in 
shared-decision making on NAC in patients with BC.
34
REFERENCES
 1. Netherlands Cancer Registry. Available at: 
http://www.cijfersoverkanker.nl [TNM 6th ed. 
2003-2009].
 2. Killelea BK, Yang VQ, Mougalian S, Horowitz 
NR, Pusztai L, Chagpar AB, et al. Neoadjuvant 
chemotherapy for breast cancer increases the 
rate of breast conservation: results from the 
national cancer database. J Am Coll Surg 
2015;220:1063-9.
 3. Heys SD, Hutcheon AW, Sarkar TK, Ogston 
KN, Miller LD, Payne S, et al. Neoadjuvant 
docetaxel in breast cancer: 3-year survival 
results from the Aberdeen trial. Clin Breast 
Cancer 2002;3:69-74.
 4. Makris a, Powles TJ, Ashley SE, Chang J, 
Hickish T, Tidy VA, et al. A reduction in the 
requirements for mastectomy in a random-
ized trial of neoadjuvant chemo-endocrine 
therapy in primary breast cancer. Ann Oncol 
1998;9:1179e84.
 5. Mieog JSD, van der Hage Ja, van de Velde 
CJH. Neoadjuvant chemotherapy for oper-
able breast cancer. Br J Surg 2007;94:1189-
200.
 6. Wolmark N, Wang J, Mamounas E, Bryant 
J, Fisher B. Preoperative chemotherapy in 
patients with operable breast cancer: nine-
year results from National Surgical Adjuvant 
Breast and Bowel Project B-18. J Natl Cancer 
Inst Monogr 2001;15212:96-102.
 7. Rastogi P, Anderson SJ, Bear HD, Geyer CE, 
Kahlenberg MS, Robidoux A, et al. Preop-
erative chemotherapy: updates of national 
surgical adjuvant breast and bowel project 
protocols B-18 and B-27. J Clin Oncol 
2008;26:778-85.
 8. Peintinger F, Symmans WF, Gonzalez-Angulo 
AM, Boughey JC, Buzdar AU, Yu TK, et al. The 
safety of breast-conserving surgery in patients 
who achieve a complete pathologic response 
after neoadjuvant chemotherapy. Cancer 
2006;107:1248-54.
 9. Cortazar P, Zhang L, Untch M, Mehta K, 
Costantino JP, Wolmark N, et al. Patho-
logical complete response and long-term 
clinical benefit in breast cancer: the CTNeoBC 
pooled analysis. Lancet 2014;384:164-72.
 10. Holmes D, Colfry A, Czerniecki B, Dickson-
Witmer D, Francisco Espinel C, Feldman E, et 
al. Guideline for the use of neoadjuvant sys-
temic therapy in the management of breast 
cancer. Ann Surg Oncol 2015;10:3184-90.
 11. Cardoso F, Costa A, Norton L, Senkus E, 
Aapro M, Andre F, et al. ESO-ESMO 2nd 
international consensus for advanced breast 
cancer (ABC2). Breast 2014;23:489-502.
 12. Dutch national breast cancer guideline. 
Available at: http://www.oncoline.nl/ mam-
macarcinoom [Version 2.0, 2012].
 13. Sobin LHWC. TNM classification of malignant 
tumours. seventh ed. Hoboken, NJ: John 
Wiley & Sons; 2009.
 14. Boog study center. Available at: https://www.
boogstudycenter.nl.
 15. Dimick JB, Ghaferi AA, Osborne NH, Ko CY, 
Hall BL. Reliability adjustment for reporting 
hospital outcomes with surgery. Ann Surg 
2012;255:703-7.
 16. Mougalian SS, Soulos PR, Killelea BK, Lannin 
DR, Abu-Khalaf MM, DiGiovanna MP, et 
al. Use of neoadjuvant chemotherapy for 
patients with stage I to III breast cancer in the 
United States. Cancer 2015;121:2544-52.
 17. Graham PJ, Brar MS, Foster T, McCall M, 
Bouchard-Fortier A, Temple W, et al. Neo-










is practice Changing? A population-based 
review of current surgical trends. Ann Surg 
Oncol 2015;22(10):3376-82.
 18. Vughts G, Maaskant-Braat AJ, Nieuwen-
huijzen GA, Roumen RM, Luiten EJ, Voogd 
AC. Patterns of care in the administration 
of neo-adjuvant chemotherapy for breast 
cancer. A population-based study. Breast J 
2016;22:316-21.
 19. Clough KB, Acosta-Marin V, Nos C, Alran S, 
Rouanet P, Garbay J, et al. Rates of neoad-
juvant chemotherapy and oncoplastic surgery 
for breast cancer Surgery: a French national 
survey. Ann Surg Oncol 2015;22:3504-11.
 20. Onitilo A a, Onesti JK, Single RM, Engel 
JM, James TA, Aiello EJ, et al. Utilization of 
neoadjuvant chemotherapy varies in the treat-
ment of women with invasive breast cancer. 
PLoS One 2013;8:7-9.
 21. Caldon LJM, Walters SJ, Ratcliffe J, Reed 
MWR. What influences clinicians’ operative 
preferences for women with breast cancer? 
An application of the discrete choice experi-
ment. Eur J Cancer 2007;43:1662-9.
 22. Kunneman M, Engelhardt EG, Hove FLL, 
Marijnen CAM, Portielje JEA, Smets EMA, et 
al. Deciding about (neo-) adjuvant rectal and 
breast cancer treatment: missed opportuni-
ties for shared decision making. Acta Oncol 
2016;55:134-9.
 23. Munro A, Brown M, Niblock P, Steele R, Carey 
F. Do Multidisciplinary Team (MDT) processes 
influence survival in patients with colorectal 
cancer? A population-based experience. 
BMC Cancer 2015;15:1-9.
 24. Van Hoeve J, de Munck L, Otter R, de Vr-
ies J, Siesling S. Quality improvement by 
implementing an integrated oncological care 




Current decisions on neoadjuvant chemotherapy for early breast 







on behalf of the NABON Breast Cancer Audit
Patient Education & Counselling 2018;101:2111-2115.
38
ABSTRACT
Purpose: To evaluate the opinion of surgical and medical oncologists on neoadjuvant 
chemotherapy (NAC) for early breast cancer.
Methods: Surgical and medical oncologists (N=292) participating in breast cancer care 
in the Netherlands were invited for a 20-question survey on the influence of patient, 
disease, and management related factors on their decisions towards NAC.
Results: A total of 138 surgical and medical oncologists from 64 out of 89 different 
Dutch hospitals completed the survey. NAC was recommended for locally advanced 
breast cancer (94%) and for downstaging to enable breast conserving surgery (BCS) 
(75%). Despite willingness to downstage, 64% of clinicians routinely recommended 
NAC when systemic therapy was indicated preoperatively. Reported reasons to refrain 
from NAC are comorbidities (68%), age >70 years (52%), and WHO-performance status 
≥2 (93%). Opinions on NAC and surgical management were inconclusive; while 75% 
recommends NAC to enable BCS, some stated that BCS after NAC increases the risk 
of a non-radical resection (21%), surgical complications (9%) and recurrence of disease 
(5%).
Conclusion: This article emphasizes the need for more consensus among specialists 
on the indications for NAC in early BC patients. Unambiguous and evidence-based 
treatment information could improve doctor-patient communication, supporting the 










Neoadjuvant chemotherapy (NAC) is an important initial strategy for the management 
of operable breast cancer (BC). In accordance with international guidelines, the Dutch 
national breast cancer guideline recommends NAC as an option for all patients aged 
<70 with an indication for systemic treatment, as similar overall and disease-free sur-
vival rates were demonstrated between preoperative and postoperative application of 
chemo-therapy1-4. These guidelines disclose that NAC may be used for large tumours 
(T3; >5cm) to increase resectability and the rate of breast conserving surgery and 
axillary preserving surgery5. Besides, chemotherapy prior to breast surgery remains a 
valuable therapeutic approach for the assessment of biological anti-tumour activity and 
clinical efficacy of new treatments6. Furthermore, administration of NAC creates a time 
frame for testing on hereditary breast cancer and planning the final type of surgery, for 
example reconstruction surgery.
Despite these arguments in favour of NAC, large national and international variation 
in the application of NAC is observed between hospitals7,8. Previous research based 
on data from the NABON Breast Cancer Audit (NBCA) revealed that most variation 
between hospitals consists in the treatment of BC stage IIB with a national average 
of 40% NAC use. For BC stage III, the national average is 80%. After adjustment for 
patient and tumour factors associated with the use of NAC, including hospital study 
participation, a consider- able unaccountable variation still remained between all 89 
Dutch hospitals9,10.
Additional factors, such as clinician preferences and the level of shared decision-mak-
ing, may play a role in the application of NAC11. Since it has been demonstrated that 
clinicians’ treatment recommendations exert one of the most powerful influences over 
patients’ preferences, the clinicians’ opinion on NAC is therefore of great importance12. 
Some specialists adhere firmly to their personal treatment preferences which may lie 
outside evidence of best practice or safety13. Consequently, differences in surgeons 
and medical oncologists’ opinions may lead to unwanted variation in treatment pat-
terns. As options of chemotherapy timing are in equilibrium for overall and disease-free 
survival, but NAC also yields several advantages, it is important to gain insight in the 
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observed variation of NAC application, as each patient indicated for NAC deserves a 
choice in chemotherapy timing.
The aim of this study is to evaluate the current opinion of surgical and medical oncolo-












On November 11, 2015, an invitation for an online survey was sent by mail to 575 
surgical and medical oncologists, invited by the network of the NABON Breast Cancer 
Audit (NBCA), covering all Dutch hospitals that are involved in breast cancer care. A 
reminder was sent to non-respondents 3 weeks later and the survey was closed on 
January 8th, 2016.
Demographics of participating hospitals were derived from the NBCA dataset. The 
surgical volume of a hospital was defined as the mean annual number of breast cancer 
surgeries during the period 2011–2015; divided into low-volume (<150), mid-range 
(150–300) and high-volume (>300) categories. Type of hospital was described as aca-
demic, teaching, and general hospitals. Academic hospitals are part of a university, and 
both academic and teaching hospitals provide medical training to surgical residents.
Survey
The survey was developed by a multidisciplinary taskforce, including a medical on-
cologist, a breast cancer surgeon, a clinical epidemiologist and medical researchers. 
Hereafter, the survey was pre-tested and modified based on the obtained feedback. 
The survey consisted of 20 questions about (contra) indications and considerations for 
NAC and general information about the survey participants. Part one of the survey 
consisted of eight questions about commonly accepted indications and contraindica-
tions of NAC on the following categories: tumour characteristics (tumour size, stage 
and biology), patient characteristics (age, performance status and comorbidities) and 
clinical disease management (genetic testing and timing of final surgery) (supplement 
1). The 5-point Likert scale was used to allow the respondent to express how much 
they agree or disagree. Part two of the survey consisted of four questions about other 
possible considerations that could influence the use of NAC (evidence in overall and 
disease-free survival benefit of NAC, axillary conservation surgery, risk of complica-
tions, risk of non-radical resections), using a yes/no scale. Throughout the survey there 
was the ability to write and add comments in the responses. To get an idea of the level 
of experience per specialist, demographic data, numbers of years in specialty, numbers 
of patients treated, and questions on study participation were included in the survey.
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Statistical analysis
Frequencies and percentages were used to display responses to individual questions. 
Differences between surgical and medical oncologists’ responses were analysed using 
Pearson chi-square. Statistical significance is defined as a two-sided p value <0.05. All 
analyses are performed in PASW Statistics version 24 (SPSS inc Chicago, IL, USA).
RESULTS
A total of 292 clinicians opened the online program, of whom 138 clinicians from 
64 out of 89 Dutch hospitals completed the survey, leading to a response rate of 
473%. Of 138 respondent clinicians, 70 surgical oncologists (43% female, 57% male) 
and 68 medical oncologists (59% female, 41% male) participated in the survey. The 
respondents had been in clinical practice for a median of 12 years (range 1-35). The 
number of annually treated breast cancer patients varied from 50 patients for medical 
oncologists (range 15-110) to 70 patients for surgical oncologists (range 30-110). The 
majority of clinicians included more than 10 patients in neoadjuvant chemotherapy tri-
als per year. This survey represented two-third of Dutch hospitals; 22 hospitals had only 
one representative and 42 hospitals were represented by 2-7 representatives. Medical 
oncologists and surgical oncologists were evenly represented according to type and 
volume of hospitals (Table 1).
Survey
Respondents rated locally advanced breast cancer (LABC) as the most distinguished 
indication for NAC (94%). The second commonly accepted indication is down staging 
of the tumour to enable breast conserving surgery (75%). Of all respondents, 64% “al-
ways to frequently” recommended NAC if systemic therapy is indicated preoperatively, 
based on known clinical tumour characteristics (Fig. 1A). Reported reasons to refrain 
from NAC were WHO-performance status ≥2 (93%), comorbidities (68%), and age >70 
years (52%) (Fig. 1C and D).
A WHO-performance score of ≥2, which implies an inability to carry out any work 
activities, was reported as the most common contraindication. Age by itself was 









seemed to be the main reason for restrained application of NAC. Clinical management 
factors, such as the time necessary for testing on hereditary breast cancer or to plan the 
final type of reconstructive surgery, were less frequently denominated as indications for 
NAC (Fig. 1B).
In the second part of the survey, clinicians were asked about other considerations that 
could influence the use of NAC (Table 2). More than half of the respondents (60%), 
especially medical oncologist (83%), stated that the evidence in overall and disease-
free survival benefits of NAC compared to adjuvant chemotherapy is not established 
yet (p-value: 0,015). While in the first part of the survey 75 percent of the respondents 









Male 40 28 0,106
Female 30 40
n of yrs in practice
<10 27 27 0,774
10 - 19 32 27
20+ 11 14
n of patients per specialist/year
<50 8 24 0,001
50 - 99 23 25
100+ 32 15
n of patients per specialist included in NAC studies/year
<10 21 12 0,001
>10 39 52
Volume of hospital*
<150 27 29 31 0,578
150-300 23 25 22
>300 20 14 11
Type of hospital*
General- 19 22 24 0,281
Teaching hospital- 43 33 34
Academic- 8 13 6
*Derived from the NBCA-registry.
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mentioned increased breast conservation rate as an indication for NAC, a concern 
about non-radical resections is raised by 21% of the respondents (surgeons 292%, 
medical oncologists 158%, p-value: 0,078). A minor consideration in performing sur-
gery after NAC was the increased chance of surgical complications (9%). Finally, in a 
relative high percentage of clinicians (63%), NAC is also being used to enable axillary 
conserving surgery.
In added comments, a frequently described benefit of neo-adjuvant therapy was the 
extra time for patient work-up for surgery, for example in case of controlling diabetes 
or smoking cessation. Reported barriers for recommending NAC were lack of patient 
cooperation, logistic challenges (for example a far travel distance to the hospital), a 
term pregnancy, oocyte preservation, or a patient’s desire to undergo surgery first.







“NAC improves the chance of achieving axillary 
conservation surgery” 63% 70,8% (46) 62,9% (39) 0,346
“NAC increases the risk of surgical complications” 9% 13,3% (8) 6,9% (4) 0,247
“Breast conservation surgery after NAC increases the 
risk of a non-radical resection” 21% 29,2% (19) 15,8% (9) 0,078
“Breast conservation surgery after NAC increases the 
risk of recurrence” 5% 6,5% (4) 4,8% (3) 0,697
“There is no evidence for an overall and disease-free 
survival benefit of NAC compared to AC”
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Figure 1A. Reported indications (tumour characteristics) for recommending NAC.
Figure 1B. Reported indications (clinical management factors) for recommending NAC.
Figure 1C. Reported contraindications (patient characteristics) for recommending NAC.
Figure 1D. Most common reported contraindication: performance status ≥ 2
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DISCUSSION
This survey depicts the opinion of 138 Dutch surgical and medical oncologists from 64 
out of 92 hospitals in the Netherlands on NAC in BC. Despite an international trend 
of increasing implementation for NAC in patients with early BC and the relatively high 
standard of care in the Netherlands, considerable variation in the use of NAC still exists 
between hospitals.
Respondents rated LABC as the most distinguished indication for NAC, in accordance 
with Dutch and international breast cancer guidelines12. In addition, the St. Gallen 
Breast Cancer Conference, that focuses exclusively on the primary therapy of early 
breast cancer, recommends to consider NAC based on tumour biology14,15. Our survey 
demonstrates that only 64% of clinicians recommends NAC instead of adjuvant che-
motherapy when systemic therapy is indicated based on tumour biology. The actual 
NAC use is even lower based on NBCA-data (40% in BC stage II). With the increased 
evidence that subgroups of patients that achieve pCR after NAC do have a better 
prognosis in terms of disease-free and overall survival, NAC should nowadays be 
considered as a preferred option in the treatment of high risk triple negative BC and 
HER2 BC3,4,16.
Another commonly accepted indication for NAC - confirmed by our survey - is to 
increase the chance of breast conservation surgery (BCS) without compromising the 
local recurrence rate. The ESMO guidelines on primary breast cancer advice primary 
systemic therapy in locally advanced and large operable cancers to allow for achieving 
operability or decreasing the extent of surgery17. In our survey, 75% of respondents 
recommend NAC to enable BCS. Contradictory, a relatively high percentage of 21% 
of respondents argued that BCS after NAC increases the risk of non-radical (i.e. resec-
tion with positive margins) resections. The restraint to use NAC to enable BCS may 
arise from the challenge for surgeons to determine the extent and original location 
of the residual lesion after NAC. More recently than our survey, a nationwide Dutch 
pathology study showed tumor-involved margins in 24.3% patients after BCS after 
NAC, compared to 103% after primary BSC18. According to Dutch National guidelines, 
a tumor-free margin is defined as the absence of tumor cells at the inked margins. 









seeds and ultrasound guided surgery, monitoring and localization techniques are still 
under research19. It is likely that clinicians’ decisions towards NAC are mainly driven by 
surgical management goals, rather than tumour biology and survival.
Other incentives to consider NAC, such as time necessary for testing on hereditary 
breast cancer, are less frequently denominated as indication of importance. Only 33% 
of the clinicians recommends NAC to await genetic testing results, while the discovery 
of a BRCA1/2 mutation may influence treatment strategies. Also, extra time for patient 
work-up to plan the final type of reconstructive surgery is less frequently considered 
important. However, NAC has the potential for improving cosmetic outcomes in onco-
plastic surgery20. Another important consideration described by clinicians in favour of 
chemotherapy prior to breast surgery is the possibility to asses anti-tumour activity and 
clinical efficacy of new treatments in neoadjuvant chemotherapy trials21.
The survey also revealed concerns that prevented clinicians from recommending NAC. 
A patients’ WHO-performance status of ≥2 was stated most frequently as reason to 
refrain from NAC, rather than advanced age. This is consistent with the idea that older 
patients, when selected correctly, can be treated safely with chemotherapy and that 
age only is no reason to refrain22. Although it can be questioned if these 138 experts 
represent the major opinion of NAC for breast cancer in the Netherlands, the main 
strength of this survey is that the respondents reflect practice preferences of 64 out 
of 89 Dutch hospitals: which means a 72% nationwide coverage, which stands for the 
treatment of almost 15.000 patients annually10. If this survey would be repeated, we 
expect same differences in opinions between experts’ to be demonstrated. However, 
surveys rely heavily on the respondents’ memory and opinion, thus bias should always 
be kept in mind when interpreting survey results.
CONCLUSION
Considerable variation exists in expert opinions on NAC for early breast cancer. This 
article highlights the complexity of decision making for early breast cancer patients 
and it emphasizes the need for more consensus among specialists on the indications 
for NAC in early BC patients.
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Practice implications
The results of this survey highlight the importance of dynamic updates of reliable clini-
cal practice guidelines, to standardize and ensure medical quality and safety. In other 
words: not only clinicians’ awareness on multiple arguments in favour of the use of NAC 
could be improved, but also the sharing of considerations and experiences - as this 
brief report detailing clinical practices of Dutch surgical and medical oncologists - will 
speed up and clarify the implementation of NAC in early breast cancer. Ultimately, it is 
important that patients receive unambiguous and evidence-based treatment informa-
tion in order to take part in a useful process of shared decision-making. The authors 
do not necessarily advocate that every patient should receive NAC; however, every 
patient eligible to NAC should receive a choice in chemotherapy timing. Another work 
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20-question survey on the influence of patient, disease, and management related factors on deci-
sions towards NAC.
General Information
1. What institute do you work for?
2. Are you working in an affiliated or other institute as well?
3. Sex m/v
4. Age
5. Specialism: surgeon / medical oncologist / other
6. Number of years in practice in current specialism (training excluded)
7. Number of new patients diagnosed with breast cancer treated per year
Diagnostics
8. Are the following diagnostic modalities typically applied prior to the commence of neoadju-
vant chemotherapy (NAC)?
 MRI  Never – Rarely – Sometimes – Often – Always
 PET-CT Never – Rarely – Sometimes – Often – Always
 Add comments
pART I. Indications and contraindications of NAC
9. Which items do you consider to be indications for the use of neoadjuvant chemotherapy 
(NAC)?
 “Locally advanced disease (stage III)”
 Never – Rarely – Sometimes – Often – Always
 “Downstage to breast conserving surgery”
 Never – Rarely – Sometimes – Often – Always
 “Any adjuvant chemotherapy candidate / systemic therapy is indicated preoperatively”
 Never – Rarely – Sometimes – Often – Always
 “Await genetic testing results”
 Never – Rarely – Sometimes – Often – Always
 “Time span for definitive surgery”
 Never – Rarely – Sometimes – Often – Always
 Other/ add comments
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10. Other / missing indications?
11. Ranking from 1 – 6 (most – less important) indication for neoadjuvant chemotherapy 
(NAC):
 Locally advanced disease (stage III)
 Downstage to breast conserving surgery
 Any adjuvant chemotherapy candidate /
 systemic therapy is indicated preoperatively
 Awaiting genetic testing results
 Time span for definitive surgery
12. Do you consider age to be a contraindication for the use of neoadjuvant chemotherapy 
(NAC)?
 No, age alone is no contraindication
 Yes, for patients aged <55
 Yes, for patients aged <60
 Yes, for patients aged <65
 Yes, for patients aged <70
 Yes, for patients aged <75
13. Do you consider the presence of comorbidities to be a contraindication for the use of 
neoadjuvant chemotherapy (NAC)?
 According to the Charlson Index Scale:
 No, comorbidities are no contraindication
 Yes, for cardiac disease
 Yes, for vascular disease
 Yes, for pulmonary disease 
 Yes, for neurological disease 
 Yes, for gastrointestinal disease 
 Yes, for urogenital disease 
 Yes, for thrombotic disease 
 Yes, for muscle and joint disease
 Yes, for endocrine system disease 









14. Do you consider a poor performance status (PS) to be a contraindication for the use of 
neoadjuvant chemotherapy (NAC)?
 According to the ECOG/WHO Performance Scale:
 No, a poor performance status is no contraindication
 Yes, if PS=0 – Asymptomatic (Fully active, able to carry on all predisease activities without 
restriction)
 Yes, if PS=1 – Symptomatic but completely ambulatory (Restricted in physically strenuous activ-
ity but ambulatory and able to carry out work of a light or sedentary nature. For example, light 
housework, office work)
 Yes, if PS=2 – Symptomatic, <50% in bed during the day (Ambulatory and capable of all self-
care but unable to carry out any work activities. Up and about more than 50% of waking hours)
 Yes, if PS=3 – Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, 
confined to bed or chair 50% or more of waking hours)
 Yes, if PS=4 – Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair)
15. Ranking from 1 – 3 (most – less important) contraindication:
 High age
 Comorbidities
 Poor performance status
15. Other / missing contraindications?
part II. Other considerations that could influence the use of NAC
16. To what extent do you agree or disagree with the following statements?
 “NAC improves the chance of achieving axillary conservation surgery”
  Agree/Disagree
 “NAC increases the risk of surgical complications”
  Agree/Disagree
 “Breast conservation surgery after NAC increases the risk of a non-radical resection”
  Agree/Disagree
 “Breast conservation surgery after NAC increases the risk of recurrence”
  Agree/Disagree




Final section about study participation and interests
18. Number of new patients included in trials a year (national and international level)
 >10 or <10
 Other/ add comments
19. Do you visit one of the following conferences on a regular base?
 SABCS




 Chirurgendagen (Dutch conference – annual conference for surgeons in general)
 No, I never visit one of these conferences
 Other/ add comments












on behalf of the Nabon Breast Cancer Audit group




Introduction: Despite potential advantages, application of chemotherapy in the neo-
adjuvant (NAC) instead of adjuvant (AC) setting for breast cancer (BC) patients varies 
among hospitals. The aim of this study was to gain insight in patients’ experiences with 
decisions on the timing of chemotherapy for stage II and III BC.
Materials and methods: A 35-item online questionnaire was distributed among female 
patients (age>18) treated with either NAC or AC for clinical stage II/III invasive BC in 
2013e2014 in the Netherlands. Outcome measures were the experienced exchange of 
information on the possible choice between both options and patients’ involvement in 
the final decision on chemotherapy timing. Chemotherapy treatment experience was 
measured with the Cancer Therapy Satisfaction Questionnaire (CTSQ).
Results: Of 805 invited patients, 49% responded (179 NAC, 215 AC). NAC-treated 
patients were younger and more often treated in teaching/academic hospitals and 
high-volume hospitals. Information on the possibility of NAC was given to a minority 
of AC-treated patients (AC, stage II: 14%, stage III: 31%). Information on pros and 
cons of both NAC and AC was rated sufficient in about three fourth of respondents. 
Respondents not always felt having a choice in the timing of chemotherapy (stage II: 
54% NAC vs 36% AC; stage III: 26% NAC, 54% AC).
Conclusion: The need to make a treatment decision on NAC was found to be made 
explicit in only a small number of adjuvant treated patients, in particular in BC stage II. 













Breast cancer (BC) care consists of a multidisciplinary approach of surgery, radiation, 
and systemic therapy including chemotherapy1. Chemotherapy intents to eliminate 
potential existing micrometastases, thus decreasing recurrence rates and mortality 2; 
it is timed either prior to or following surgery, respectively neoadjuvant (NAC) or 
adjuvant (AC), both leading to similar disease free and overall survival1,3,4. NAC versus 
AC yields several advantages. Down-staging of the primary tumour increases resect-
ability and the possibility of breast conserving surgery (BCS)4 and axillary preserving 
surgery5. Moreover, the response to chemotherapy can be assessed1,3,4,6, creating a 
platform to study the activity of (novel) agents or therapeutic combinations in a patient-
personalized way 3,4,7,8.
(Inter)national BC guidelines recommend NAC over AC for patients with locally ad-
vanced BC (stage III) aged <70 years, while NAC can also be considered for patients 
with stage II BC with a clear indication for adjuvant chemotherapy1,9,10. The use of 
NAC for early BC is increasing, but despite its advantages, NAC is still applied less 
frequently than AC11. In the Netherlands, 12% of all newly diagnosed BC patients 
was treated with NAC in 2014, whereas in that same year 31% of patients received 
AC. Also, a considerable variation (0-97%) in NAC-application between hospitals was 
observed12. Significant predictors for the use of NAC (stage III) appeared to be young 
age, a diagnostic MRI, large tumour size, advanced nodal disease and a negative 
hormone receptor status.
However, not all variation could be explained by tumour and patient characteristics13, 
implicating that other factors play a part in the timing of chemotherapy. Nowadays, 
treatment decisions are shared between the physician and patient. Important in the 
process of shared decision-making (SDM) is that both patient and physician are aware 
of a decision being required, knowing and understanding all available information 
on treatment options, and sharing the decision by incorporating both the physicians’ 
advice as the patients’ preferences14. Therefore, the goal of this study was to gain 
insight in patients’ experiences with decisions on the timing of chemotherapy for stage 




Fifty-two hospitals were invited to participate; nineteen were willing to cooperate. 
We attempted an equal distribution in hospital volume (low, middle, high) and type 
(general, teaching, academic), and an equal geographical scatter. Patients of these 
hospitals were selected from the Netherlands Cancer Registry (NCR): a nationwide 
registry in which all newly diagnosed cancer patients are registered, hosted by the 
Netherlands Comprehensive Cancer Organisation (IKNL), which includes all items for 
the NABON Breast Cancer Audit12.
We selected surgically treated patients (aged 18 or older) who were diagnosed with 
primary invasive BC stage II/III between 2013 and 2014 and received NAC or AC. 
Patients with previous malignancies and/or metastases were excluded. A sub-set of 
40-50 patients per participating hospital was randomly selected, with an average of 
43 per hospital.
A total of 805 patients (367 NAC-treated, 438 AC-treated) were invited by a letter 
through their treating physician between August 24th, 2015 and January 1st, 2016 
to participate in our online questionnaire. The survey was offered within a secured 
web-based environment named PROFILES15; paper questionnaires were provided on 
request. Completed questionnaires were collected until the 28st of February 2016. 
Respondents gave consent on an adjective (online) form for processing their answers 
and merging them to their clinical data available in the NCR. Approval from the Com-
mittee of Privacy of the NCR and the Medical Ethical Committee of the Netherlands 
Cancer Institute - Antoni van Leeuwenhoek were obtained for this study.
Questionnaire
The thirty-five-item questionnaire (appendix A) consisted of questions on SDM, com-
pleted with questions on the patients’ experience and satisfaction with chemotherapy 
care in general. SDM was defined as by the study of Legare et al.: both health care 
provider and patient recognise and acknowledge that a decision is required, while 
knowing and understanding all best available relevant evidence, taking into account 












Questions (Q) 1 to 9 asked about general mental and physical health and timing and type 
of chemotherapy received. The following questions dealt with the conditions of SDM. To 
determine whether patients were informed on the possible choice between NAC and 
AC, patients were asked whether they received information on chemotherapy prior to 
surgery (Q10) and whether (Q11) and with whom (oncologist, surgeon, nurse practitioner, 
nurse specialised on BC, general practitioner; Q12) NAC was discussed. To assess wheth-
er information on evidence of both options was provided, patients were asked if pros and 
cons of both NAC and AC were discussed (Q13). To determine if patient preferences were 
taken into account, questions were posed on whether the patient understood on what 
arguments the final decision was made (Q14 to Q17, Q19). The patients experienced 
SDM was based on questions whether they felt they shared the decision on the timing 
of chemotherapy (Q18) and had enough time to make a decision (Q20). In addition, to 
determine the overall level of patient information we asked questions on chemotherapy 
treatment information in general (Q21 to Q24). To determine chemotherapy treatment 
experience, all questions from the Cancer Therapy Satisfaction Questionnaire (CTSQ) 
were included (Q25 to Q30), consisting of three domains: Expectation of Therapy (EOT), 
Feelings about Side Effects (FSE), and Satisfaction With Therapy (SWT)16. General items 
such as nationality, level of education, and living and working status were requested as 
well (Q31 to Q35). A patient panel contacted through the Dutch BC patient association 
(Borstkankervereniging Nederland) critically reviewed and adjusted the questionnaire in 
comprehensible language and added additional explanations.
Analysis
Completed questionnaires were merged with the clinical data registered in the NCR. 
Generalisability of the results was determined by comparing characteristics of respon-
dents to non-respondents (Pearson’s chi-square). Furthermore, NAC-treated and AC-
treated respondents were compared on patient, tumour, and treatment characteristics 
(Pearson’s chi-square). The answers to the questionnaire were assessed separately for 
stage II and III; NAC-treated compared to AC-treated patients. Conditions of SDM 
were chi-square tested, as well as the experience with general information on che-
motherapy (Q21 to Q24). At last, treatment experience was described by calculating 
CTSQ-scores17: a score between 0 and 100 was assessed separately for each domain 
for respondents that answered a minimum amount of questions. Higher scores are 
associated with better responses (better therapy expectations, feeling less impact of 
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side effects, and greater satisfaction with therapy). Means were calculated by the sum 
of all assessed scores divided by the number of respondents that a score was assessed 
to. Mean scores were compared using a T-test; we reported 95%-confidence intervals 
as well. Statistical significance was defined as a p-value <0.05 (two-sided). All analyses 
were performed in STATA 14.
RESULTS
Respondents to questionnaire (Table 1)
A response rate of 49% (394/805) was reached; 179 (45%) NAC-treated patients versus 
215 (55%) AC-treated patients. Respondents did not differ significantly from the non-
respondents on patient (age), tumour (year of diagnosis, clinical stage, morphology), 
and hospital characteristics (volume, type). The ratio of NAC versus AC was comparable 
between respondents and non-respondents.
NAC-treated respondents were more often treated in a teaching or academic hospital 
(including BC specialised hospitals) and in a high-volume hospital. Moreover, they were 
generally younger and had a higher SES, and were more often classified with clinical 
stage III disease (30%) compared to AC treated patients (7%). Also, there were more 
triple-negative and Her2-receptor positive tumours in the NAC-treated group. The 
majority of NAC-treated patients received breast conserving surgery for BC stage II 
(58%); AC-treated patients received a mastectomy more often (54%, all p<0.05).
Conditions of SDM (Table 2)
For BC stage II, 98% and 84% of NAC-treated and AC-treated patients, respectively, 
received information on chemotherapy prior to surgery (p=0.000). Among AC-treated 
patients, receiving information was more common in younger patients (p=0.061). 
Further on, information was provided four times as often by the medical oncologist 
for NAC-treated compared to AC-treated patients respectively (Fig. 1). If information 
on chemotherapy was provided prior to surgery, 100% of NAC-treated patients versus 
14% of AC-treated patients received information on NAC as a possible treatment op-













Of all respondents that received information on NAC, 85% and 63% of NAC and AC-
patients, respectively, stated they received sufficient evidence on the pros and cons 
of both NAC and AC (p = 0.008). Eventually, NAC-patients could explain more often 
why she and/or her physician decided the given treatment plan (97% NAC vs 66% AC, 
p=0.000).
For BC stage III, 92% and 93% of NAC and AC-treated patients, respectively, received 
prior to surgery any information on chemotherapy (p=0.959). Provided information on 
pros and cons of NAC was stated sufficient in both groups (p=0.947); almost every 
patient was able to explain why she and or her physician decided on either NAC or AC 
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Figure 1. Information on chemotherapy provided prior to surgery by physicians during pre-surgical consultation(s), 
NAC vs AC, stage II (a) and stage III (b) separately (Q12).
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<40 19 11% 14 7%
40-49 74 41% 65 30%
50-59 55 31% 58 27%
60+ 31 17% 78 36%
Comorbidities
0.987
None 119 66% 140 65%
1 48 27% 59 27%
2 or more 10 6% 13 6%
Missing 2 1% 3 1%
Socio-economic status (SES)*
0.008
High 65 36% 55 26%
Medium 73 41% 82 38%
Low 41 23% 78 36%
Education
0.093
Secondary school (low level) or lower 19 11% 43 20%
Secondary school (medium level) 38 21% 49 23%
Secondary school (high level) 22 12% 26 12%
Intermediate vocational training (MBO) 39 22% 41 19%
Higher vocational training (HBO) and university 58 32% 50 23%
Other/unknown 3 2% 6 3%
Tumour characteristics
Stage (short), clinical
0.000II 126 70% 201 93%
III 53 30% 14 7%
Hormone receptorstatus (based on biopsy supplemented with post-OK information)
0.028
Triple negative 33 18% 29 13%
Hormone-negative, Her2-positive 15 8% 14 7%
Hormone-positive, Her2-positive 29 16% 23 11%
Hormone-positive, Her2-negative 99 55% 149 69%
Unknown 3 2% 0 0%
Treatment characteristics
Type of surgery (based on final surgery)
Stage II (clinical)
0.032Breast Conserving/Lumpectomy 73 58% 92 46%












The patient’s opinion on SDM (Table 3, Fig. 2)
About half of all respondents with stage II BC (54% NAC, 36% AC) felt they had a real 
choice in their treatment plan (p=0.004); 68% and 50% of NAC-treated and AC-treated 
patients, respectively, described they wanted to decide themselves or shared their 
decision with their physician (Fig. 2). However, patients who stated they received in-
formation on the possibility of chemotherapy (Q10) and NAC specifically (Q11) in both 
groups felt equally involved in making a decision (54% NAC, 58% AC, p=0.854 (not in 
table)). For BC stage III, the treatment plan was already decided in 64% of NAC-treated 
patients and 50% of AC-treated patients (p=0.521) (Table 3).
Experience with general information on chemotherapy
No significant differences were found in the patients’ experience with general infor-
mation on chemotherapy. Over 95% of all respondents received information on their 
chemotherapy scheme and understood this information (95% NAC, 96% AC). Over 
80% of respondents was informed on side-effects of their chemotherapy (NAC 88%, 
AC 84%). Both groups scored very high regarding understanding the information they 
received on chemotherapy (94% NAC, 96% AC). Respondents felt they had the op-









0.124Breast Conserving/Lumpectomy 14 26% 1 7%




General 47 26% 79 37%
Teaching or academic
(incl. BC specialised hospital) 132 74% 136 63%
Hospital surgical volume **
0.000
Low 58 32% 112 52%
Middle 77 43% 75 35%
High 44 25% 28 13%
* Socio-economic status (SES) of the patients was based on four-digit postal code at time of surgery; SES scores 
are provided by the Netherlands Institute for Social Research (Sociaal Cultureel Planbureau) and divided into three 
groups based on the delivered rank numbers: low (1st-3rd deciles), intermediate (4th-7th) and high (8th-10th) SES.
** Hospitals were categorised by surgical volume for primary breast cancer, defined as the mean annual number of 
BC surgeries during the period 2011-2015; categorised as low (<150), medium (150-300), and high (300<) volume.
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Treatment experience with chemotherapy (CTSQ, Fig. 3)
Significant differences between NAC-treated and AC-treated patients, respectively, 
were found in the treatment experience (Fig. 3). Mean EOT-scores for both NAC-
treated and AC-treated patients were high (68 NAC, 68 AC; p=0.948), meaning that 
overall, respondents had a high believe in chemotherapy contributing to their cancer 
treatment. FSE-scores were moderate (46 NAC, 45 AC; p=0.714), meaning respondents 
felt their side effects were as severe as expected beforehand. In totality, NAC-treated 
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Table 2. Conditions of Shared Decision-Making (SDM), NAC vs AC; separate for stage II and III
Q NAC (%) AC (%) P (Chi2)
Stage II (n=126 NAC, 201 AC)
10 Patients received information on chemotherapy in 
general before surgery (n=126 NAC, 201 AC)
124 98% 169 84% 0.000
11 Patient was given information about NAC (n=124 
NAC, 169 AC)
124 100% 24 14% 0.000
13 Patient received sufficient information on pros and 
cons of both AC and NAC (n=124 NAC, 24 AC)
106 85% 15 63% 0.008
14, 
16
Patient was able to explain why she and/or the 
physician chose for either NAC or AC (n= 126 NAC, 
201 AC)
122 97% 132 66% 0.000
Stage III (n=53 NAC, 14 AC)
10 Patients received information on chemotherapy in 
general before surgery (n=53 NAC, 14 AC)
49 92% 13 93% 0.959
11 Patient was given information about NAC (n=49 
NAC, 13 AC)
49 100% 4 31% 0.000
13 Patient received sufficient information on pros and 
cons of both AC and NAC (n=49 NAC, 4 AC)
36 73% 3 75% 0.947
14, 
16
Patient was able to explain why she and/or the 
physician chose for either NAC or AC (n=53 NAC, 
14AC)
50 94% 14 100% 0.362






Stage II (n=126 AC, 201 AC)
18 Patient felt she did have a choice in either choosing 
for NAC or AC (n=126 NAC, 201 AC)
68 54% 72 36% 0.008
20 Patient felt she had enough time to decide on either 
NAC or AC (n=68 NAC, 72 AC)
67 99% 72 100% 0.302
Stage III (n=53 NAC, 14 AC)
18 Patient felt she did have a choice in either choosing 
for NAC or AC (n=53 NAC, 14AC)
19 36% 7 50% 0.521
20 Patient felt she had enough time to decide on either 
NAC or AC (n=19 NAC, 7 AC)
19 100% 7 100% 0.923
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DISCUSSION
This study highlights important aspects in the decision-making process on the timing 
of chemotherapy (NAC vs AC) for early breast cancer. If information on chemotherapy 
was provided prior to surgery, 100% of NAC-treated patients versus 14% of AC-treated 
patients received information on NAC as a possible treatment option. Of those who 
received information on NAC, 85% and 63% of patients treated with NAC and AC, 
respectively, stated that they received sufficient evidence on the pros and cons of both 
NAC and AC.
The results of this survey confirm that the choice regarding either NAC or AC is often 
not discussed with patients with stage IIIII breast cancer prior to treatment. This sug-
gests that clinicians rarely express that a treatment decision needs to be made, and 
patients may not realize that neoadjuvant treatment is a valid choice. In order to make a 
decision, sufficient information and relevant evidence on pros and cons of all treatment 
options should be provided before the start of therapy. Patients treated with AC were 
less informed about this treatment decision than NAC-treated respondents, and stage 


























95% CI lower bound 95% CI upper bound mean
Figure 3. Treatment experience, mean CTSQ-scores per domain* and chemotherapy treatment, incl. 95% lower 
and upper confidence interval for NAC and AC separately (n ¼ 179 NAC,215 AC).*domains: Expectation of Therapy 












Further on, both patients’ and clinicians’ preferences should be incorporated in 
treatment plans14. Few AC-treated respondents with BC stage II were able to explain 
reasons for adjuvant timing of systemic treatment instead of neoadjuvant timing. 
Moreover, about half of respondents did not feel they had a choice regarding timing of 
systemic treatment. These results reveal the impaired role of participation of patients 
in SDM on NAC.
Several potential explanations are present. First, the Dutch and international breast 
guidelines are straightforward about the recommendation of NAC for stage III BC1,9,10, 
but the evidence of NAC for stage II BC is not included in the guidelines yet, since it is 
based on promising preliminary data and research18,19. Seemingly, treatment decisions 
are predominantly guideline-congruent, and when guidelines are not clear, clinicians’ 
recommendations to patients are not uniform either. Consequently, differences in clini-
cians’ opinions may lead to variation in treatment patterns, as confirmed by the NBCA 
audit results and other recent studies 11,13.
Moreover, clinicians’ opinions exert one of the most powerful influences over patients’ 
preferences20. Also, patients are often not aware that a treatment decision is required 
20. The health professional first speaking with the patient plays an important role in how 
information is conveyed, whether this is a surgeon, medical oncologist, nurse practitio-
ner, or physician assistant. This will most likely drive the treatment decision. According 
to our survey, most of the information about NAC was provided by medical oncolo-
gists, of whom we expect stronger support for applying NAC than from surgeons. A 
referral from the surgeon to the medical oncologist defines whether a patient actually 
will have a consultation with an oncologist. In addition, appropriate information and 
additional support is essential to make quality decisions. Decision support-systems 
may help patients allow them to be primary decision maker21. Thirdly, the level of 
training of clinicians, conference attendance, and multidisciplinary meeting groups on 
a regular base may play a crucial role by creating more choice-awareness in preference-
sensitive decisions.
Also, the preferred role of patients in preference-sensitive decisions is influenced 
by patients’ age and education. Older and less educated patients are more likely to 
prefer a passive or collaborative role22, whereas an active role is generally preferred by 
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younger and better educated patients23. We observed that NAC-treated patients treat-
ed were younger and better educated, while being better informed as well. Patient’s 
participation in their treatment plan is important because a high level of involvement 
is associated with improved outcome in quality of life, physical and social function-
ing. Patient’s involvement led to high levels of satisfaction with the decision and the 
subsequent treatment they received24. Even if the fit of treatment to preferences is 
not enhanced, the fact that patients are involved and felt meaningful to the situation 
may increase satisfaction25. Moreover, patients could be pleased to know whether their 
tumour responded or progressed on NAC, which can be valuable contribution under 
conditions of uncertainty.
Finally, the most common explanations for the application of NAC in stage II and 
stage III patients were tumour size and axillary metastases. These explanations cor-
respond with reported results from cancer registries11,13. While NAC aims to downsize 
the tumour to improve the possibility of breast conservation surgery, it was expected 
that more respondents were treated with BCS after NAC4,26. However, in our survey 
the patient’s desire for BCS was the major reason for NAC in only 28% of BC stage II 
patients. Valid options to refrain from chemotherapy (NAC or postoperative) may have 
been contraindications such as poor performance status or severe comorbidity. Also, it 
may be possible that women prefer to undergo surgery first, but these considerations 
should be clearly discussed.
Overall, the results of our study showed that general experience (CTSQ) with che-
motherapy in terms of side effects was scored equal in both groups, but significant 
differences between groups were found in final satisfaction with care; NAC-treated 
patients seem to be less satisfied. The most likely explanation for this result, is the 
difference in approach in NAC-treated patients, in which NAC is commonly being 
used for down-staging of the tumour to increase resectability and enable BCS. When 
the response to chemotherapy appears to be disappointing and BCS does not seem 
possible, satisfaction could be less. Also, mostly young women receive NAC, which will 
have a big impact on their daily lives. However, these negative perceptions reiterate 













To our knowledge, this is the first study reflecting patients’ experiences with decisions 
on the timing of chemotherapy for early BC. Previous literature focused mainly on 
experiences with decisions on adjuvant therapies for BC27,28. In the context of an 
increasing trend in NAC use11,26, insight in patients’ experience in SDM on NAC is 
extremely relevant.
Because of the connection between the clinical cancer registry and the patient re-
ported experiences, this study is unique in design. We reached a high response rate of 
almost 400 respondents (49%) and selected a homogeneous comparable population 
compared to non-responders. The absolute number of BC stage III respondents was 
small, but because of the strict indication of NAC for these patients, this group was less 
relevant to discuss. Participation was opt-in, leading to selection bias in which those 
who responded were probably more critical on SDM then non-responders; providing 
paper questionnaires on request could lead to an underrepresentation of patients with 
lack of computer skills or access. Also, recall bias is a known limitation of all survey stud-
ies. Idem, creating a patient-comprehensible questionnaire is a difficult task. We were 
favoured by input from the Dutch patient association on breast cancer. Besides, we 
emphasize the fact that patient-reported data is based on the experience of patients, 
rather than a factual reflection of how decisions on chemotherapy timing were made. 
Furthermore, unfortunately, the numbers of respondents per hospital were too small to 
analyse intra-hospital variation in SDM; this would be interesting for further research.
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CONCLUSION
In conclusion, our study revealed that the need to make a treatment decision on the 
timing of chemotherapy (NAC vs AC) for early breast cancer was discussed with only 
a small number of patients, in particular in BC stage II. Less than half of the respon-
dents felt they had a real choice. Clinicians’ opinions exert one of the most powerful 
influences over patients’ preferences. National guidelines that are frequently updated 
and a continuous audit system integrating detection and real-time feedback will help 
in providing clear guidance to physicians for chemotherapy treatment timing with 
decision-making as a result of team work of all involved disciplines. By understanding 
patient preferences and incorporating them into treatment decisions, it will be possible 
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35-question item questionnaire consisted of questions on SDM, patients’ experiences on timing of 
chemotherapy and satisfaction with chemotherapy care in general.
0.  What is your date of birth?
 ..-..-19..
1.  How was, in your own perception, your physical health over the past three months?
 Excellent – very well – well – moderate – bad
2. How was, in your own perception, your mental health over the past three months?
 Excellent – very well – well – moderate – bad
3. At time of your treatment with chemotherapy, did you suffer from one or more of 
undermentioned diseases?
 Any other type of cancer – lung disease - cardiovascular disease – gastro-intestinal disease 
– illness of urinary or reproductive system – musco-skeletal disease - central nerve system 
– illness of metabolism or coagulopathy - infectious disease – none – other
4. Were you menopausal at time of your treatment with chemotherapy?
 Premenopausal – perimenopausal – postmenopausal – I don’t know – not applicable
5. Were you treated with chemotherapy anterior or posterior to your surgical treatment 
for breast cancer?
 Anterior (neoadjuvant chemotherapy) – posterior (adjuvant chemotherapy) – both anterior 
as posterior (combination of neoadjuvant and adjuvant)
6. Which type of chemotherapy did you receive at the start of your chemotherapy treat-
ment?
 TAC – AC – FEC – FEC followed by taxane – AC followed by taxane – Trastuzumab (Her-
ceptin) and chemotherapy – I don’t know – other
7. How many courses of chemotherapy treatment did you receive?
 .. courses
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8. Did you finish the total amount of chemotherapy courses that were planned for you?
 Yes (proceed with question 10) – no (proceed with question 9)
9. What was the reason for premature termination of your chemotherapy treatment?
 Because of (severe) side effects – by own preference – the chemotherapy did not (suf-
ficient) affect the cancer – I don’t know – other
10. Was the necessity of chemotherapy within your treatment plan discussed with you 
previous to receiving your surgical treatment?
 Yes – no – I don’t know
11. Was the option of starting with chemotherapy prior to surgery discussed with you 
previous to receiving your surgical treatment?
 Yes – no – I don’t know
12. With whom did you discuss treatment with chemotherapy prior to surgery?
 Oncologist – surgeon – nurse practitioner – breast cancer nurse – general practitioner – 
other
13. Did you receive information on the pros and cons of both treatment with chemo-
therapy initiated either prior or subsequently to surgical treatment?
 Yes – yes, but not as much as I preferred – no – I don’t know
14. Do you know why you were treated with chemotherapy prior to receiving surgery?
 Not applicable, I received adjuvant chemotherapy treatment – No, I don’t know – Yes, I do 
know
15. In case you do know why you were treated with chemotherapy prior to surgery, what 
was the reason for choosing this treatment option?
 Tumour size – axillary metastases – preferring a breast conserving surgery – to stretch time 
to surgery – my physician decided this – my physician decided this, because… -  I don’t 
know – other
16. Do you know why you were treated with chemotherapy after receiving surgery?













17. In case you do know why you were treated with chemotherapy after receiving sur-
gery, what was the reason for choosing this treatment option?
 Tumour size – axillary metastases – I preferred this type of chemotherapy  – my physician 
decided this – my physician decided this, because… -  I don’t know – other
18. Do you feel you could co-decide with your physician on treatment with chemotherapy 
either prior or after receiving surgery?
 Yes, because… - no, because…
19. Who helped you in deciding on chemotherapy treatment order?
 I decided myself – my physician – my partner – family – friends – information on the 
internet - patient association – ‘fellow-sufferers’ – other
20. Do you feel you had enough time to decide on chemotherapy treatment order?
 Yes – no
21. Was the chemotherapy treatment scheme explained clearly to you?
 Yes, and I fully understood the explanation – yes, but I did not fully understand the expla-
nation – no – I don’t know
22. Were the side effects of chemotherapy explained prior to receiving chemotherapy?
 Yes, prior to treatment and sufficient – Yes, prior to treatment but not sufficient – Yes, but 
not prior to treatment – No – I don’t know
23. Did you understand the information you received on chemotherapy?
 Yes – no – not applicable, I received no information on chemotherapy in general – I don’t 
know
24. Was there the opportunity to ask questions to your physician on chemotherapy?
 Yes, sufficient – yes, somewhat – no – I don’t know
25. How often during chemotherapy treatment did you feel that..
 (never – rarely – sometimes – mostly – always)
a. chemotherapy would help you to return to a normal life?
b. chemotherapy would get rid of the cancer?
c. chemotherapy would help prevent the cancer from coming back?
d. chemotherapy would stop the cancer from spreading?
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e. chemotherapy limited your daily activities?
f. Upset about side effects?
g. chemotherapy was worth taking even with side effects?
h. chemotherapy would help you live longer?
i. How often did you think about stopping chemotherapy?
26. Overall, how worthwhile was your chemotherapy?
 Very worthwhile – pretty worthwhile – fairly worthwhile – a little worthwhile – not worth-
while
27. Overall, was taking chemotherapy as difficult as expected?
 A lot more difficult – slightly more difficult – as difficult as I expected – slightly easier – a 
lot easier
28.a. Overall, how well did the benefits of chemotherapy meet your expectations?
28.b. Overall, were side effects as expected?
 A lot better/more than expected – slightly better/more than expected – met my expecta-
tions – slightly less than expected – a lot less than expected
29.a. How satisfied were you with the form of your chemotherapy?
29.b. How satisfied were you with your most recent chemotherapy?
 Very satisfied – satisfied – neither satisfied nor dissatisfied – dissatisfied – very dissatisfied
30.a. If given choice again, would you decide to take this chemotherapy treatment?
30.b. Would you recommend this type of chemotherapy to others in a similar situation?
 Absolutely – probably – I don’t know – probably not – absolutely not
31. At time of your breast cancer treatment, what were the four digits of your postal 
code?
 _ _ _ _
32. What is your highest completed education? (completed with diploma or certificate)












33.  What is currently your marital status?
 Married/relationship – divorced/separated – widow/widower/partner diseased – single
34. What description is most applicable to you at this moment? (please tick one answer)
 Attending school/education – paid employment – unemployed/seeking work – incapaci-
tated – housewife – retirement
35. What is your nationality?
 Dutch – Moroccan – Surinamese – Turkish – German – Belgian – Other
 Do you have any questions/remarks?
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ABSTRACT
Introduction: NAC has led to an increase in breast conserving surgery (BCS) world-
wide. This study aims to analyse trends in the use of neoadjuvant chemotherapy (NAC) 
and the impact on surgical outcomes.
Methods: We reviewed all records of cT1-4N0-3M0 breast cancer patients diagnosed 
between July 2011 and June 2016 who have been registered in the Dutch National 
Breast Cancer Audit (NBCA) (N=57.177). The surgical outcomes of ‘BCS after NAC’ 
were compared with ‘primary BCS’, using a multivariable logistic regression model.
Results: Between 2011 and 2016, the use of NAC increased from 9% to 18% and ‘BCS 
after NAC’ (N = 4170) increased from 43% to 57%. We observed an involved invasive 
margin rate (IMR) of 6,7% and a re-excision rate of 6,6%. As compared to ‘primary 
BCS’, the IMR of ‘BCS after NAC’ is higher for cT1 (12,3% versus 8,3%; p < 0.005), 
equal for cT2 (14% versus 14%; p=0.046) and lower for cT3 breast cancer (28,3% versus 
31%; p<0.005). Prognostic factors associated with IMR for both ‘primary BCS’ as for 
‘BCS after NAC’ are: lobular invasive breast cancer and a hormone receptor positive 
receptor status (all p<0,005).
Conclusion: The use of NAC and the incidence of ‘BCS after NAC’ increased exponen-
tially in time for all stages of invasive breast cancer in the Netherlands. This nationwide 
data confirms that ‘BCS after NAC’ compared to ‘primary BCS’ leads to equal surgi-
cal outcomes for cT2 and improved surgical outcomes for cT3 breast cancer. These 












Neoadjuvant chemotherapy in breast cancer patients has resulted in an increased rate 
of breast conserving treatment (BCT) consisting of breast conserving surgery (BCS) and 
radiation treatment1-3. Due to down-staging of the tumour by NAC, patients who were 
initially planned for mastectomy could receive BCS. The advantages of BCS compared 
to mastectomy obviously include less morbidity and thereby improved aspects of qual-
ity of life3-5. Another benefit of NAC includes the opportunity to deescalate surgical 
treatment of the axilla6-8. BCS after NAC introduces challenges as identification of origi-
nal tumour location and monitoring tumour response using imaging9,10. The efficacy of 
NAC to downsize or achieve a pathologic complete response (pCR) has improved due 
to more efficient targeted drug regimens, and pCR rates of up to 60-80% in the triple 
negative and HR-/ HER2. subtypes are now being reached11,12. These promising results 
have led to challenging new trials investigating the potential of non-operative therapy 
for invasive breast cancer by utilizing accurate image-guided percutaneous biopsy to 
document pathologic complete response13-15.
While improved breast imaging and the promising concept of non-operative therapy 
in patients that reach pCR after NAC are currently being investigated, surgical man-
agement with the primary goal to remove the (residual) tumour with clear margins 
is still the standard of care. In the present study, we analyse trends in the surgical 
performance after NAC for breast cancer in the Netherlands between 2012 and 2016 
(1), we describe the surgical outcomes including margins and re-excision rates for BCS 
after NAC compared to primary BCS (2) and identify prognostic factors associated with 




The NABON Breast Cancer Audit (NBCA) is a multidisciplinary nationwide registry of 
all diagnostic and treatment modalities of patients who are surgically treated for newly 
diagnosed breast cancer in the Netherlands. All 89 hospitals in the Netherlands partici-
pating in breast cancer care participate in this nationwide registry. Data completeness 
of the NBCA is estimated to be at least 95%. Available data from the NBCA dataset 
include demographic variables (year of incidence, age), tumour variables (histologic 
subtype, clinical tumour stage, clinical nodal stage and hormone receptor status) 
and treatment variables (use of systemic therapy, radiotherapy and type of surgery). 
Furthermore, the volume and type of hospital is being registered. Hospital volume 
was based on the surgical volume, which was defined as the mean annual number of 
breast cancer surgeries during the period 2012-2016. The cut-off points of <150 and 
300<, were based on those reported in a publication of the European Society of Breast 
Cancer Specialist (EUSOMA)16. Hospital type was described as academic, teaching and 
general. Academic hospitals are part of a university, and both academic and teaching 
hospitals provide medical training to surgical residents.
Data selection
Data records of patients aged 18-98 years diagnosed with cT1-4N0-3M0 invasive 
breast cancer between July 2011 and June 2016 were abstracted from the NBCA. We 
excluded patients with a prior cancer diagnosis or unknown timing of chemotherapy. 
Neoadjuvant chemotherapy (NAC)was defined as chemotherapy given within four 
weeks prior to surgery. In accordance with international guidelines, the Dutch national 
breast cancer guidelines indicate NAC for patients with locally advanced disease (stage 
III) and recommended it in patients with stage II disease with an indication for systemic 
treatment17,18. Trends in the use of NAC and the surgical performance after NAC during 
the years were analysed.
Surgical performance
Type of surgery (BCS or mastectomy) and the pathology report of the surgical speci-
men was derived from the NBCA database. Resection margins of the surgical specimen 










of the quality indicator defined by the NBCA audit19. In the Dutch guidelines, the 
definition for focally involved margins for invasive breast cancer is described as residual 
tumour in the resection surface over a maximum length of 4 mm. More than focally 
involved margins is defined as residual tumour in the resection surface over more than 
4 mm. According to the Dutch guidelines, focally involved margins do not mandate 
re-excision. In case of more than focally involved (positive) margins, a re-excision is 
indicated unless the positive margin is the dorsal margin and the fascia has been 
resected. In addition to radiation after BCS, a radiation therapy boost may be applied 
when one or more of the following indications is present: age <50 years, an estimated 
local recurrences risk 1% per year, grade 3, positive tumour margins and lymphvascular 
space invasion20,21.
Statistical analysis
Statistical analysis was performed in PASW Statistics version 20 (SPSS inc Chicago, IL, 
USA). Descriptive analyses were used to report on the trends in the use of NAC and in 
the surgical outcomes after NAC. Bivariate comparisons of surgical outcomes of BCS 
with and without NAC were performed with chi-square tests. Secondly, a multivariable 
logistic regression model was used to determine which factors were independent as-
sociated for tumour involved margins in BCS with and without NAC. Statistical tests 
were 2-sided and statistical significance was defined as a p value <0.05.
RESULTS
Overall, 62.982 patients were diagnosed with cT1-4N0-3M0 invasive breast cancer 
in the Netherlands between July 2011 and June 2016, and registered in the NBCA 
registry. Patients with a prior cancer diagnosis (N=5661) or unknown timing of che-
motherapy (N=144) were excluded for further analyses, resulting in data of 57.177 
patients available for our study. Median age was 62 years (range 19-98) and most of 
the patients were diagnosed with a clinical tumour stage of cT1 (N=34.678; 60,7%) or 
cT2 (N=18.482; 32,3%), without nodal involvement (N=47.512; 83,1%).
Primary surgery without NAC was performed in 85.8% of all patients (N=49.712); of 
which 65% were treated with BCS (N=32.305) and 35% with a mastectomy (N=17.407). 
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Table 1. Clinical-pathological and hospital characteristics of patients with invasive cT1-4M0 breast cancer (N=8195) 
who have received NAC followed by surgery (2012-2016).
NAC + BCS NAC + Mastectomy
(N=4170) (N=4025)
Year of incidence <0,005
2012 (07-2011 – 06-2012) 424 43% 553 57%
2013 (07-2012 – 06-2013) 626 47% 716 53%
2014 (07-2013 – 06-2014) 836 50% 838 50%
2015 (07-2014 – 06-2015) 1086 52% 1008 48%
2016 (07-2015 – 06-2016) 1198 57% 910 43%
Age <0,005
<40 395 39% 626 61%
40-50 1307 49% 1341 51%
50-60 1462 55% 1173 45%
60-70 872 55% 704 45%
70-100 132 42% 181 58%
Histologic subtype <0,005
Ductal 3633 53% 3287 48%
Lobular 331 41% 482 59%
DCIS component 0,009
No 2684 52% 2463 48%
Yes 1486 49% 1562 51%
Clinical tumor stage <0,005
cT1 706 59% 488 41%
cT2 2948 63% 1763 37%
cT3 442 26% 1246 74%
cT4 74 12% 528 88%
Clinical nodal stage <0,005
cN0 1976 59% 1401 41%
cN1 1921 47% 2164 53%
cN2 80 38% 128 62%
cN3 192 37% 329 63%
Hormone receptor status 0,007
Triple - 890 55% 743 45%
HR -, HER2+ 338 48% 367 52%
HR +, HER2+ 610 54% 529 46%
HR +, HER2- 2237 50% 2267 50%
Type of hospital 0,016










In 14.2% of patients NAC was applied before surgery (N=8195); of which 50.9% 
were treated with BCS (N=4170) and 49.1% with a mastectomy (N=4025). Clinical-
pathological and hospital characteristics of patients treated with NAC are shown in 
Table 1. Women who received NAC followed by BCS instead of a mastectomy tended 
to be older (>50 yrs of age), except of patients aged >70 years of age. Tumour charac-
teristics associated with NAC followed by BCS are ductal invasive histologic subtype, 
no multifocality, a cT1-2 clinical tumour stage and cN0 disease (all P<0.005).
Between 2011 and 2016, there were 37 general-, 43 teaching and 9 academic hospitals 
in the Netherlands; divided into low-volume <150 (N=44), mid-range 150-300 (N=34) 
and high-volume 300< (N=11) hospitals. NAC was most often applied in academic 
hospitals (26% NAC; N=1517) compared to teaching- (13% NAC; N=3991) and general 
hospitals (12% NAC; N=2687). The type or volume of hospital is not associated with 
the type of surgery received after NAC [Table 1].
Trends in the surgical performance after NAC
In the last 5 years the use of NAC increased from 9% in 2012 to 18% in 2016 and 
applies to the clinical tumour stages cT1-3 [Table 2]. There is no increasing trend 
in the use of NAC for cT4 breast cancer (a stable percentage around 63% over the 
years). A greater upward trend per tumour stage in the use of NAC is seen in the sub 
selection of patients with nodal involvement (N=9665); the use of NAC increased from 
38% (N=636) in 2012 to 61% (N=1168) in 2016; for cT1N+ from 17% (N=80) to 38% 
(N=169), for cT2N+ from 35% (N=289) to 63% (N= 613) and for cT3N+ from 67% 
(N=159) to 80% (N=283).
Table 1. (continued)
NAC + BCS NAC + Mastectomy
(N=4170) (N=4025)
Teaching- 1987 50% 2004 50%
Academic- 827 55% 690 45%
Hospital surgical volume 0,472
< 150 1043 51% 988 49%
150-300 1557 50% 1531 50%
> 300 1562 51% 1493 49%
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As presented in Table 1, ‘BCS after NAC’ increased from 43% in 2012 to 57% in 2016, 
which is a relative increase of 33%. For ‘Primary BCS’, an increased percentage of 
63% in 2012 to 69% in 2016 is observed, which is a relative increase of only 9,5%. 
As depicted in Fig. 1A, an upward trend of ‘BCS after NAC’ for cT1N0 breast cancer 
is described from 43% (N=20) to 61% (N=99), for cT2N0 from 65% (N=139) to 70% 
(N=437) and for cT3N0 from 30% (N=14) to 43% (N=54). Shown in Fig. 1B, an equal 
upward trend of ‘BCS after NAC’ is seen in the sub selection of patients with nodal in-
volvement; for cT1N+ from 58% (N=46) to 69% (N=116), for cT2N+ from 56% (N=161) 
to 62% (N=377) and for cT3N+ from 18% (N=29) to 31% (N=87). The group of cT4 
breast cancer patients treated is too small for reliable analyses (N<110 of patients 
treated with NAC per year).
For ‘Primary BCS’, increased percentages of more BCS per tumour stage is observed. 
However, this increase is to a lesser extent; from 76% to 80% for cT1N0, from 49% to 
51% for cT2N0 and from 6% to 11% for cT3N0. For patients with nodal involvement: 
from 51% to 58% for cT1N+, from 24% to 26% for cT2N+ and from 4% to 6% for 
cT3N+.
Table 2. Patients with invasive cT1-4M0 breast cancer who have received NAC followed by surgery, per tumour 
stage; 2012 compared to 2016.
Total NAC % Followed by surgery No NAC % Primary surgery
2012 BCS Mastectomy BCS Mastectomy
cT1 6600 129 2% 52% 48% 6471 98% 74% 26%
cT2 3445 508 15% 60% 40% 2937 85% 44% 56%
cT3 475 216 45% 20% 80% 259 55% 5% 95%
cT4 197 124 63% 8% 92% 73 37% 8% 92%
cT1-4 10717 977 9% 43% 57% 9740 91% 63% 37%
2016
cT1 7161 335 5% 65% 35% 6828 95% 79% 21%
cT2 3768 1271 33% 66% 34% 2526 67% 48% 52%
cT3 666 432 62% 35% 65% 256 38% 9% 91%
cT4 198 153 62% 19% 81% 75 38% 17% 83%










Surgical outcomes of BCS after NAC
Table 3 shows the surgical outcomes of ‘BCS after NAC’ in terms of focally or more 
than focally involved invasive margins and re-excision rates. Of all patients treated with 
BCS after NAC between 2011 and 2016 (N=4170), 8,5% (N=355) had focally involved 
invasive margins and 6,7% (N=281) had more than focally involved invasive margins. 
The re-excision rate was 6,6%; consisting of almost all patients with more than focally 
involved margins. For primary BCS (N=32.305), these percentages are 6,3% and 3,1% 





















2012 2013 2014 2015 2016


















2012 2013 2014 2015 2016





Figure 1a. Trends in NAC followed by BCS per tumour stage in patients with cN0 disease; 2012-2016.





















2012 2013 2014 2015 2016


















2012 2013 2014 2015 2016





Figure 1b. Trends in NAC followed by BCS per tumour stage in patients with nodal involvement; 2012-2016.
*N= patients treated with NAC.
90
On multivariable analysis, prognostic factors associated with involved invasive margins 
for both patients treated with primary BCS as for BCS after NAC are: lobular invasive 
breast cancer, an increasing clinical tumour stage and a hormone receptor positive 
receptor status (all p<0,005; Table 4). The type of hospital, the year of incidence, a 
DCIS component and nodal involvement are only associated with involved invasive 
margins for primary BCS (all p<0,005). From a sub-analysis on re-excision rates, lobular 
invasive breast cancer was the only significant factor associated with a mastectomy if a 
re-excision was performed because of involved margins in BCS after NAC.
As shown in Fig. 2, there is a significant difference in involved invasive margins (in terms 
of focally or more than focally) in patients treated with BCS after NAC compared to 
patients treated with primary BCS per tumour stage. While the percentage of involved 
Table 3. Surgical outcomes of patients with invasive cT1-4M0 breast cancer who have received breast conserving 
surgery with or without chemotherapy upfront (2012-2016).






(Invasive or DCIS) <0,005
> focally 286 6,9% 1075 3,3%
Focally 439 10,5% 3124 9,7%
No 3391 81,3% 27994 86,7%
Involved invasive margins <0,005
> focally invasive 281 6,7% 1001 3,1%
Focally invasive 355 8,5% 2021 6,3%
No 3480 83,5% 29171 90,3%
Involved DCIS margins* 0,107
> focally DCIS 32 2,3% 510 3,3%
Focally DCIS 126 9,1% 1423 9,3%
No 1229 88,6% 13342 87,3%
Re-excision <0,005
No 3823 91,7% 29309 90,7%
Yes 275 6,6% 1699 5,3%
missing 72 1,7% 1297 4,0%
Type of re-excision 0,661
BCS 146 53,1% 933 54,9%










Table 4. Multivariable logistic regression for the odds of involved invasive margins in patients with invasive cT1-4M0 





95% CI 95% CI
OR Lower Upper OR Lower Upper
Year of incidence 0,318 <0,005
2012 ref. ref.
2013 1,158 0,784 1,712 0,823 0,721 0,939
2014 0,881 0,602 1,291 0,79 0,694 0,9
2015 1,186 0,828 1,698 0,831 0,73 0,947
2016 1,113 0,78 1,587 0,793 0,696 0,904
Age 0,561 0,038
<40 0,912 0,62 1,343 0,977 0,703 1,359
40-50 1,02 0,805 1,292 1,126 0,973 1,302
50-60 ref. ref.
60-70 1,107 0,856 1,431 0,919 0,825 1,023
70-100 0,649 0,335 1,258 1,05 0,939 1,174
Histologic subtype <0,005 <0,005
Ductal ref. ref.
Lobular 4,684 3,559 6,165 2,912 2,602 3,259
DCIS component 0,024 <0,005
No ref. ref.
Yes 1,273 1,032 1,57 1,182 1,081 1,292
Clinical tumor stage <0,005 <0,005
cT1 ref. ref.
cT2 1,275 0,966 1,683 1,676 1,523 1,844
cT3 2,622 1,837 3,744 3,202 1,853 5,532
cT4 3,333 1,805 6,157 2,904 1,365 6,178
Clinical nodal stage 0,017 <0,005
cN0 ref. ref.
cN1 1,291 1,054 1,581 1,664 1,419 1,952
cN2 2,013 1,06 3,822 2,639 1,187 5,867
cN3 1,49 0,928 2,393 4,776 1,736 13,138
Hormone receptor status <0,005 <0,005
Triple - 1,311 0,627 2,742 0,523 0,433 0,633
HR -, HER2+ ref. 0,064 0,233 ref. 0,064 0,233
HR +, HER2+ 2,908 1,444 5,86 0,709 0,523 0,962
HR +, HER2- 8,184 4,29 15,612 0,844 0,714 0,998
Type of hospital 0,035 <0,005
General- 1,118 0,88 1,421 1,148 1,044 1,263
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invasive margins (IMR) for cT1 patients treated with BCS after NAC is higher than after 
primary BCS (12,3% compared to 8,3%; p<0,005) and comparable for cT2 patients 
(14,0% compared to 13,7%; p=0,046), the percentage of IMR is significant lower for 
cT3 patients treated with BCS after NAC compared to primary BCS (28,3% versus 
31,0%; p<0.005).
When we analysed the data for cT3 patients, lobular invasive breast cancer and a hor-
mone receptor positive receptor status were associated with IMR, with no difference 




























Figure 2. Percentage of patients with invasive cT1-4M0 breast cancer and involved invasive margins who have re-






95% CI 95% CI
OR Lower Upper OR Lower Upper
Teaching- ref. ref.
Academic- 1,405 1,086 1,817 1,254 1,085 1,449
Hospital surgical volume 0,956 0,031
< 150 ref. ref.
150-300 0,986 0,752 1,294 1,029 0,921 1,151











This population-based study showed an increase in the use of NAC from 9% in 2011 
to 18% in 2016 and an increase of more ‘BCS after NAC’ from 43% to 57% compared 
to ‘primary BCS’ from 63% to 68% in patients with primary breast cancer in the Neth-
erlands. The increasing implementation of NAC is consistent with previous studies on 
the trend of NAC in breast cancer care22-24. Together with this international trend, it is 
demonstrated that NAC increases the rates of breast preservation in tumours of >2 
cm25,26. However, this study shows an increasing trend towards more BCS after NAC not 
only for larger tumours but for all stages of breast cancer.
There are several explanations for this upward trend towards more ‘BCS after NAC’ 
for all stages of disease. With the increased evidence that subgroups of patients who 
achieve a complete pathological tumour (pCR) after NAC do have a better prognosis 
in terms of disease-free and overall survival, NAC is nowadays be considered as a pre-
ferred option in the treatment of triple negative and HER2. breast cancer27-29. Secondly, 
the amount of a pCR response reported has increased dramatically in the past years 
because of improvements of targeted therapies. Up to half of the patients in specific 
groups such as her2-positive patients achieve a complete remission after NAC, which 
has subsequently led to more BCS30-33. Furthermore, the development of innovative 
approaches to axillary staging after chemotherapy has most likely contributed to more 
BCS followed by NAC in patients with nodal involvement at diagnosis6,8,34,35. Thereby, 
the growing experience and confidence with NAC among clinicians due to informa-
tion from nationwide clinical quality registries, the use of quality indicators providing 
benchmark information on surgical outcomes and the exchange of knowledge by a 
multidisciplinary approach and cross-border hospital collaborations may all be attrib-
uted to the upward trend towards more BCS after NAC.
The involved invasive margin rate in our study is 6,7% for ‘BCS after NAC’ compared to 
3,1% for ‘primary BCS’. The overall positive margin rate in our study is 6,9% for ‘BCS af-
ter NAC’ compared to 3,3% for ‘primary BCS’. These rates are relatively low compared 
to other studies. In a systematic review performed by Volders et al. in which they aimed 
to determine surgical outcomes for BCS after NAC, involved margins ranged from 5% 
to 39.8% after NAC versus 13.1%-46% for primary BCS36. These percentages were 
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based on ten studies describing involved margins with or without NAC, but a clear 
comparison between these studies was not possible due to variation in terminology 
and variation amongst patient groups. Because of the nationwide character of our 
study in which all patients treated with invasive breast cancer are included, a 6,9% 
involved margin rate for BCS after NAC and a 3,3% involved margin rate for primary 
BCS is a reliable baseline for the quality of care in the Netherlands nowadays.
An important result of this nationwide data is that BCS after NAC leads to equal surgical 
outcomes for cT2 and improved outcomes for cT3 invasive breast cancer compared to 
primary BCS. Boughey et al. already described in 2006 using data from 1998 to 2005, 
that NAC reduces the volume of tissue excised in patients with T2 and T3 breast cancer 
treated with BCS, without an increase in rates of reexcision37. Ever since, improvements 
of targeted therapies to achieve a pathologic complete response (pCR) in combination 
with improvements in the identification of the original tumour location have led to more 
BCS after NAC with less involved invasive margins and a lower re-operation rates9-12,22.
Our multivariable analyses detailed important prognostic factors associated with a 
higher risk of involved invasive margins for patients who will receive BCS after NAC: 
lobular invasive breast cancer, an increasing clinical tumour stage and a hormone 
receptor positive receptor status. A decreased feasibility for successful BCS has been 
described in the setting of lobular histology, multicentricity and diffuse calcifications 
noted on preoperative mammography38. And, it is known that HR-positive subtypes are 
associated with the lowest rates of pathological complete response (pCR)30. Another 
interesting assumption made by Landscaper et al. is that cancer subtypes may have 
an independent association with a surgical outcome, reported that triple-negative 
patients not receiving NAC had the lowest reoperation rate. This result correlates 
with our findings that a positive hormone receptor status was clearly associated with 
involved invasive margins for cT3 tumours, with no difference between patients receiv-
ing NAC and patients receiving no NAC. Because larger tumour size and higher grade 
are characteristics commonly reported on triple negative patients and because NAC is 
the standard of care for many of these patients39, this will have contributed to the lower 
rate of involved margins for cT3 invasive breast cancer patients treated with NAC as 
seen in our study. Moreover, it supports the biologic heterogeneity of invasive breast 










Unaddressed issues are recurrence rates and cosmetic outcomes for patients treated 
with BCS after NAC, which we were unable to investigate in this study. A strong as-
sociation of improved long-term outcomes in patients with pCR compared to patients 
with residual invasive tumour at the time of surgery has been consistently reported 
by many groups11,30,40,41. However, the surrogacy of pCR as an endpoint for long-term 
clinical outcome has not been established42. Future analyses of randomized trials of 
targeted agents in homogeneous tumour subtypes will help elucidate whether there is 
a significant association between pCR and long-term outcomes. Cosmetic outcomes 
for NAC followed by BCS have only been reported in retrospectives studies and no 
conclusions can be drawn yet43,44. Several studies do describe a lower resected volume 
in patients treated with neoadjuvant therapy compared to adjuvant therapy, what 
potentially could lead to better cosmetic outcomes and an improved quality of life. 
Although we did not specify resection volumes and cosmetic outcome in this study, 
we emphasize the fact that follow-up on this subject is necessary and of major impact 
in delivering quality care to patients. A poor cosmetic outcome after BCS should be 
avoided at any time. Work has been established to link patient reported outcome 
measurements (PROMS) to clinical data of patients treated with BCS after NAC and 
will eventually show the patients’ satisfaction and long term cosmetic outcomes. This 
information will be of great value empowering patients to be effective advocates for 
their health, and that they can make informed decisions in light of it.
To our knowledge, this is one of the largest studies on a nationwide level demonstrat-
ing a trend of more BCS after NAC in relation to surgical outcomes. However, our 
study is limited by the retrospective nature and incomplete information on tumour 
response after NAC. Also, we were unable to retrospectively determine the percentage 
of patients eligible for BCS at the time of diagnosis.
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CONCLUSION
The increasing implementation of NAC have led to an increase in ‘BCS after NAC’ in 
the Netherlands between 2011 and 2016. Moreover, this nationwide data confirms 
that BCS after NAC results in equal surgical outcomes for cT2 and improved surgical 
outcomes for cT3 invasive breast cancer compared to primary BCS. In view of the 
trend towards de-escalation of surgical treatment in selected patients with excellent 
pathologic response, these promising results confirm that clinicians are increasingly 
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Table A. Clinical-pathological and hospital characteristics of cT1-4M0 breast cancer patients (N=36.475) who have 
received breast conserving surgery with or without chemotherapy upfront (2012-2016).
BCS BCS after NAC
(N=32.305) (N=4170)
Year of incidence <0,005
2012 6118 19% 424 10%
2013 6466 20% 626 15%
2014 6720 21% 836 20%
2015 6368 20% 1086 26%
2016 6633 21% 1198 29%
Age <0,005
<40 617 2% 395 9%
40-50 3308 10% 1307 31%
50-60 8787 27% 1462 35%
60-70 10852 34% 872 21%
70-100 8735 27% 132 3%
Histologic subtype <0,005
Ductal 26920 90% 3633 92%
Lobular 2979 10% 331 8%
DCIS component <0,005
No 16487 51% 2684 64%
Yes 15818 49% 1486 36%
Clinical tumor stage <0,005
cT1 26003 80% 706 17%
cT2 6156 19% 2948 71%
cT3 92 0% 442 11%
cT4 54 0% 74 2%
Clinical nodal stage <0,005
cN0 30678 95% 1976 47%
cN1 1558 5% 1921 46%
cN2 42 0% 80 2%
cN3 26 0% 192 5%
Hormone receptor status <0,005
Triple - 2793 9% 890 22%
HR -, HER2+ 707 2% 338 8%
HR +, HER2+ 2113 7% 610 15%
HR +, HER2- 25000 82% 2237 55%
Type of hospital <0,005
General- 12635 39% 1356 33%
Teaching- 17019 53% 1987 48%
Academic- 2651 8% 827 20%
Hospital surgical volume <0,005
< 150 8635 27% 1043 25%
150-300 12202 38% 1557 37%










Table B. Clinical-pathological and hospital characteristics associated with tumour free margins in cT1-4M0 breast 






Year of incidence 0,823
2012 395 94% 25 6%
2013 567 93% 43 7%
2014 777 94% 52 6%
2015 1004 93% 74 7%
2016 1092 93% 87 7%
Age 0,017
<40 377 96% 14 4%
40-50 1203 93% 86 7%
50-60 1337 93% 108 7%
60-70 791 92% 68 8%
70-100 126 97% 4 3%
Histologic subtype <0,005
Ductal 3419 95% 169 5%
Lobular 239 73% 87 27%
DCIS component 0,606
No 2473 93% 177 7%
Yes 1362 93% 104 7%
Clinical tumor stage <0,005
cT1 672 96% 27 4%
cT2 2731 94% 177 6%
cT3 367 84% 68 16%
cT4 65 88% 9 12%
Clinical nodal stage 0,024
cN0 1837 94% 113 6%
cN1 1752 92% 145 8%
cN2 69 87% 10 13%
cN3 176 93% 13 7%
Hormone receptor status <0,005
Triple - 865 98% 16 2%
HR -, HER2+ 333 99% 3 1%
HR +, HER2+ 590 98% 15 2%
HR +, HER2- 1958 89% 244 11%
Type of hospital <0,005
General- 1242 93% 90 7%
Teaching- 1855 94% 113 6%
Academic- 738 90% 78 10%
Hospital surgical volume 0,672
< 150 950 93% 74 7%
150-300 1438 94% 98 6%
> 300 1440 93% 108 7%
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ABSTRACT
Objectives: To evaluate patterns of care in axillary surgery for Dutch clinical T1-4N0M0 
(cT1-4N0M0) breast cancer patients and to assess the effect of the American College 
for Surgeons Oncology Group (ACOSOG)-Z0011 and After Mapping of the Axilla: Ra-
diotherapy Or Surgery (AMAROS) trial on axillary surgery patterns in Dutch cT1-2N0M0 
sentinel node positive breast cancer patients.
Background: Since publication of the ACOSOG-Z0011 and AMAROS trial, omitting 
a completion axillary lymph node dissection (cALND) in sentinel node positive breast 
cancer patients is proposed in selected patients.
Methods: Data were obtained from the nationwide Nationaal Borstkanker Overleg 
Nederland breast cancer audit. Descriptive analyses were used to demonstrate trends 
in axillary surgery. Multivariable logistic regression analyses were used to identify 
factors associated with the omission of cALND in cT1-2N0M0 sentinel node-positive 
breast cancer patients.
Results: Between 2011 and 2015 in cT1-4N0M0 breast cancer patients, the use of 
sentinel lymph node biopsy as definitive axillary staging increased from 72% to 93%, 
and (c)ALND as definitive axillary staging decreased from 24% to 6% (P<0.001). The 
use of cALND decreased from 75% to 17% in cT1-2N0 sentinel node-positive patients 
(P<0.001). Earlier year of diagnosis, lower age, primary mastectomy, invasive lobular 
subtype, increasing tumor grade, and treatment in a nonteaching hospital were associ-
ated with a lower probability of omitting cALND (P<0.001).
Conclusions: This study shows a trend towards less extensive axillary surgery in Dutch 
cT1-T4N0M0 breast cancer patients; illustrated by an overall increase of sentinel 
lymph node biopsy and decrease in cALND. Despite this trend, particularly noticed in 
cT1-2N0 sentinel node-positive patients after publication of the ACOSOG-Z0011 and 








Axillary lymph node management in breast cancer patients has changed dramatically 
during past decades.1 Previously, performing an axillary lymph node dissection (ALND) 
was the standard of care for all nonmetastatic breast cancer patients. In the early 90s, 
sentinel lymph node biopsy (SLNB) was introduced as an accurate and less invasive 
axillary staging procedure, omitting the need for ALND in cT1-2N0M0 sentinel lymph 
node-negative breast cancer patients.2,3 Despite, only small studies investigated ac-
curacy of SLNB in cT3 sentinel lymph node-negative breast cancer patients, SLNB is 
also widely used in this group of patients.4,5 In the early years after the introduction of 
SLNB, a completion ALND (cALND) was indicated in all patients with a positive sentinel 
lymph node.6
The additional value of cALND was first questioned in 2 randomized controlled tri-
als—the American College for Surgeons Oncology Group (ACOSOG)-Z0011 trial and 
the After Mapping of the Axilla: Radiotherapy Or Surgery (AMAROS) trial.7,8 In the 
ACOSOG-Z0011 (accrual 1999–2004, published 2011), cT1- 2N0M0 breast cancer 
patients with 1 to 2 positive sentinel lymph nodes treated with breast-conserving 
therapy followed by whole breast radiotherapy were randomized between a cALND 
or no further axillary treatment.7 Ten years cumulative incidence of ipsilateral axillary 
recurrences was 0.5% in the ALND group and 1.5% in the SLNB-alone group, with no 
significant difference in locoregional recurrence-free survival.9
The AMAROS trial (accrual 2001–2010, published 2014) evaluated whether regional 
control was comparable between cALND and axillary radiation therapy in cT1-2N0M0 
breast cancer patients with 1 to 2 (and 5% >2) positive sentinel lymph nodes, treated 
with breast-conserving therapy, including whole breast radiotherapy or mastectomy 
with or without radiotherapy to the chest wall. There was no significant difference in 
the 5-year axillary recurrence rate between patients treated with cALND or axillary 
radiotherapy; 0.43% versus 1.19%. Axillary radiotherapy was associated with signifi-
cantly less morbidity.8 The AMAROS results indicated that in case of a positive sentinel 
node, both cALND and axillary radiotherapy provide excellent and comparable axillary 
control disease-free and overall survival for patients with cT1-2N0M0 primary breast 
cancer.
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The first presentation of results of the ACOSOG-Z0011 in 2011 generated great de-
bate under physicians. Some argued that the results should be considered unreliable 
since patients’ accrual was discontinued before the foreseen number of patients was 
included. In addition, questions were raised regarding the selection of a favorable 
subgroup of patients; not all patients were treated with whole-breast radiotherapy as 
planned and lack of consistent documentation of radiation fields.10–14 The safety of 
omitting cALND in sentinel node-positive breast cancer patients was questioned and 
resulted in hesitations to implement axillary lymph node-conserving treatment. This is 
illustrated by the 2012 Dutch Breast Cancer Guideline, merely suggesting omission of 
cALND in cT1-2N0M0 breast cancer patients with a maximum of 2 positive sentinel 
nodes treated with breast-conserving treatment and adjuvant systemic therapy. Based 
on previous literature and preliminary experience with the AMAROS trial, this guideline 
also suggested that axillary irradiation could serve as an alternative to cALND in sentinel 
node-positive patients for whom treatment of the axillary was considered necessary.15
The first aim of this study was to demonstrate patterns of care in axillary surgery for 
all Dutch cT1-4N0M0 breast cancer patients diagnosed between 2011 and 2015. The 
second aim was to evaluate the effects of the ACOSOG Z0011 and AMAROS trials 
in Dutch daily clinical practice. Furthermore, this study identified patient, tumor, and 
hospital-related factors associated with axillary surgery in cT1-2N0M0 sentinel node-








Data were obtained from the Dutch Nationaal Borstkanker Overleg Nederland Breast 
Cancer Audit (NBCA). The NBCA is a multidisciplinary nationwide registry of all di-
agnostic and treatment modalities of patients who are surgically treated for breast 
cancer in the Netherlands since 2011. It is facilitated by the Comprehensive Cancer 
Center Netherlands (IKNL) and the Dutch Institute for Clinical Auditing (DICA). Data are 
registered directly by the hospital itself or by IKNL data managers. The quality of the 
Dutch Cancer registry is high and data completeness is estimated to be at least 95%.16
Patients and Hospitals
The current study sample consisted of Dutch patients diagnosed with cT1-4N0M0 
invasive breast cancer between January 2011 and October 2015. Patients with the 
following criteria were excluded: <18 years of age, those who received neoadjuvant 
systemic therapy, had any prior surgery of the breast or those of whom information on 
the axillary surgery was indistinct. Data from 85 different Dutch hospitals (9 academic, 
38 teaching, and 38 general nonteaching hospitals) were included. Not every hospital 
is represented in each year due to mergers or acquisitions, resulting in 82 entities in 
2011 versus 71 entities in 2015.
Construction of Variables
Hospitals were divided into groups according to their teaching status (general non-
teaching, teaching, academic) and surgical hospital volume. Teaching and academic 
hospitals both provide in-house surgical training to residents, with distinction that aca-
demic hospitals are directly connected with a medical faculty of a university. Specialized 
oncologic hospitals were classified as academic hospitals. Hospital volume was defined 
as the number of patients who underwent breast cancer surgery per year. Hospitals 
were divided into low volume (<150 resections), middle volume (150–300 resections), 
and high volume (>300 resections) on average per year. The cut-off points chosen were 
based on those reported in a publication of Eusoma, the European Society of Breast 
Cancer Specialist,17 and those reported in an article from Greenup et al.18 A positive 
sentinel node included micrometastases and macrometastases; isolated tumor cells 
were considered as sentinel node-negative.
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Since the NBCA did not register the radiation fields, we could not describe whether 
or not a patient received radiotherapy on the breast (partial or whole) and/or axilla 
and/or other regions. Furthermore, we did not have access to information on adjuvant 
hormonal therapy in all patients.
Statistical Analyses
Descriptive analyses were used to report on the trends in axillary surgery for all cT1-
4N0M0 breast cancer patients. The outcome of interest was the definitive surgical 
axillary treatment and was divided into 4 groups: no surgical nodal staging; SLNB–
negative; SLNB-positive, no cALND; (c)ALND. The fourth group consisted of patients 
who were treated with SLNB followed by cALND, and of patients treated with ALND 
directly.
Univariable and multivariable logistic regression analyses were used to determine the 
probability to omit a cALND in selected cT1-2N0M0 sentinel node-positive breast can-
cer patients. A P value of <0.05 was considered statistically significant. Data analysis 









In all, 44,902 patients were diagnosed with cT1-4N0M0 invasive breast cancer between 
January 2011 and October 2015, and registered in the NBCA. Exclusion of patients 
<18 years of age (n=14), those who received neoadjuvant systemic therapy (n=3333), 
had any prior surgery of the breast (n=4014), or those of whom information on the 
axillary surgery was indistinct (n=21), resulted in a study population of 37,520 patients 
(see flowchart of exclusion criteria, supplement). Median age was 63 years (19-98); 
5335 patients (12%) were older than 75 years. Most of the patients were diagnosed 
with a cT1 tumor (72%, n=27,066), whereas 26% of the patients were diagnosed with a 
cT2 tumor (n=9575), 2% with a cT3 tumor (n=743), and 0.4% with a cT4 tumor (n=136) 
(see supplemental Table A, which demonstrates the clinical-pathological and hospital 
characteristics of all cT1-4N0M0 patients [n= 37,520] and percentages of an ALND).
Trends in Axillary Surgery in cT1-4N0M0 Breast Cancer Patients
In 2011, 92% of all cT1-4N0M0 breast cancer patients were staged using SLNB, in-
creasing to 98% in 2015. According to the tumor stage the use of SLNB increased from 
93% to 98% in cT1 tumors, from 92% to 98% in cT2 tumors, from 68% to 88% in cT3 














Figure 1. Trend in percentages of sentinel lymph node biopsy (SLNB) in cT1-4N0M0 breast cancer patients in the 
Netherlands from 2011 to 2015 according to clinical tumor (cT) stage.
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In case of a positive SLNB within the group of cT1-4N0M0 breast cancer patients 
(n=8539), the use of a cALND decreased between 2011 and 2015. As shown in Fig. 
2, this decline was noticed in all clinical tumor stages of disease: from 74% to 13% for 
cT1 (n=5159) tumors and 77% to 23% for cT2 tumors (n=3032). Of note, also in cT3 
and cT4 tumors, a decreasing trend was observed in the use of a cALND: from 88% to 
27% in cT3 tumors (n=307) and from 50% to 17% in cT4 tumors (n=41), respectively.
Figure 3 shows the percentage of patients according to their definitive axillary staging 
in the period 2011 to 2015. Hence, these are percentages of the complete group of 
patients diagnosed with cT1-4N0M0 invasive breast cancer (n=37,520) divided into the 
following groups: no axillary staging (n=954), SLNB (negative = 27,200 or positive = 
5154) without an ALND and (c)ALND (n=4572). Obviously, the proportion of patients 
with a positive SLNB as definitive axillary staging procedure increased from 6% (n=282) 
in 2011 to 18% (n=1411) in 2015 (P < 0.001). In these cT1-4N0M0 sentinel node-
positive breast cancer patients, a cALND was omitted.
Rarely, in a proportion of patients with a negative SLNB (n= 27,526), a cALND was 
performed (1%, n=326). This percentage remained unchanged over the years and 














Figure 2. Trend in percentages of complementary axillary lymph node dissection (cALND) in cT1-4N0M0 sentinel 







all 37,520 (2.3%) cT1-4N0M0 breast cancer patients received ALND directly, without 
previous axillary staging. Overall, percentages of SLNB as defi nitive axillary staging 
increased from 72% in 2011 to 93% in 2015, and percentages of (c)ALND as defi nitive 
axillary staging declined from 24% in 2011 to 6% in 2015 (P<0.001).
Trends in Axillary Surgery in cT1-2N0M0 Sentinel Node-positive Breast 
Cancer Patients
A subgroup analysis was performed in cT1-2N0M0 breast cancer patients with 1 to 2 
(and 1.8% >2) positive sentinel lymph nodes; a group comparable with the ACOSOG-
Z0011 and AMAROS trial population. A total of 8191 out of 36,641 cT1-2N0M0 patients 
were sentinel node-positive with a median age of 60 years (22–96).
The clinical, pathological, and hospital characteristics of this population are shown in 
Table 1. Most of these patients underwent breastconserving surgery (61%, n=4959) 
and were classifi ed with a ductal, unifocal, hormone receptor-positive, and human 
epidermal growth receptor (HER)2-negative breast tumor. The majority (84%, n=5939) 
of the cT1-2N0M0 sentinel node-positive patients received radiotherapy on any region 
and 62% (n=4646) of the patients received adjuvant chemotherapy.
 
SLNB posi�ve ALNDNo surgical nodal staging SLNB nega�ve
2012 2013 2014 20152011
Figure 3. Trends in the defi nitive axillary staging in cT1-4N0M0 breast cancer patients in the Netherlands from 2011 
to 2015.
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Table 1. Clinical- pathological and hospital characteristics of cT1-2N0M0 sentinel node positive patients (N=8191) 
and percentages of complementary axillary lymph node dissection (cALND), 2011 -2015.
N cALND p-Value
Incidence year
2011 1111 833 75% <0.001
2012 1815 947 52%
2013 1905 723 38%
2014 1730 430 25%
2015 1630 276 17%
Age
<40 326 183 56% <0.001
40-50 1309 624 48%
50-75 5394 2035 38%
75+ 1162 367 32%
Histologic subtype
ductal 7112 2721 38% <0.001
lobular 1079 488 45%
Clinical tumor stage
cT1 5159 1807 35% <0.001
cT2 3032 1402 46%
Multifocality
unifocal 6893 2583 37% <0.001
multifocal 1298 626 48%
Receptor status
triple - 456 225 49% <0.001
HR -, Her2+ 212 102 48%
HR+, Her2+ 650 267 41%
HR+, Her2- 6361 2374 37%
unknown 512 241 47%
Grade
I 1753 586 33% <0.001
II 4217 1634 39%
III 2101 933 44%
unknown 120 56 47%
Initial surgery
mastectomy 3232 1691 52% <0.001
breast conserving treatment (BCT) 4959 1518 31%
Radiotherapy (on any region)
no 1138 672 59% <0.001
yes 5939 1760 30%







As shown in Table 1, within this subgroup of cT1-2N0M0 sentinel node-positive pa-
tients, the performance of a cALND decreased from 75% in 2011 (ACOZOG-Z0011 
published), to 25% in 2014 (AMOROS published) and 17% in 2015. In cT1-2N0M0 
sentinel node-positive breast cancer patients, younger patients were more likely to 
receive a cALND. Over time, the rate of cALND for patients aged <40 decreased from 
89.6% in 2011 to 61.8%, 47.0%, 37.7%, and 39.6% in 2012, 2013, 2014, and 2015, 
respectively. The rate of cALND for patients aged 50 to 75 decreased from 76.4% in 
2011 to 51.1%, 37.1%, 23.3%, and 15.9% in 2012, 2013, 2014, and 2015, respectively.
Regarding the receptor status, triple negative patients had a higher probability in 
receiving cALND. Over time, the rate of cALND in triple negative patients declined 
from 79.0% in 2011 to 56.6%, 50.0%, 33.7%, and 25.3%in 2012, 2013, 2014, and 2015, 
respectively.
In case of breast-conserving therapy, a cALND was omitted more often (69%) com-
pared with mastectomy (48%) (P<0.001). Figure 4 shows the type of primary surgery of 
cT1-2N0M0 sentinel node-positive patients treated with a cALND from 2011 to 2015. 
The proportion of patients receiving cALND declined for both types of surgery over the 




no 2937 781 27% <0.001
yes 4646 2135 46%
unknown 607 293 48%
Type of hospital
general non-teaching 2993 1353 45% <0.001
teaching hospital 4582 1684 37%
academic 616 172 28%
Hospital surgical volume
<150 2450 1076 44% <0.001
150-300 3060 1113 36%
>300 1988 732 37%
unknown 693 288 42%
cALND complementary axillary lymph node dissection, cT clinical tumor, HR hormone receptor, Her2 human epider-
mal growth receptor 2
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Prognostic Factors Omitting a cALND in cT1- 2N0M0 Sentinel Node-
positive Patients
A multivariable logistic regression analysis was used to determine independent predic-
tors in omitting cALND (Table 2). Apart from an earlier year of diagnosis, lower age 
and patients being treated with mastectomy, also invasive lobular subtype, increasing 
tumor grade and being treated in a general nonteaching hospital were independently 
associated with a lower probability in omitting cALND (all P<0.001). Hospital surgical 
volume and receptor status were not independently associated with omitting cALND 
in multivariable analysis.
Table 2. Univariable and multivariable analyses for the performance of complementary axillary lymph node dissec-
tion (cALND) among cT1-2N0M0 sentinel node positive patients (N=8191), 2011 -2015.
Univariable Multivariable
Odds CI Interval p-Value Odds CI Interval p-Value
Incidence year
2011 ref. <0.001 ref. <0.001
2012 0,364 (0,309 - 0,429) 0,359 (0,297 - 0,435)
2013 0,204 (0,173 - 0,241) 0,206 (0,17 - 0,249)
2014 0,111 (0,093 - 0,132) 0,092 (0,075 - 0,113)
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Figure 4. Percentages of cT1-2N0M0 sentinel node positive breast cancer patients in which a complementary axillary 









Odds CI Interval p-Value Odds CI Interval p-Value
Age
<40 ref. <0.001 ref. <0.001
40-50 0,712 (0,564 - 0,918) 0,723 (0,535 - 0,976
50-75 0,473 (0,383 - 0,602) 0,638 (0,482 - 0,845)
75+ 0,361 (0,284 - 0,464) 0,297 (0,216 - 0,407)
Histologic subtype
ductal ref. <0.001 ref. 0,023
lobular 1,33 (1,171 - 1,516) 1,214 (1,027 - 1,433)
Clinical tumor stage
cT1 ref. <0.001 ref. <0.001
cT2 1,596 (1,456 - 1,748) 1,303 (1,156 - 1,469)
Multifocality
unifocal ref. <0.001 ref. 0,035
multifocal 1,554 (1,38 - 1,751) 1,18 (1,012 - 1,377)
Receptor status
triple - ref. <0.001 ref. 0,185
HR -, Her2+ 0,952 (0,687 - 1,319) 0,822 (0,557 - 1,213)
HR+, Her2+ 0,716 (0,562 - 0,911) 0,732 (0,548 - 0,978)
HR+, Her2- 0,611 (0,505 - 0,74) 0,786 (0,617 - 1,001)
Grade
I ref. <0.001 ref. 0,012
II 1,968 (1,863 - 2,078) 1,052 (0,91 - 1,216)
III 2,567 (2,425 - 2,717) 1,271 (1,068 - 1,513)
Initial surgery
mastectomy ref. <0.001 ref. <0.001
nreast conserving treatment(BCT) 0,402 (0,367 - 0,441) 0,335 (0,295 - 0,381)
Type of hospital
general non-teaching ref. <0.001 ref. <0.001
teaching hospital 0,704 (0,641 - 0,774) 0,664 (0,566 - 0,779)
academic 0,47 (0,388 - 0,568) 0,335 (0,263 - 0,426)
Hospital surgical volume
<150 ref. <0.001 ref. 0,327
150-300 0,913 (0,876 - 0,953) 1,125 (0,963 - 1,315)
>300 0,861 (0,822 - 0,903) 1,113 (0,926 - 1,337)
CI confidence interval, Ref reference, cT clinical tumor, HR hormone receptor, Her2 human epidermal growth receptor 2
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DISCUSSION
This study showed a trend towards less extensive axillary surgery in Dutch cT1-T4N0M0 
breast cancer patients in the ACOSOG-Z0011 and AMAROS era. Particularly in cT1-
T2N0M0 sentinel node-positive invasive breast cancer patients, the performance of a 
cALND decreased from 75% in 2011 to 17% in 2015. The downward trend observed 
in the use of cALND in cT1- 2N0 sentinel node-positive breast cancer patients reflects 
the implementation of the study concept of the ACOSOG-Z0011 and AMAROS trials 
in the Netherlands. In these patients, axillary surgery varied between patients treated 
with breast-conserving therapy and mastectomy. In 2011, the percentage of patients 
without a cALND was higher in the breast-conserving therapy group (28%) compared 
with the mastectomy group (21%). Only a small percentage of patients (0% in the 
ACOSOG-Z0011 and 18% in the AMAROS trial) were treated with mastectomy, which 
could be a reason why omitting cALND in mastectomy patients was less likely adopted 
by surgeons.
As expected, due to the presentation of the results of the ACOSOG-Z0011 trial, a re-
duction in the number of cALND performed in patients treated with breast-conserving 
therapy was observed. While the results of the AMAROS trial were presented in 2014, a 
reduction in the percentage of cALND in patients treated with mastectomy was already 
observed in 2013. This may reflect the confidence of physicians in the concept that not 
every positive axillary sentinel lymph node will develop into clinical detectable axillary 
disease.7,19
In some patients, physicians were still reluctant to omit cALND. As reported in this 
study, the probability of omitting cALND decreased when patients were younger (<40 
years), were treated in a general nonteaching hospital, or had more aggressive tumor 
biology. The relation of younger age (<40 years) to higher cALND rates may reflect the 
hypothesis that treatment of the axilla should be more aggressive in younger patients 
to optimize overall survival. However, the prognostic relevance of young age on the 
occurrence of regional recurrences is controversial.20–22 Physicians may extrapolate the 
higher risk of young patients to develop a local recurrence to the regional recurrence 








On the contrary, the ACOSOG-Z0011 10-year follow-up data showed that the number 
of regional recurrence is very low in both the ALND group (0.5%) and the SLNB-only 
group (1.5%), and no association of young age (<50 years) with loco-regional recur-
rences was observed.9 Hence, it does not seem justified to be reluctant to omit a 
cALND based only on the age of the patient. This study reported that triple nega-
tive breast cancer patients with a positive SLNB were more likely to receive a cALND 
compared with hormone receptor-positive patients. This practice may be based on 
the criticism that in the ACOSOG-Z0011, only small numbers of patients with triple 
negative breast cancer were included and thus the results were not applicable for triple 
negative patients.26,27 However, several studies do not support such an aggressive ap-
proach. Firstly, van Roozendaal et al questioned in their study whether triple negative 
patients with a clinically T1-2N0 status were more at risk for regional recurrences. Their 
5-year follow-up showed a regional and distant recurrence rate of 2.9% and 12.2%, 
respectively. It was concluded in this study that triple negative tumors rarely recur 
regionally and that their disease-free survival was more threatened by distant recur-
rence.28 Secondly, being at high risk to develop distant metastasis does not necessarily 
mean being at high risk for axillary nodal recurrence.26 Thirdly, a recent follow-up study 
on the ACOSOG-Z0011 eligible patients was publicized. It was reported that after a 
median follow-up of 31 months, high-risk patients (ie, triple negative tumors, HER2-
positive tumors, and age <50 years) compared with average-risk patients had the same 
risk of regional recurrence, but a higher risk of developing distant metastasis.27 Hence, 
although longer follow-up data are preferable, it does not seem justifiable to perform 
a cALND based on receptor status only.
We evaluated a significant variation in omitting cALND between different types of 
hospitals, revealing the presence of early and late adopters. While the first hospitals 
started omitting cALND in 2011, other hospitals still performed this procedure in 2015, 
as has been reported by other authors.29–31 van Steenbergen et al29 evaluated in 2010 
the implementation of SLNB in the Netherlands and showed that general nonteach-
ing hospitals were late adopters of the SLNB procedure by performing ALND more 
frequently than other hospitals. This variation might be explained by the degree of 
dedication of the multidisciplinary breast cancer treatment teams within a hospital or 
whether a radiotherapy center was located nearby the treating hospital. Within the 
current study, there was no information about these possible influencing factors which 
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should be evaluated in future studies. This variation is not favorable, but unfortunately 
the implementation process following the presentation of evidence-based studies and 
guidelines is seldom monitored and reasons for nonadherence are largely unknown.
Another notable pattern of care was the downward trend of cALND in cT3-4N0M0 
sentinel node-positive breast cancer patients, which was in line with the decreasing 
trend in cT1-2N0M0 sentinel node-positive breast cancer patients. No randomized 
trials have been published to justify less extensive axillary surgery in cT3-4N0M0 sen-
tinel node-positive breast cancer patients. Nonetheless, the decreasing trend in the 
numbers of cALNDs performed in all tumor stadia might reflect the growing argument 
for less extensive surgery in the axilla of breast cancer patients.
In addition, this study revealed an increase in the use of SLNB, especially in cT3 and 
cT4 patients, from 68% to 87% and 29% to 70%, respectively. This increasing trend 
in the use of SLNB for nodal staging in breast cancer patients reflects the growing 
confidence in the concept of this procedure, even in patients with T3 and T4 tumors. 
The accuracy in performing SLNB in cT3 tumors seems to be comparable to T1 and 
T2 tumors according to the available literature. Although, the evidence supporting this 
practice is debatable, since only small studies were published.4,5 No conclusive data 
are available on the accuracy of SLNB in cT4N0M0 breast cancer patients.
To our knowledge, this is the largest study demonstrating patterns of care of axillary 
surgery in breast cancer patients. It shows that trial results of the ACOSOG-Z0011 and 
AMAROS were progressively implemented in axillary treatment plans of breast cancer 
patients nowadays. Our study is limited by its retrospective nature and by incomplete 
information on radiation therapy and fields. Therefore, we could not explore the poten-
tial effect of radiation on the axilla. These considerations should be taken into account 
when discussing axillary treatment options. Excluding neoadjuvant treated patients 
could result in biased underuse of cALND through the omission of high-stage breast 
cancer patients who underwent neoadjuvant treatment. Despite the discussion on both 
trials, we observed a notable early adoption and increasing trend in omitting the use of 
cALND in sentinel nodepositive cT1-2N0M0 breast cancer patients, both treated with 








This study shows a trend towards less extensive axillary surgery in Dutch cT1-T4N0M0 
breast cancer patients, illustrated by an overall increase of SLNB and decrease in 
cALND. Despite this decreasing trend particularly noticed in cT1-2N0M0 sentinel 
nodepositive patients after the presentation of the ACOSOG-Z0011 and AMAROS 
trial, hospital-related variation in axillary surgery is still present. This emphasizes the 
need for a uniform implementation strategy after the publication of national guidelines 
which includes an education program for surgeons and patients, to minimize variations 
in patterns of care in oncologic breast cancer surgery.
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Table A. Clinical- pathological and hospital characteristics of all cT1-4N0M0 patients (N=37520) and percentages of 
an axillary lymph node dissection (ALND), 2011 -2015.
N ALND p-Value
Incidence year
2011 4663 1100 24% <0.001
2012 8097 1346 17%
2013 8507 1029 12%
2014 8362 653 8%
2015 7891 444 6%
Age
<40 1135 227 20% <0.001
40-50 4615 806 17%
50-75 26435 2770 10%
75+ 5335 769 14%
Histologic subtype
ductal 32804 3793 12% <0.001
lobular 4716 779 17%
Clinical tumor stage
cT1 27066 2367 9% <0.001
cT2 9575 1866 19%
cT3 743 284 38%
cT4 136 55 40%
Multifocality
unifocal 32919 3564 11% <0.001
multifocal 4601 1008 22%
Receptor status
triple - 3323 376 11% <0.001
HR -, Her2+ 1024 160 16%
HR+, Her2+ 2686 356 13%
HR+, Her2- 28159 3320 12%
unknown 2328 360 15%
Grade
I 9797 818 8% <0.001
II 17528 2298 13%
III 9289 1369 15%
unknown 904 87 10%
Initial surgery
mastectomy 11961 2719 23% <0.001
breast conserving treatment (BCT) 25559 1853 7%
Radiotherapy on any region
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Figure A. Flowchart of exclusion criteria.
Excl exclusion, SN sentinel node, ALND axillary lymph node dissection
Table A. (continued)
N ALND p-Value
yes 26566 2373 9%
unknown 3419 846 25%
Adjuvant chemotherapy
no 20958 1412 7% <0.001
yes 12317 2670 22%
unknown 4242 490 12%
Type of hospital
general non-teaching 13393 1971 15% <0.001
teaching 21208 2372 11%
academic 2919 229 8%
Hospital surgical volume
<150 11384 1584 14% <0.001
150-300 13745 1606 12%
>300 9175 989 11%
unknown 3216 393 12%
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How to improve patient safety and quality of care in breast implant 














Background: Although the use of breast implants is generally considered to be safe, 
breast implants are associated with short- and long-term complications. To evaluate 
and improve the quality of breast implant surgery, and increase our knowledge of im-
plant performance, the national Dutch Breast Implant Registry (DBIR) was established 
in 2015. DBIR is one of the first up-and-running breast implant registries worldwide and 
follows an opt-out structure.
Objective: This article provides an overview of the first outcomes and experiences of 
the DBIR.
Methods: The national coverage of DBIR was studied, using data from the Dutch 
Health and Youth Care Inspectorate. For 2016 and 2017 the incidence rate of breast 
implants was calculated, and patient, device, and surgery characteristics were com-
pared between cosmetic breast augmentations or reconstructive indications. Four 
infection control measures were selected to demonstrate the variation in the Dutch 
clinical practice.
Results: In 2016, 95% of the hospitals and 78% of the private clinics participated in 
DBIR. Between 2015 and 2017, a total of 15,049 patients and 30,541 breast implants 
were included. A minimum breast implant incidence rate of 1 woman per 1,691 women 
could be determined for 2017. The majority of devices was inserted for a cosmetic 
indication (85.2%). In general, patient, device, and surgery characteristics differed per 
indication group. Substantial variation was seen in the use of infection control measures 
(range 0-100%).
Conclusion: Preliminary results obtained from DBIR show high national participation 
rates and support further developments towards the improvement of breast implant 










Since the introduction of breast implant surgery approximately six decades ago, 
numerous studies have evaluated the health effects and safety of breast implants.1 
These studies suggested that breast implants are to be considered safe. Nonetheless, 
a variety of surgical complications may occur following breast implant surgery, such as 
infection, implant rupture or deflation, late seroma, and capsular contracture.2,3,4
Recently, an association between Anaplastic Large Cell Lymphoma (ALCL) of the breast 
has been found.5,6,7 Furthermore, the debate on possible associations between silicone 
exposure and various autoimmune diseases or connective tissue diseases continues 
(e.g., ASIA, an autoimmune/inflammatory syndrome induced by adjuvants).8,9,10,11,12 
Therefore, the outcomes of ‘real world’ data are becoming of increasing scientific and 
clinical importance to assess the effect of various intraoperative techniques and the 
use of different types of breast implants, while controlling for confounding factors 
adequately.13,14
In response to this, several countries have developed breast devices registries, among 
which the Dutch Breast Implant Registry (DBIR).15,16,17,18,19,20 In April 2015, the DBIR 
started to register all patients undergoing breast implant surgery in the Netherlands 
(both implantations and explantations).21 Currently, the audit provides hospitals and 
private clinics with weekly updated, benchmarked information on their performance. 
Additionally, the registry can be used as a track-and-trace system in case of an implant 
recall and identify patients who have the implant(s) of interest. DBIR follows an opt-out 
construct, which is unique compared to other breast implants registries worldwide.
Recent research has shown that the estimated prevalence of women with breast 
implants was 3,3% in the Netherlands in 2015.5 However, incidence rates and further 
details on surgery techniques used, types of inserted devices, and national trends are 
not known yet. By using data of the DBIR, this study aims to provide more insight 
into the patient characteristics of women undergoing breast implant surgery in the 






The Dutch Breast Implant Registry (DBIR), founded in 2014, was an initiative of the 
Netherlands Society for Plastic Surgery (NVPC).22 It provides an audit system for plastic 
surgeons on outcomes of breast implant surgery and serves as a track-and-trace system 
for breast implants. More information on the establishment, organization, and funding 
of the registry can be found in the paper of Rakhorst et al. and the annual report.21,23
Quality indicators
The primary purpose of the DBIR is to provide healthcare providers with reliable, bench-
marked information on structure, process and outcome parameters. These quantitative 
measures cover different aspects of breast implant surgery: patient characteristics, 
information about intraoperative techniques, and short- and long-term outcomes of 
implants. A first set of quality indicators was defined by the DBIR group and external 
stakeholders (e.g., Dutch Health and Youth Care Inspectorate (IGJ), healthcare insur-
ance companies, the Federation of hospitals, and patient advocates). For 2018, three 
quality indicators will be made publically transparent for all hospitals and private clinics 
performing breast implant surgery in the Netherlands: (1) Participation in the registry, 
(2) Percentage of registered breast implants compared to the actual inserted/explanted 
devices, and (3) Percentage of completely registered records.
Data collection
Registration in the DBIR is done using an internet-based program and data are stored 
at a central server.24 The dataset consists of four levels: (1) General patient information 
(e.g. anonymized patient identification number, age), (2) Patient characteristics during 
surgery (e.g. date of surgery, ASA classification, smoking, Body Mass Index (BMI), (3) 
Surgery techniques on breast level (e.g. indication, incision site, flap cover, or when 
applicable the indication for revision), and (4) Implant characteristics (e.g. manufacturer, 









Data verification and participation rate
The quality of the DBIR database is evaluated on three levels: (1) National coverage: 
the participation of all Dutch hospitals and private clinics participating in breast implant 
surgery, (2) Completeness: the number of registered procedures versus the actual 
number of procedures performed at each center, and (3) Validity: the quality of the 
data compared to the electronic patient records in the hospitals.
In this study, the national coverage was assessed by comparing the number of institu-
tions in DBIR to the number of eligible institutions known by the Dutch Health and 
Youth Care Inspectorate (IGJ).
No gold standard is known for the evaluation of completeness of the DBIR yet. By 
now, data from the industry is far from complete, and national insurance data does not 




Per record (i.e., breast), information on the date of birth, date of surgery, type of surgery 
(insertion/ replacement/explantation only), and device type was minimally required to 
be eligible for analysis. The minimum incidence rate was calculated using the total num-
ber of women between 20 and 80 years of age in the Netherlands, in 2016 and 2017.25
For further analysis, all patients who had received a breast implant from the start of 
the DBIR on April, 1st 2015 until the end of the second complete registration year 
at December, 31st 2017, with a known indication (either reconstructive or cosmetic), 
were included. Patients who had received a tissue expander were excluded from the 
analysis. The population was divided into two cohorts: cosmetic and reconstructive. 
The cosmetic group included all patients with a breast augmentation. The reconstruc-
tive group included all patients with the following indication: reconstruction post 
(prophylactic) mastectomy, reconstruction for a benign condition or reconstruction for 
a congenital deformity. To identify differences between hospital/clinics, and to identify 
where improvement can be made, four examples of used infection control measures 
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were selected: glove change prior to implant handling, antiseptic rinse before inser-
tion, the use of postoperative drains, and the use of prophylactic antibiotics.
Analyses
Differences in patient characteristics, device characteristics, and surgical techniques 
are described using percentages, means, and medians (depending on the distribution). 
Records with a missing indication (either cosmetic or reconstructive) are presented 
separately. Categorical variables were analyzed using the chi-square test, and continu-
ous variables were analyzed using Student’s t-test. Nationwide variation in the use of 
the four selected operative techniques was calculated in percentages per hospital per 
year and is visualized by scatterplots including the national mean. All analyses were 
performed using SPSS version 24.0 (SPSS Inc Chicago, IL, USA).
RESULTS
Nationwide participation rate DBIR
In the first full registration year (2016), 101 institutions were included in DBIR, of which 
73 hospitals and 28 private clinics. This means coverage of 95% of the hospitals, and 
78% of the private clinics when compared to the number of the eligible institutions 
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Figure 1. Nationwide participation rate DBIR (2016)









Patients and minimum breast implantation incidence rates
In total, 48,493 records (i.e., breasts) have been registered with an operation date 
between the start of DBIR on April 1st, 2015 and December 31st, 2017, of which 48,026 
(99.0%) were eligible for analysis (Supplementary Figure 1). Of these, 41,919 were 
registered for the insertion of a breast implant. In 2016, 7,528 women received one 
or more permanent breast implant(s), accounting for a minimum incidence rate of one 
woman per 1,649 women. In 2017, the minimum incidence rate was one per 1,691 
women (number of insertions: 7,391).
For further analysis, the indication for surgery needed to be known (either reconstruc-
tive or cosmetic). Therefore, 11,378 of the 41,919 records (27.1%) were excluded 
(36.8% in 2015, 32.8% in 2016, 15.1% in 2017). Eventually, 15,049 unique patients, 
16,574 surgical procedures, and 30,541 breasts were included (Figure 2).
Patient characteristics
Patient characteristics per unique surgical procedure are presented in Table 1. In 
general, patients who had undergone a cosmetic breast augmentation were younger 
and had a lower ASA score compared with patients who received a breast reconstruc-
tion (all p’s <0.001). Information on smoking and Body Mass Index (BMI) has been 
collected since September 2017. However, this information was missing in more than 
5% of the records for both indications. Supplementary Table 1a contains all patient 
characteristics of the records in which no indication was specified.
Device characteristics
Between April 2015 and December 2017, 26,036 (85.2%) breast implants were inserted 
for a cosmetic breast augmentation, and 4,505 (14.8%) for a breast reconstruction. In 
both cosmetic and reconstructive indications, most devices had a textured shell (93.1% 
and 92.5%, respectively) with a silicone coating (96.3% and 91.6%, respectively), and 
with silicone filling (97.2% and 82.6%, respectively). Implants used in reconstructive in-
dications were more often anatomically shaped instead of round (86.0% versus 30.6%, 
p <0.001). The median volume of inserted implants was higher in the reconstructive 
group (415cc, IQR 325-520) compared to the cosmetic group (350cc, IQR 300-405; p 
<0.001).
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Between 2016 and 2017, a decrease in the use of textured implants was seen for both 
indication groups (cosmetic: 96% to 89%, p < 0.001; reconstructive: 94% to 92%, p = 
0.04) (Figure 3). A similar trend was observed for the use of silicone coated devices 
(cosmetic: 98% to 95%, p < 0.001; reconstructive: 95% to 90%, p < 0.001). Furthermore, 
in the reconstructive group, an increase in the use of round implants (11% to 15%, p 
<0.001) and silicone fi lled implants (78% to 85%, p <0.001) was found. Characteristics 
of the 11,378 devices inserted for no specifi ed indication are listed in Supplementary 
Table 1b.
Surgery characteristics
In the patients with a known indication for surgery, 26,036 (85.2%) breast implants 
were inserted for a cosmetic breast augmentation. Almost all cosmetic procedures 
were performed bilaterally (99.0%). Patients in the reconstructive group, however, 
more frequently underwent a unilateral procedure (52.1%, 2,349 of the 4,505 devices). 
As shown in Table 2, the incision site for a cosmetic breast augmentation was most 
frequently the inframammary fold (93.7%), while in reconstructive procedures the mas-































indications, most devices were placed with full coverage of the pectoral muscle (26.2% 
and 39.6%, respectively) or dual plane (47.4% and 33.6%, respectively). Autologous 
flap cover, fat grafting or a MESH or Acellular Dermal Matrix (ADM) were not often used 
for both indications. See Supplementary Table 1c for all surgery characteristics of the 
records in which no indication was specified.
Table 1. Patient characteristics per surgical procedure, presented on patient level (2015-2017)
Cosmetic Reconstructive
n % n % P
PatientsA 13,148 3,426
Age <0.001
<30 6,227 47.4 205 6.0
30-39 4,140 31.5 488 14.2
40-49 1,794 13.6 876 25.6
50-59 783 6.0 1,112 32.5
>60 204 1.6 745 21.7
ASA classification <0.001
I 12,493 95.0 2,235 65.2
II 532 4.0 1,040 30.4
III-IV 30 0.2 90 2.6
Unknown 93 0.7 61 1.8
SmokingB <0.001
Yes 218 10.5 61 9.9
No 1,028 49.5 383 62.1
Unknown 830 40.0 173 28.0
BMIB (kg/m2) <0.001
<18.5 109 5.3 11 1.8
18.5-25 1,529 73.7 273 44.2
25 - 30 218 10.5 148 24.0
>=30 32 1.5 55 8.9
Unknown 188 9.1 130 21.1
A Patients per unique surgical procedure, no unique patients.
B Registered since September 2017. Percentages are calculated for a smaller population: n=2.076 (cosmetic), n=617 
(reconstructive).
ASA: American Society of Anesthesiologists. BMI: Body Mass Index.
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National variation in the use of infection control measures
A wide variation was observed between hospitals/clinics in the use of four selected 
perioperative infection control measures (all ranged 0-100%) (Figure 4). From 2016 
to 2017, the proportion of procedures (per breast) in which surgeons changed their 
gloves before the insertion of an implant increased from 88% to 89% in reconstruc-
tive indications, and from 61% to 80% in cosmetic augmentations. Furthermore, an 
increase was observed regarding rinsing the breast implant with an antiseptic solution 
before insertion (from 70% to 78% (reconstructive), and from 78% to 85% (cosmetic)). 
Increased use of prophylactic intravenous antibiotics before the incision was noticed 
too; from 95% to 97% (reconstructive) and from 91% to 93% (cosmetic). The use of 
drains decreased in reconstructive procedures (80% to 78%) but increased in cosmetic 
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Figure 3. Device characteristics per inserted device (2015-2017) Textured vs Smooth shell, Silicone vs Polyurethane 
coating, Silicone vs Saline fi ll, Anatomical vs Round shape. NB. 2015 was not a complete registration year, and is 
therefore not included in this fi gure. Cosmetic (2016 n=8,995; 2017 n=11,253), Reconstructive (2016 n=1,546; 2017 









Table 2. Surgery characteristics, presented on breast level (2015-2017)
Cosmetic Reconstructive
n % n %
BreastsA 26,036 4,505
Incision site
Inframammary 24,404 93.7 854 19.0
Mastectomy scar 194 0.7 2,391 53.1
Axillary 55 0.2 1 0.0
Areolar 109 0.4 370 8.2
Latissimus Dorsi 0 0.0 218 4.8
Other 1,072 4.1 344 7.6
Unknown 202 0.8 327 7.3
Plane
Subglandular 3,584 13.8 173 3.8
Subfascial 1,823 7.0 34 0.8
Sub fl ap 13 0.0 360 8.0
Subcutaneous 20 0.1 52 1.2
Full pectoral muscle 6,830 26.2 1,783 39.6
Dual plane 12,343 47.4 1,512 33.6
Unknown 1,423 5.5 591 13.1
Mastopexy
Yes 935 3.6 212 4.7
No 24,567 94.4 3,659 81.2
Unknown 534 2.1 634 14.1
Autologous fl ap cover
Yes 95 0.4 511 11.4
No 25,386 97.5 3,362 74.6
Unknown 555 2.1 632 14.0
Fat grafting
Yes 14 0.1 87 1.9
No 25,486 97.9 3,791 84.2
Unknown 536 2.1 627 13.9
Mesh/ADM use
Yes 16 0.1 333 7.4
No 25487 97.9 3,776 83.8
Unknown 533 2.0 396 8.8
A Breasts per unique surgical procedure, no unique breasts.
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Figure 4. Nationwide variation for a selection of infection control measures (2016-2017), presented on breast level.










This study provides an overview of the first outcomes and experiences of the Dutch 
Breast Implant Registry (DBIR), one of the first opt-out breast implant registries in the 
world. Since the national rollout in April 2015, information on 41,919 breast implants 
has been registered, including details of patients, devices, and procedures. The par-
ticipation rate of hospitals (95%) and private clinics (78%) is high compared to other 
breast implant registries in the world with a maximum participation rate of 80% (or un-
known capture rates).15,16,17,18 For the first time, we were able to calculate the minimum 
breast implantation incidence rate in the Netherlands. In 2016 and 2017, at least one 
woman per 1,649 women, or one per 1,691, respectively, received one or more breast 
implant(s). However, it must be realized that this incidence rate is an underestimation, 
considering the current nationwide coverage of procedures.
Essentially, there were two groups of patients undergoing breast implant surgery with 
significant differences in characteristics: elective patients undergoing augmentation 
for cosmetic reasons who are generally young, healthy adults versus more complex 
patients requiring reconstructive surgery (mainly) after breast cancer treatment. Within 
our population, there was a predominance of textured silicone gel implants used for 
both indications. However, a significant increase in the use of smooth implants was 
observed, that appears to coincide with the critical issue of breast implant-associated 
Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare cancer of the immune system be-
lieved to be causally associated with textured breast implants.26,27 In recent research of 
Becherer and de Boer et al., data of the DBIR and the Dutch Nationwide Network and 
Registry of Histo- and Cytopathology (PALGA) was combined, resulting in a dataset with 
both pathological, clinical and implant related information. This result demonstrated 
the potential of DBIR as an important tool for health risk assessments of implants.28
The DBIR aims to provide a pragmatic source of evidence of potential risks and ben-
efits associated with clinical practice. For example, previous studies have suggested 
that the risk of capsular contracture is reduced by the use of an inframammary fold 
incision compared to periareolar incisions.29 Or implants placed in a subpectoral posi-
tion appeared to result less often in malposition of the implant or the development of 
capsular contracture.30 However, these studies are often biased or unreliable due to 
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confounding by indication or loss to follow-up. Moreover, other factors such as the use 
of antiseptic precautions or the type of implants used may influence adverse outcomes 
as well. Therefore, only epidemiologically sound, longitudinal data such as from the 
DBIR, will be able to reveal optimal surgical treatment strategies and differences in 
implant performance by taking risk adjustment factors (casemix) into account.
The main purpose of the DBIR is to improve the quality of breast implant surgery in the 
Netherlands by providing benchmarked information on a set of process and outcome 
measures (quality indicators). Several other clinical audits have preceded, leading to 
substantial improvements in quality of care.31,32,33 As an example of possible interesting 
process indicators, the national variation in the use of 4 infection control measures was 
presented (the use of antibiotics, antiseptic rinse of the implant, glove change prior to 
implant handling and the use of postoperative drains). A wide variation from 0 to 100% 
between hospitals and clinics in the use of these measures was seen. Understanding 
the nature of this variation and the effect of infection prevention on clinically relevant 
outcomes, such as postoperative surgical site infections, is paramount in decision-
making about improvement efforts. Other examples of potential outcome indicators 
are: the percentage of explanations due to complications within an x number of days 
or long-term capsular contracture or implant rupture rates.
A balance is required between capturing all valuable information on the one hand and 
spending an acceptable amount of time needed for data entry on the other hand. To 
reduce the administrative burden an minimize the chance of typing errors, the GS-1 
barcode system was implemented in the online data form of DBIR. With the help of this 
barcode, relevant implant characteristics, including the unique device identification 
(UDI) number, is automatically retrieved and registered. This will also help to decrease 
the amount of missing information on implant characteristics. Fortunately, an increasing 
amount of implant manufacturers are using a correct GS1 barcode in the Netherlands.
In general, completeness of the DBIR data has increased over the last three years.23 It 
can be deduced from our results that missing data is not random; but namely patient 
records in certain hospitals. The DBIR online system provides already instant feedback 
on missing records using a ‘list of errors’. Also, a data verification project to evaluate 









coverage, linking data from external databases could catalyse completeness of the 
DBIR data; e.g. external databases from the industry, the Dutch NABON Breast Cancer 
Audit (NBCA) and the Dutch Pathology Databanking and Biobanking (PALGA).
Internationally, the International Collaboration of Breast Registry Activities (ICOBRA) 
has defined an internationally agreed minimum core set of data points to be used by 
all breast device registries globally.34 This dataset is integrated into the DBIR data-
set. A future step is to combine breast implant registries globally to perform implant 
surveillance and evaluate clinical outcomes on an international level. Long-term data 
will eventually reveal the actual health effects of breast implants and breast implant 
surgery.
CONCLUSION
The opt-out Dutch Breast Implant Registry (DBIR) is one of the first up-and-running 
breast implant registries worldwide, which is the result of collaborative and conjoint 
efforts from clinicians, health care providers, and policymakers. First experiences with 
DBIR and its preliminary results show that DBIR has the potential to provide answers 
to clinically relevant questions and to provide quality assurance and outcome research 
for breast implant surgery.
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DBIR April 2015 - Dec 2017  
n = 48.493 records (breasts)
n = 48.026  
(99,0%)
n = 41.919  
(87,3%)
n = 30.541  
(72,9%)
Reconstructive 
n = 4.505  
(14,8%)
Cosmetic 
n = 26.036  
(85,2%)
n = 11.378  
(27,1%)
n = 6.107  
(12,7%)
n = 467  
(1,0%)
Eligible for analysis 
(date of birth / date of surgery /
type of surgery / device type)
Type of surgery: insertion
Indication known









Supplementary Table 1a. Patient characteristics per 
surgical procedure in which no indication was specified, 























25 - 30 0 0.0
>=30 0 0.0
Unknown 36 85.7
A Patients per unique surgical procedure, no unique 
patients.
B Registered since September 2017. Percentages are 
calculated for a smaller population: n=42.
ASA: American Society of Anesthesiologists. BMI: Body 
Mass Index.
Supplementary Table 1b. Device characteristics per in-























VolumeA (median, in cc with 
IQR)
N/A
A Registered since September 2017. Percentages are 
calculated for a smaller population: n=0.
IQR: Interquartile Range. N/A: not applicable.
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Mastectomy scar 2,389 21.0
Axillary 10 0.1
Areolar 150 1.3






Sub flap 393 3.5
Subcutaneous 53 0.5
Full pectoral muscle 3,035 26.7


















A Breasts per unique surgical procedure, no unique breasts.




























Objective: To identify an internationally agreed minimum set of data points and their 
definitions to be used by all breast device registries globally.
Background: The Poly Implant Prothese (PIP) incident and breast implant associated 
Anaplastic Large Cell Lymphoma (ALCL) have raised awareness of the need for devel-
oping uniform device registries for breast implants. A uniform set of data points and 
data definitions is key to monitoring the performance of breast implants and collecting 
comparable information about procedures and outcomes of breast device surgery on 
an international level.
Methods: The International Collaboration of Breast Registry Activities (ICOBRA) 
convened an international multidisciplinary working group of surgeons, consumer 
representatives, specialist nurses, registry experts and medical device regulators. Data 
points collected by all currently operating breast implant registries were reviewed. A 
list of items to be used in the consensus process was defined. A modified Delphi ap-
proach was used, with surveys requiring the panellists to rate the importance of each 
data point to be included in the global minimum data set on a six point Likert scale.
Results: Data points from six different national breast implant registries were compared. 
Data points were divided into nine categories: clinical, implant related, and patient-
reported findings, operation details (including antibiotics) and implanting technique 
details, patient characteristics, unique device identifiers (UDIs), unique patient identi-
fier (UPI), and clinical demographics. A total of 52 data points which were collected 
by over 33% of currently national running registries were identified for the consensus 
(Delphi) process. After five rounds, 34 data points formed the global dataset and 17 
data points were classified as the optional dataset for registries to collect globally. Data 
definitions were subsequently agreed upon.
Conclusion: We defined an internationally agreed minimum dataset to be used in 
breast device registries. This collaborative approach to share data will allow datasets to 














Breast implants are increasingly popular worldwide for breast reconstruction as well as 
breast augmentation.1 In the Netherlands, the estimated prevalence of breast implants 
is 3,3% of the adult female population.2 The safety and health effects of breast implants 
have been debated since their introduction over 50 years ago.3,4,5 It has been observed 
that the longer breast implants remain in situ, the greater the likelihood of complica-
tions or adverse events.6,7 Recently, Anaplastic Large Cell Lymphoma which, although 
a rare disease, has been shown to be associated to breast implants (BIA-ALCL).8,2 In 
order to determine the health effects of breast implants and to determine implant 
performance, reliable long-term systematically collected data are needed.
Registry data provide a pragmatic source of evidence to address such issues of public 
health and safety. However, insufficient capture rates or dependence on implant pro-
ducers made previous national and international patient registries unreliable.9,10 Stake-
holders including the UK Medicines and Healthcare Products Regulatory Agency, the 
Food and Drug Administration and the Australian Therapeutic Goods Administration 
have highlighted the importance of well-organized clinical registries that can provide 
early warning of underperforming devices such as breast devices, independent from 
the industry.11,12,13,14 They are also an effective tool for recall procedures in the case 
of an adverse event. An example of this followed the recent withdrawal of Silimed 
implants from the market. Within a few hours the number of Silimed implants in the 
Dutch Breast Implant Registry could be determined, thereby providing clarity for 
patients, institutions as well as governmental organizations, and reassuring the vast 
majority who were unaffected.15
In 2012, the International Collaboration of Breast Registry Activities (ICOBRA) was 
established to improve breast device registries by sharing datasets and connecting 
organizations.16 The members of ICOBRA include national plastic surgery societies 
or multidisciplinary breast implant registries of several countries, including Australia, 
Austria, Canada, France, Germany, Ireland, Italy, the Netherlands, New Zealand, South 
Africa, the United Kingdom, and the United States.
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A number of countries have independent registries that are using largely similar 
datasets. Harmonization of these data points and data definitions is key to be able 
to compare and pool data from registries. Pooling is crucial to amplify the data and 
reduce the time needed to identify implants performing well and those associated with 
higher rates of adverse events, such as BIA-ALCL or capsular contraction. Therefore, 
we aimed to identify and define an internationally agreed minimum set of data points 













Selection of data points
Registries for breast implants and tissue expanders were included in our study. Meth-
ods of enrolment, estimated total market of implants/100.000 adult female inhabitants, 
number of registered implants and capture rates were collected but were not part of 
this Delphi process.
Through ICOBRA, the six eligible countries with functioning breast device registries 
were invited to share their data sets, including the Australian Breast Device Registry 
(ABDR),14 the Dutch Breast Implant Registry (DBIR),15 the Bröstimplantatregistret of 
Sweden (BRIMP),17 the Austrian Breast Implant Register (ABIR),18 the Breast and Cos-
metic Implant Registry of the United Kingdom (BCIR),19 and the US National Breast 
Implant Registry (NBIR). In addition, all invitees provided their data definitions.
Data points were divided into nine categories: clinical, implant related, and patient-
reported findings, operation (including antibiotics) and implanting technique details, 
patient characteristics, unique device identifiers (UDIs), unique patient identifier (UPI), 
and clinical demographics. Data points collected identically by the various registries 
were divided into three groups based on the percentage of registries that collect a 
specific data point. Groups were >66% , 33-66% and <33%.
On the 7th and 8th of April 2017, ICOBRA organized an in-person meeting at Monash 
University in Prato, Italy and 26 participants from eleven countries attended, represent-
ing clinicians, regulators, registry science experts, data managers and administrators; 
Australia (8), Austria (1), Germany (1), the Netherlands (3), New Zealand (1), Russia (1), 
Saudi (2), South Korea (2), Spain (1), Sweden (2), the United Kingdom (4), the United 
States (1). The theme of the meeting was “Consensus planning”. The categorized data 
points were shared and the Delphi method was introduced. It was agreed that the 
number of data points should be reduced to a minimum and that a minimum overlap 
of 33% was required for a data point to become a candidate for the global minimum 
data set using a Delphi process.
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Modified Delphi process to obtain consensus on the core Tier 1 
data points
The consensus process followed a modified Delphi approach,20 which took place 
between July and November 2017. This process consisted of four rounds of online 
surveys using Qualtrics,21 with each round of survey followed by a video teleconfer-
ence. A pilot data collection form which included the global data set was designed and 
circulated among all the clinicians in the Delphi panel. All clinicians were encouraged 
to test the form by filling it out after their procedures. Clinicians provided feedback 
after trialling the form during 5-10 procedures, and suggested additional data points, 
so one further round was organised in November 2018 which included additional data 
points identified during testing of the dataset.
Expert panel members were selected to represent a wide range of stakeholders. The 
panel was international and multi-disciplinary, with representatives from each of the 
functioning breast implant registries (Australia, Austria, the Netherlands, Sweden, UK, 
US), other specialists in breast device surgery (breast surgeons and cosmetic surgeons 
and a breast-care nurse), two consumer representatives to confirm that the dataset 
would identify outcomes that were important for them, national regulators to help 
maximize the utility of the dataset and ensure the work aligned with other international 
registries, biostatisticians to ensure the statistical rigor of the methodology, and was 
chaired by a registry science expert.
The survey required the panelists to rate the importance of each data point on a six 
point Likert scale to be included in the global minimum data set. Data points were 
considered when they met the following criteria: (i) median score of 5 or 6, (ii) more 
than 70% of the panel scoring a 5 or 6, and (iii) no disagreement according to the 
RAND criteria.22
After each round, results from the survey were shared with the panel members prior 
to the next teleconference. As feedback and preparation for teleconferences, panel 
members received their own individual score and the overall group score (median) for 
each data point. If consensus was not reached to include a data point in the global data 












Data definitions for Tier-1 and Tier-2 data points
Data definitions for all the data points included in the modified Delphi process were 
then finalized. The ABDR data definitions, which were obtained from established stan-
dard sources where they existed, or adapted from the medical literature, were used as 
the starting point. If no definitions were available from the ABDR data definitions, the 
definitions for those data points were developed by the ICOBRA team. The Delphi 
panel voted on these definitions as being ‘acceptable’ or ‘requiring amendment’. This 
process consisted of 2 rounds of online surveys with each round of survey followed by 
a video teleconference, until the majority of panel members agreed to all definitions, 
with the same process used for further additions from the November 2018 round. Eth-
ics approval was obtained from Monash University Human Research Ethics Committee. 
All panelists consented to participating in the study.
RESULTS
General characteristics of the six included national, functioning breast device registries 
are listed in Table 1. The results of the categorization of data points are listed in Table 
2. The highest number of items were collected on implant related findings, operation 
details, and Unique Device Identifiers (UDI). Fewer similarities in data points were 
detected on patient characteristics and patient-reported outcomes.
Table 1. General characteristics of the current running breast device registries
Breast Device 
Registry
Since Method of 
enrollment
Implants per 1,000 
inhabitantsa per year
Registrations per year Capture rate
ABDR 2015 Opt-out 0.4 – 0.8 10,000-15,000 not known yet
DBIR 2015 Opt-out 1.2 – 2.9 15,000 – 25,000 80%-90%
BRIMP 2014 Opt-out < 1.0 < 5,000 61% -70%
ABIR 2004 Opt-in < 1.1 < 5,000 not known yet
BCIR 2016 Opt-in 0.8 – 1.5 25,000 – 50,000 not known yet
NBIR 2018 Opt-out 1.3 – 1.7 175,000 – 225,000 not known yet
ABDR: Australian Breast Device Registry, DBIR: Dutch Breast Implant Registry, BRIMP: Bröstimplantatregistret of 
Sweden,
ABIR: Austrian Breast Implant Register, BCIR: Breast and Cosmetic Implant Registry of the UK,
NBIR: US National Breast Implant Registry
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Table 2. Overlap in data points in the six current running nationwide breast device registries Bold = 100% overlap.

































Patient dissatisfied with volume/
shape
Breast pain
Worried for implant/desire to 
remove






























Antiseptic rinse of the pocket
Nipple Guards
Glove change before insertion
Sleeve/funnel (Keller funnel)












History of medical issues







UDI (unique device identifier)
Device manufacturer
Device serial no.









Date of insertion of removed 
implants
Device details of explanted 
device
Volume of implant removed
Coating







ALCL: Anaplastic Large Cell Lymphoma, ASIA: Auto Immune/Inflammatory Syndrome induced by Adjuvants, TE: 
Tissue Expander,
UDI: Unique Device Identification, ADM: Acellular Dermal Matrix, ASA: American Society of Anaesthesiologists 












Delphi analysis on data points
The Delphi process included fi ve rounds of surveys and videoconferences. The vid-
eoconferences focused on the importance of collecting the data point based on its 
usefulness and the feasibility of collecting. The results and the participation from the 
panel at each round is shown in Figure 1. All data points that (i) were modifi ed or (ii) did 
not achieve consensus in one round were included in the next round. The fi ve rounds 
resulted in 34 data points (78 including sub-points) that were voted in the global data 
set by the panel (see Table 3). The optional data set consisted of 17 data points which 
are listed in Table 4.
Webconferences lead to renaming of datapoints
Discussions in webinars resulted in rewording of some data points (includes data points 
already in the global data set), introduction of some new data points to capture more 
meaningful information from multiple data points, and the inclusion of additional 
information. One data point (device malposition/rotation) and four sub-points (Infec-
tion leading to explantation, seroma, hematoma, risk reducing mastectomy) that had 
achieved consensus in round 1 had the wording clarifi ed in the second round. Another 













































Figure 1. Modifi ed Delphi process fl ow diagram.
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Table 3. List of the global data points
Domain No. Data point




1. Reason for revision/explantation Round 1
a) Patient preference Round 2
b) Asymptomatic Round 1
c) Complication Round 1
2. Infection leading to explantation Round 1&2*
3. Seroma Round 1&2*
4. Hematoma Round 1&2*
5. Capsular contracture Round 1
6. BIA-ALCL Round 1
a) Suspected Round 5
b) Confirmed Round 5
IMPLANT RELATED FINDINGS
7. Device rupture Round 1
8. Device malposition/rotation Round 1&2*
PATIENT REPORTED FINDINGS 9. Breast pain Round 4
OPERATION DETAILS
10. Postoperative antibiotics Round 1
11. Preoperative antibiotics Round 2
12. Laterality Round 1
13. Indication for surgery Round 1
a) Cosmetic augmentation Round 1
b)  Reconstruction post-risk reducing mastectomy Round 1&2*
c) Reconstruction (benign) Round 1
d) Reconstruction post-mastectomy for cancer Round 1
14. Type of intervention Round 1
a) Primary Round 1
b) Secondary Round 1
c) Revision Round 1
d) Explant only Round 1
15. Timing of reconstruction Round 5
a) Immediate Round 5












Table 3. List of the global data points (continued)
Domain No. Data point




16. Implant position/plane Round 1
a) Sub glandular Round 1
b) Sub pectoral Round 1
c) Sub fascial Round 1
d) Sub flap Round 1
e) Sub cutaneous Round 1
f) Dual plan Round 1
g) Others (please specify) Round 1
17. Incision site Round 2
a) Inframammary Round 2
b) Periareolar Round 2
c) Axillary Round 2
d) Mastectomy scar Round 2
e) Others (please specify) Round 3
18. Nipple sparing Round 1
19. Flap cover Round 1
20. Fat grafting Round 1
21. Concurrent mastopexy Round 5
22. Capsulectomy Round 1&4*
a) Partial capsulectomy Round 2
b) Full capsulectomy Round 3
IMPLANTING TECHNIQUE
23. Rinse of the pocket Round 3
a) Antibiotics Round 3
b) Antiseptics Round 3
c) Others (please specify) Round 3
24. Drain use Round 2
25. Glove change before insertion Round 2
PATIENT CHARACTERISTICS
26. Previous radiotherapy Round 1
27. Date of birth/Age of patient Round 4
28. Height Round 4
29. Weight Round 4
158
the pocket with options to include antiseptics, antibiotics and other’ (see table 5 for 
details on these changes). The global data points that required multiple rounds of 
discussion were either in the ‘Patient characteristics’ category or the ‘Patient reported 
findings’ category. With date of birth/age of patient, the discussion showed that dif-
ferent formats are used and that the European Union does not allow the international 
transfer of such identifiable information, so age of patient will be used instead. The 
panel had concerns about the collection of height and weight relating to the reliability 
of data obtained.23 Breast pain, which is a patient reported finding, was seen to be 
subjective and difficult to define. Another data point, ‘Capsulectomy’, which did not 
have a consistent definition, also required four rounds of discussion before it was voted 
in the global dataset.
Table 3. List of the global data points (continued)
Domain No. Data point




30. Device details# Round 1
a) Device manufacturer Round 1
b) Device serial number Round 1
c) Catalogue reference number Round 1
d) Device lot number Round 1
e) Texture Round 1
f) Fill Round 1
g) Shape Round 1
h) Volume of implant Round 1
31. ADM/Mesh used Round 1
a) Device details of the ADM/Mesh used Round 1
32. Date of insertion of removed implants Round 1
33. Device details of explanted device Round 1
a) Texture Round 1
b) Fill Round 1
c) Shape Round 1
34. Marker/Medical record of explanted device if known Round 2
BIA-ALCL: Breast Implant Associated Anaplastic Large Cell Lymphoma, ADM: Acellular Dermal Matrix, UDI: Unique 
Device Identification
Please note:
* Data point voted on in earlier round and wording confirmed in later rounds












Table 5. Changes made to data points
Data points Modification
Infection Wording changed to ‘Infection leading to explantation’.
Seroma/Hematoma Split into two separate data points, ‘Seroma’ and ‘Hematoma’.
ALCL Changed to ‘BIA-ALCL’ (not included in the round 2 survey as the modification was minor)
Device malposition Changed to ‘Device malposition/rotation’
Capsulectomy Included two sub-points, ‘Full capsulectomy’ and ‘partial capsulectomy’
Prophylactic 
mastectomy
Changed to ‘Risk reducing mastectomy’
Changing implant 
size and Desire to 
remove/change 
implant
A data point ‘Patient preference’ will be sufficient to capture meaningful information 
relating to these two data points
Antiseptic rinse of 
the pocket
Changed to ‘Rinse of the pocket with options to include antiseptics, antibiotics and other’
BIA-ALCL: Breast Implant Associated Anaplastic Large Cell Lymphoma
Table 4. List of the optional data points
Domain No. Data point % of registries collecting
CLINICAL FINDINGS
1. (Newly diagnosed) Breast cancer >66%
2. Skin scarring problem 33-66%
3. Flap problem 33-66%
4. Double capsule (Panellist suggestion) 33-66%









8. Changing implant size 33-66%
9. Desire to remove/change implant 33-66%
ANTIBIOTICS/
OPERATIONS DETAILS
10. Neopocket formation 33-66%
IMPLANTING TECHNIQUE
11. Occlusive nipple shields 33-66%
12. Nipple absent 33-66%
PATIENT 
CHARACTERISTICS




16. Volume of tissue expander 33-66%
17. Volume of removed implant 33-66%
ADM: Acellular Dermal Matrix, UDI: Unique Device Identification, ASA: American Society of Anaesthesiologists 
physical status classification
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The round 3 teleconference slides compared the results for each of the data points 
under consideration across the three rounds. This was done to evaluate whether further 
consensus could be achieved for the data points. It was decided during the teleconfer-
ence that further consensus on the remaining data points would be unlikely after the 
next round, and therefore any remaining data points would be included in the optional 
dataset.
An additional round included data points that were identified during pilot testing of 
the dataset by the panel. The additions made were ‘timing of surgery’ and ‘concur-
rent mastopexy’ which were both voted in as global data points in the survey and 
‘Autoimmune/inflammatory Syndrome Induced by Adjuvants (ASIA)’ was included as 
an optional data point.
Delphi analyses on data definitions
The first round of survey included 72 data points with definitions and the response rate 
was 93%. The definitions for 31 data points received no comments from the panellists 
and were voted as ‘acceptable’. The definitions for the remaining 41 data points were 
discussed in the teleconference which had participation from 60% panellists and re-
sulted in definition options for each of the 41 data points. The second round of survey 
included all the definition options for the data points and the most popular definition 
was chosen as the preferred definition. The final round also included definitions for 
the additional data points. The panel considered a number of published definitions of 
ASIA24,25,26, but were unable to reach consensus, largely as the causative role of silicone 
in ASIA remains unproven, therefore this data point does not currently have a working 
definition. See table 6 for the list of definitions for all other data points.
DISCUSSION
We have outlined the process undertaken by ICOBRA, an international multidisciplinary 
group with expertise in breast device registries including consumer representatives, 
national regulators and biostatisticians, to develop a global minimum dataset for 
breast implant registries, to enhance patient safety and quality of care. After the Delphi 












Table 6. List of finalised definitions for all data points
The global dataset 




The main reason for undertaking revision of a breast implant
a Patient preference The choice of the patient
b Asymptomatic
Procedure performed due to a device recall, or a planned revision, or 
asymmetry, or revision due to a complication on the other breast
c Complication Any deviation from the normal post-operative course
2.
Infection leading to 
explantation
An infection associated with a breast implant in place, which leads to its 
explantation. Usually involves redness, localised pain or tenderness, abscess 
or persistent serous liquid formation around the implant even with distinct 
clinical signs it might be culture-negative
3. Seroma An abnormal accumulation of serum around the device
4. Hematoma
A collection of blood outside the blood vessels which can be localised in an 
organ, space, or tissue
5. Capsular contracture
The shrinkage of the foreign body encapsulation scar tissue that forms 
around artificial implants imbedded in body tissues
6. BIA-ALCL
A current or previous diagnosis (pathology based) of breast implant 
associated anaplastic large cell lymphoma (BIA-ALCL), where BIA-ALCL is a 
CD30+, ALK-, T-cell derived lymphoma within the non-Hodgkin lymphoma 
group. This data point to include (a) Suspected and (b) Confirmed.




Any instance in which the implant is outside its intended position
9. Breast pain As noted by the patient
10. Preoperative antibiotics Use of antibiotics provided IV, Orally, or IM before incision
11. Postoperative antibiotics
Use of antibiotics provided IV, Orally, or IM at any time after 3 hours post-
surgery
12. Laterality The left or the right breast
13. Indication for surgery The reason for surgery
a Cosmetic augmentation A cosmetic procedure for enlarging breasts
b
Reconstruction post risk 
reducing mastectomy
Surgery to remove one or both breasts to reduce the risk of developing 
breast cancer
c Reconstruction – benign
Surgery to restore or create shape and symmetry in patients with loss or 
absence of all or some breast tissue due to benign breast conditions, 




Surgical procedures performed to recreate a breast after one or both breasts 
are removed as a treatment for breast cancer
14. Type of intervention
Type of intervention to include sub-points primary, secondary, revision, or 
explant only.
a Primary An initial insertion of a new device, i.e. an implant or expander
b Secondary Removal of an expander and insertion of an implant
c Revision Revision of an in situ device, i.e. an implant or an expander revision
d Explant only Removal of an implant
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Table 6. List of finalised definitions for all data points (continued)
15.a
Timing of reconstruction 
Immediate
Breast reconstruction carried out at the time of mastectomy
15.b
Timing of reconstruction 
Delayed
Breast reconstruction carried out at a later time than the mastectomy
16. Implant position/plane
The surgical plane in which an implant is inserted. This data point to include 
sub-points (i) Sub glandular, (ii) Sub pectoral, (iii) Sub fascial, (iv) Sub flap, (v) 
Sub cutaneous, (vi) Dual plane, and (vii) Others (please specify)
17. Incision site The site where the incision is placed
a Infra-mammary An incision in, or beneath, the infra-mammary fold
b Periareolar An incision around the areola
c Axillary An incision in the axilla
d Mastectomy scar An incision at the site of an existing mastectomy incision
e Others (please specify) Any other incision site
18. Nipple sparing
Removal of the breast tissue with preservation of the breast skin envelope 
and the nipple and areola complex
19. Flap cover
Any type of flap used for breast reconstruction (concurrent or previous) that 
covers an implantable breast device or adds volume to the breast mound
20. Fat grafting Transfer of aspirated fat to the breast region
21. Concurrent mastopexy Indicating whether the procedure involves a mastopexy (breast lift)
22. Capsulectomy Removal of the encapsulating scar tissue surrounding the breast implant
a Partial capsulectomy Surgical release and/or partial removal of the capsule
b Full capsulectomy Complete removal of the capsule including thoracic part of the capsule
23. Rinse of the pocket Rinse of the surgically created pocket before implant insertion
a Antiseptics Intraoperative wash of the surgical pocket with an antiseptic solution
b Antibiotics Intraoperative wash of the surgical pocket with an antibiotic solution
c Other (please specify) Any other type of rinse used
24. Drain use Intra-operative insertion of drains
25.
Glove change before 
insertion
Change of gloves immediately prior to insertion of the implant
26. Previous radiotherapy
Radiotherapy to the breast or chest wall at any time prior to the current 
device operation
27.
Date of birth OR Age of 
patient
As identified in the medical record
28. Height A person’s self-reported height, measured in centimetres (or inches)
29. Weight The weight (body mass) of a person measured in kilograms (or lbs)
30.
Device details / Unique 
Device Identifier (UDI)
Details of the implanted device / Unique Device Identifier
a Device manufacturer Name of the manufacturer of the implanted device




Catalogue reference number of the implanted device












Table 6. List of finalised definitions for all data points (continued)
e Texture The surface texture of the device being inserted or explanted
f Fill
The material used to fill the breast implant: saline solution, silicone gel, or 
other
g Shape
The shape of the device being inserted into or explanted from the breast; 
where the shape of the device is either Round: implant is shaped like a 
flattened sphere or Shaped: a contoured shape that re-creates the more 
teardrop outline of a mature breast
h Volume of implant
As determined by the manufacturer or measured intraoperatively by weight, 
or displacement, or fill volume
31. ADM / Mesh used
The use of either an ‘absorbable or non-absorbable synthetic mesh’ or 
‘acellular dermal matrix’ which are medical devices used in breast implant 
surgery where the mesh or matrix provide a soft tissue scaffold
a
Device details of the ADM 
/ Mesh used
Details of the ADM / Mesh
32.
Date of insertion of 
removed implants
Date the explanted implants were inserted (known or estimated)
33.
Device details of 
explanted device (UDI)
Any available details of the implant at the time of explantation
34.
Marker / medical record 
of explanted device (if 
known)
The explanted device’s specific markings indicating type, manufacturer, 
serial number or lot number
The optional dataset
No. Data point Definition
1.
Newly diagnosed breast 
cancer
Recommend not using this data point; hence no definition
2. Skin scarring problem
An abnormal or suboptimal cutaneous or dermal scarring. Includes keloid 
formation, hypertrophic scarring, poor scar contour or orientation causing 
distortion or compromise of the reconstructive or aesthetic result. Does not 
include capsular contracture
3. Flap problem
When a flap is used as part of a reconstruction, includes but not limited to 
one or all of the following problems: Total flap loss, partial flap loss, vessel 
thrombosis, flap hematoma, flap infection, sub-flap seroma, flap fat necrosis, 
size mismatch resulting in incomplete coverage. Does NOT include donor 
site complications
4. Double capsule
A second thin tissue layer encasing the usually textured implant 
subsequently leading to permanent separation from the outer capsule
5.
Autoimmune Syndrome 
Induced by Adjuvants 
(ASIA)
No accepted definition as yet – kindly refer to
Tervaert, J. W. C. (2018). Autoinflammatory/autoimmunity syndrome induced 
by adjuvants (ASIA; Shoenfeld’s syndrome): A new flame. Autoimmunity 
reviews.
6. Silicone extravasation Extrusion of silicone beyond the limits of the capsule
7. Asymmetry As determined by the patient and identifiable by the surgeon
8. Changing implant size Patient preference to change the size of implant
9.
Desire to remove / change 
implant
As determined by the patient
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be included in the global dataset. Data points for which consensus was not achieved 
and were not voted into the global dataset, became the optional dataset. Consensus 
definitions for all data points were achieved, using the ABDR data definitions as the 
starting point, with the exception of ASIA, for which no definition is currently provided. 
It is expected that the global dataset will be adopted by currently operating breast de-
vice registries within two years and by all new breast implant registries in the ICOBRA 
network.
The use of the global set and the optional set ensures that countries can maintain 
their independence in selecting data points that suit them. The global dataset can 
be described as a “data spine”, and will be reviewed every three years in light of new 
evidence. The optional dataset can be described as a “data rib” and encompasses 
all other data points collected by any country, which may be used to reflect regional 
preferences or to further investigate a clinical issue, and can be expanded upon.
Consensus for the majority of data points was easily achieved in the first round, while 
some others required multiple rounds of discussion before consensus for inclusion in 
the global dataset was achieved. Although not everyone could be present at the video 
teleconferences, all participants were able to add their remarks beforehand and all 
contributions were discussed. Approximately 56% of the global data points were al-
Table 6. List of finalised definitions for all data points (continued)
10. Neopocket formation Formation of a new pocket
11. Occlusive nipple shields
The use of adhesive film dressing covering the nipple-areola complex 
to prevent perioperative expression of bacteria from nipple ducts 
contaminating the operative field
12. Nipple absent Absence of the nipple at the time of device insertion
13. ASA classification
A system used by anaesthesiologists’ to stratify severity of patients’ 
underlying disease and potential for suffering complications from general 
anaesthesia
14. Smoking As identified by the patient
15. Gender Self-identified gender (options to include male, female, other)
16. Volume of tissue expander
Intraoperative fill volume, as determined by the surgeon at the time of the 
procedure
17.
Volume of removed 
implant












ready being collected by >66% of registries, meaning that for the currently functioning 
registries, incorporation of these data points will be straightforward.
The ICOBRA global dataset is designed as a minimum dataset. The data collection 
itself should facilitate the documentation for the clinical personnel at the frontline of 
medical/operative documentation, instead of posing another burden. The dataset is 
epidemiologically sound, meaning that clinical judgement is not required to collect 
the data, such as might be required for example with the Baker grading of capsular 
contracture. Ideally data collection is built into a routine workflow in an institution’s 
electronic patient record system. Incorporating the ICOBRA global dataset into the 
electronic medical record also eliminates double/redundant documentation and 
facilitates bulk-uploading to the registry. Combining it with administrative databases 
improves the quality of the data overall, and diminishes a cherry-picking type of record 
keeping.
The value of the ICOBRA global dataset is clear. Pooling data from breast implant 
registries will allow active surveillance and comparative outcomes evaluation, provid-
ing denominator data for adverse events to identify under-performing devices earlier. 
This will safeguard the health of recipients of breast implants by preventing implanta-
tion of defective devices, reducing risks and costs associated with early revision, and 
providing manufacturers with greater ability to deliver safe products to the market.27 
Further, collecting comparable information about procedures and outcomes feeds into 
clinical auditing and facilitates benchmarking on an international level, which can drive 
quality improvement at participating institutions, again reducing complications and 
costs.28 In the absence of high-quality, randomized controlled trials to assess the effect 
of various intraoperative techniques, such as the use of antiseptic rinse, glove change 
prior to implant handling, and the use of nipple guards and postoperative drains, 
registry data provide a pragmatic alternative source of evidence (clinical practice based 
evidence).29,30 Best surgical techniques can be identified in a real-world environment 
and new implant technologies can be reliably evaluated. Importantly, the use of large 
pooled international datasets is the only way we can address the critical issue of BIA-
ALCL2, a rare cancer of the immune system believed to be causally associated with 
breast implants. Moreover, this information will be of great value empowering patients 
to be effective advocates for their health, so that they can make informed decisions.
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There are significant complexities and practical hurdles when transferring large datas-
ets internationally.31 Care must be taken to protect the privacy of patients as well as the 
security of data when bringing together the ICOBRA global dataset. Regulations vary 
according to region with the use of de-identified data. European Union regulations do 
not allow the export of identifying information including date of birth, with the threat 
of heavy fines.32 It remains to be determined whether de-identified data (with the risk 
of re-identification) or aggregate analyses will be combined.
Now that a global minimum dataset for breast implant surgery has been established, 
further international initiatives should be undertaken. The ICOBRA network col-
laborates on research projects and post-market surveillance of breast implants, similar 
to the work of the International Consortium of Orthopedic Registries,33 and aims to 
establish a global patient-reported outcome measure (PROM) to provide early warning 
of under-performing devices using patient reports of breast symptoms. In addition, 
there is potential for breast device registries to support low-cost randomized controlled 
trials.34 Collaboration with industry can lead to benefits such as a reduced registration 
load by prefilling device characteristics using a Unique Device Identifier (UDI). Uniform 
barcode processing with accepted international standards will increase patient safety 
and further reduce the burden of data entry. Further, the usage of stock and supply 
information functions as valuable validation system of the registry database to calculate 
the capture rate on a nationwide level.
CONCLUSIONS
We have defined a global minimum dataset to be collected for breast implant surgery 
in routine clinical practice. Datasets will be combined in the future with the aim of 
early detection of under-performing breast devices and to guide treatment protocols. 
This will provide better information about outcomes of breast implant surgery and 













 1. Albornoz CR, Bach PB, Mehrara BJ, et al. A 
Paradigm Shift in U.S. Breast Reconstruction: 
Increasing Implant Rates. Plast Reconstr Surg. 
2013;131(1):15-23.
 2. de Boer M, van Leeuwen FE, Hauptmann M, 
et al. Breast implants and the risk of analplas-
tic large-cell lymphoma in the breast. JAMA 
Oncol. 2018;4(3):335-341.
 3. Angell M. Shattuck Lecture - evaluating the 
health risks of breast implants: the interplay of 
medical sciens, the law, and public opinion. N 
Engl J Med. 1996;334(23):1513-8.
 4. Balk EM, Earley A, Avendano EA, et al. Long-
term health outcomes in women with silicone 
gel breast implants: a systematic review. Ann 
Intern Med. 2016;164(3):164-175.
 5. Janowsky EC, Kupper LL, Hulka BS. 
Meta-analyses of the relation between 
silicone breast implants and the risk of 
connective-tissue diseases. N Engl J Med. 
2000;342(11):781-90.
 6. Update on the Safety of Silicone Gel-Filled 
Breast Implants Center for Devices and 
Radiological Health. Silver Spring, Maryland, 
U.S. Food & Drug Administration (FDA), 





 7. Stevens WG, Harrington J, Alizadeh K, et al. 
Eight-Year Follow-Up Data from the U.S. Clini-
cal Trial for Sientra’s FDA-Approved Round 
and Shaped Implants with High-Strength Co-
hesive Silicone Gel. Aesthet Surg J. 2015;35 
Suppl 1:S3-10.
 8. de Jong D, Vasmel WL, de Boer JP, et al. Ana-
plastic large-cell lymphoma in women with 
breast implants. JAMA 2008;300(17):2030-5.
 9. Jeeves AE, Cooter RD. Transforming Aus-
tralia’s Breast Implant Registry. Med J Aust. 
2012;196:232-4.
 10. Hopper I, Ahern S, McNeil JJ, et al. 
Improving the safety of breast implants: 
implant-associated lymphoma. Med J Aust. 
2017;207(5):185-186.
 11. Wilkinson J, Crosbie A. A UK medical devices 
regulator’s perspective on registries. Biomed-
izinische Technik Biomedical engineering. 
2016;61(2):233-7.
 12. Krucoff MW, Normand S, Edwards F, et al. 
Recommendations for a national medical 
device evaluation system. Silver Spring, 
Maryland, U.S. Food & Drug Administration 





 13. Inspectie voor de Gezondheidszorg. 
Medische technologie Siliconen borstimplan-




 14. Hopper I, Ahern S, Best RL, et al. Australian 
Breast Device Registry: breast device 
safety transformed. ANZ journal of surgery. 
2017;87:9-10.
 15. Rakhorst H, Mureau MA, Cooter RD, et al. 
The new opt-out Dutch National Breast 
Implant Registry - lessons learnt from the road 
to implementation. J Plast Reconstr Aesthet 
Surg. 2017;70(10):1354-1360.
168
 16. Cooter RD, Barker S, Carroll SM, et al. 
International Importance of Robust Breast 
Device Registries. Plast Reconstr Surg. 
2015;135(2):330-6.
 17. The Bröstimplantatregistret of Sweden 
(BRIMP). Available at: http://stratum.regis-
tercentrum.se/brimp. Accessed March, 31, 
2018.
 18. Wurzer P, Rappl T, Friedl H, et al. The Aus-
trian Breast Implant Register: Recent Trends in 
Implant-Based Breast Surgery. Aesthetic Plast 
Surg. 2014;38(6):1109-15.
 19. The Breast and Cosmetic Implant Registry 
of the United Kingdom (BCIR). Available at: 
http://content.digital.nhs.uk/bcir. Accessed 
March, 31, 2018.
 20. Dalkey NC.  The Delphi Method: An experi-
mental study of group opinion. Rand Corp 
Public RM-58888-PR.  Santa Monica: Rand 
Corp; 1969.
 21. (Qualtrics, Provo, UT) - Intext Qualtrics. 
Queltrics Software. Provo, Utah USA, 2005.
 22. Fitch K, Bernstein SJ, Aguilar MD, et al. The 
RAND/UCLA appropriateness method user’s 
manual. DTIC Document, 2001.
 23. Kuskowska-Wolk A, Bergström R, Boström G. 
Relationship between questionnaire data and 
medical records of height, weight and body 
mass index. Int J Obes. 1992;16:1-9.
 24. Watad A, Quaresma M, Bragazzi NL, et al. The 
autoimmune/inflammatory syndrome induced 
by adjuvants (ASIA)/Shoenfeld’s syndrome: 
descriptive analysis of 300 patients from the 
international ASIA syndrome registry. Clin 
Rheumatol. 2018;37(2):483-93.
 25. Jara LJ, Garcia-Collinot G, Medina G, et 
al. Severe manifestations of autoimmune 
syndrome induced by adjuvants (Shoenfeld’s 
syndrome). Immunol Res. 2017;65(1):8-16.
 26. Vera-Lastra O, Medina G, Cruz-Dominguez 
Mdel P, et al. Autoimmune/inflammatory syn-
drome induced by adjuvants (Shoenfeld’s syn-
drome): clinical and immunological spectrum. 
Expert Rev Clin Immunol. 2013;9(4):361-73; 
Shoenfeld: Video Q&A: what is ASIA? An 
interview with Yehuda Shoenfeld. BMC 
Medicine 2013 11:118.
 27. Ahern S, Hopper I, Evans SM. Clinical qual-
ity registries for clinician-level reporting: 
strengths and limitations. Med J Aust. 
2017;206:427-429.
 28. Arthuur J, Anne G, Madeline C, et al. Reduc-
ing Healthcare Costs Facilitated by Surgical 
Auditing: A Systematic Review. World J Surg. 
2015 Jul;39(7)1672-80
 29. Henderson JR, Kandola S, Hignett SP, et al. In-
fection Prophylaxis for Breast Implant Surgery: 
Could We Do Better? Eplasty 2017;17:172-9.
 30. Vandenbroucke JP. Observational research, 
randomized trials, and Two Views of Medical 
Science. PLoSMed. 2008; 5(3):e67.
 31. Becherer BE, Spronk PER, Mureau MAM, 
et al. High Risk Device Registries: Global 
Value, Costs, and Sustainable Funding. J 
Plast Reconstr Aesthet Surg. 2018;S1748-
6815(18)30203-1.
 32. https://www.eugdpr.org
 33. Sedrakyan A, Paxton EW, Marinac-Dabic D. 
Stages and tools for multinational collabora-
tion: The perspective from the Coordinating 
Center of the International Consortium of 
Orthopaedic Registries (ICOR). J Bone Joint 
Surg Am. 2011 Dec 21;93 Suppl 3:76-80
 34. Peled AW, Foster RD, Stover AC, et al. Out-
comes after Total Skin-sparing Mastectomy 
and Immediate Reconstruction in 657 Breasts. 












This thesis is about clinical quality audits, used to measure and improve the quality of 
health care; focusing on the quality of breast cancer care (see: the NBCA) and on the 
quality of breast implant surgery (see: the DBIR) in the Netherlands.
Evaluation and improvement of the quality of care is of crucial importance in the daily 
clinical practice, in health insurance and in policymaking. Different tools have been 
developed to monitor the quality of care, including regulatory inspections, surveys of 
consumers’ experiences, internal assessments and clinical audits.1 A clinical quality au-
dit is a quality improvement process that seeks to improve patient care and outcomes 
through a systematic review of care against explicit criteria or standards, established 
using the principles of evidence-based medicine.2 The goals of clinical quality audits, 
in general, are to increase the knowledge about diseases, to improve awareness and 
understanding of disease and treatment practices and it is an important tool in con-
necting networks of clinical expertise.
With funding from the Dutch Ministry of Health, the Association of Surgeons of the 
Netherlands (ASN) proceeded to develop the first national clinical quality audit in the 
Netherlands in 2009: the Dutch Surgical Colorectal Audit (DSCA).3 Subsequent to the 
success of the DSCA, the Dutch Institute of Clinical Auditing (DICA) was founded in 
2011 with the objective to facilitate the start-up of new nation-wide clinical audits in 
the Netherlands.4 Concurrently, the Dutch Health Care Inspectorate observed a high 
rate of tumor-positive margins after breast-conserving surgery in a number of hospitals 
in the Netherlands, which confirmed the need for a national audit for the monitoring 
of the quality of breast cancer care.5 In 2011, the NABON Breast Cancer Audit (NBCA) 
was instituted as a nation-wide audit to address the quality of breast cancer care in the 
Netherlands.6 Meanwhile, more than 100.000 newly diagnosed patients treated for 
breast cancer have been registered. And within 7 years auditing, multiple processes 
and outcome measures (quality indicators) that cover different aspects of the multidis-
ciplinary care path for breast cancer patients have been evaluated in order to examine 
improvement. Subsequently, new audit initiatives and quality assurance programs for 
other diseases have been developed and rapidly emerging in the Netherlands (21 
audits facilitated by DICA today including the DBIR).7
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part I: Quality assurance in breast cancer care; the NABON 
breast cancer audit (NBCA)
Breast cancer is the most common cause of cancer among women. In the Netherlands 
over 15.000 women get diagnosed with breast cancer every year.8 Over the past 
decades, many refinements of treatment modalities have been widely implemented 
in the field of breast cancer. In order to monitor the quality of the delivered breast 
cancer care, the NBCA audit was founded by clinicians of different disciplines involved 
in breast cancer.
In chapter 2, we focused on trends in the use of Neoadjuvant Chemotherapy (NAC) in 
breast cancer treatment. Chemotherapy is timed either prior to or following surgery, 
respectively neoadjuvant (NAC) or adjuvant (AC), both leading to similar disease-free 
and overall survival.10,11 Chemotherapy intents to eliminate potential existing micro 
metastases, thus decreasing recurrence rates and mortality.9
NAC has several benefits compared to AC. Firstly, NAC aims to downsize the tumour 
to improve the possibility of a radical resection or to enable breast conservation 
surgery.12,13 Another benefit of NAC includes the opportunity to de-escalate surgical 
treatment of the axilla.14,15 Other potential advantages of NAC include the opportunity 
to investigate tumor biology, to monitor response and adapt to suboptimal response. 
Moreover, it is demonstrated that NAC, when compared to adjuvant chemotherapy, 
may even improve survival in triple-negative and HER2 positive BC subtypes when a 
pathological complete response (pCR) is achieved.16
In accordance with international guidelines, the Dutch national breast cancer guideline 
recommends NAC for patients with stage III BC aged <70 years. From 2011 to 2015, 
a high consistent rate of NAC (77%) was observed in our population of women aged 
18-70 years with stage III BC, However, inter-hospital variation in the rate of NAC use 
was noticed varying between 0 % to 100%. We found the following predictive patient 
and tumour factors for the use of NAC in patients with breast cancer: young age, large 
tumour size, advanced nodal disease, and a negative hormone receptor status. After 
adjustment for these predictive factors known, the variation between the 89 Dutch 






observed a significantly higher use of NAC in hospitals participating in neoadjuvant 
clinical studies (83% versus 73%).
In chapter 3, we evaluated the opinion of surgical and medical oncologists on the use 
of NAC for breast cancer. Clinicians (70 surgical and 68 medical oncologists) participat-
ing in breast cancer care in the Netherlands completed a 20-question online survey on 
the influence of patient, disease, and management related factors on their decisions 
towards NAC. NAC was recommended for locally advanced breast cancer according 
to most of the clinicians (94%). Despite the willingness to downstage (75%), only 64% 
of clinicians stated that they routinely recommended NAC when systemic therapy was 
indicated preoperatively. Concerns that prevented clinicians from recommending NAC 
are: comorbidities, age >70 years, and WHO-performance status ≥ 2. Opinions on 
surgical management after NAC were inconclusive; while 75% recommends NAC to 
enable BCS, some stated that BCS after NAC increases the risk of a non-radical resec-
tion (21%), surgical complications (9%) and recurrence of disease (5%).
In chapter 4, we gain insight into patients’ experiences with decisions on the timing of 
chemotherapy. A 35-item online questionnaire was distributed among female patients 
(age>18) treated with either NAC or AC for stage II and III breast cancer, and almost 
400 responded. Outcome measures were the experienced exchange of information on 
the possible choice between both options and patients’ involvement in the final deci-
sion on chemotherapy timing. The need to make a treatment decision on the timing of 
their chemotherapy (NAC or AC) was found to be made explicit in only a small number 
of adjuvant treated patients, in particular in breast cancer stage II. Less than half of the 
respondents felt they had a real choice.
In chapter 5, we analyzed trends in the use of neoadjuvant chemotherapy (NAC) and 
the impact on surgical outcomes (in terms of positive margins and re-operations). 
Between 2011 and 2016, the use of NAC in the Netherlands increased from 9% to 
18%. Coinciding with this trend, we demonstrated that NAC increases the rates of 
breast-conserving surgery (BCS) for all stages of breast cancer from 43% in 2011 to 
57% in 2016. The overall positive margin rate in our study is 6,9% for ‘BCS after NAC’ 
compared to 3,3% for ‘primary BCS’, leading to a re-operation rate of 6,6% in ‘BCS 
after NAC’ and 5,3% in ‘primary BCS’. Moreover, this nationwide data showed that 
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‘BCS after NAC’ compared to ‘primary BCS’ results in equal surgical outcomes for cT2 
invasive breast cancer and improved surgical outcomes for cT3 invasive breast cancer. 
In view of the trend towards de-escalation of surgical treatment in selected patients 
with an excellent pathologic response, these promising results confirm that clinicians 
are increasingly able to perform ‘BCS after NAC’.
In chapter 6, we evaluated the management of axillary lymph-node positive breast 
cancer in the Netherlands. Axillary lymph node management in breast cancer patients 
has changed dramatically during past decades. Previously, performing an axillary 
lymph node dissection (ALND) was the standard of care for all non-metastatic breast 
cancer patients. However, ALND is associated with a significant risk of complications 
such as arm swelling (lymphedema), pain, restricted shoulder movement, and sensory 
changes in the arm and hand.17,18 In the early 90s, sentinel lymph node biopsy (SLNB) 
was introduced as an accurate and less invasive axillary staging procedure, omitting 
the need for ALND in early-stage sentinel lymph node-negative breast cancer patients.
Since the publication of the results of the ACOSOG-Z0011 and AMAROS trial, omit-
ting a ALND in sentinel node-positive breast cancer patients is proposed in selected 
patients.19,20,21,20 The results of these trials are illustrated by the 2012 Dutch breast 
cancer guideline, suggesting omission of ALND in cT1-2N0 breast cancer patients with 
a maximum of two positive sentinel nodes treated with breast conserving treatment 
and adjuvant systemic therapy.22
Between 2011 and 2015, the use of sentinel lymph node biopsy as definitive axillary 
staging increased from 92% to 98% for all breast cancer patients. ALND as definitive 
axillary staging decreased from 24% to 6%. This decreasing trend in the numbers of 
ALNDs for all tumour stadia might reflect the growing experience and the confidence 







part II: Quality assurance in breast implant surgery; the Dutch 
Breast Implant Registry (DBIR)
Breast augmentation is the most commonly performed surgical procedure in plastic 
surgery worldwide. Most of the procedures performed are for cosmetic purposes, a 
smaller part for breast reconstructive reasons. In the Netherlands, approximately 3.3% 
of all mature women have breast implants.23
Although the use of breast implants is generally considered to be safe, breast implants 
are associated with short- and long-term complications, such as infection, implant 
rupture or deflation, late seroma, and capsular contracture.24,25,26 In particular, implant 
scandals from the Dow-Corning crisis in the 1980s to the more recent PIP crisis have 
raised public awareness.27 Recently, an association between breast Anaplastic Large 
Cell Lymphoma (ALCL) has been found.28,29 Furthermore, it has been suggested that 
there is an association between autoimmunity and silicon exposure resulting in ASIA 
(autoimmune/inflammatory syndrome induced by adjuvants) and various autoimmune 
diseases.30,31,32
In response to these emerging safety concerns, several national societies around the 
world developed breast devices registries of which six up and running registries today, 
including the Australian Breast Device Registry (ABDR),33 the Bröstimplantatregistret 
of Sweden (BRIMP),34 the Austrian Breast Implant Register (ABIR),35 the Breast and 
Cosmetic Implant Registry of the United Kingdom (BCIR),36 the US National Breast 
Implant Registry (NBIR)37, and the Dutch Breast Implant Registry (DBIR).38
The DBIR registry was founded in 2015, with the objective to facilitate and organize the 
initiation of nationwide breast implant-related outcome measures in the Netherlands. 
A unique feature of the DBIR is its opt-out construct, without the need for informed 
consent. The national coverage has been assessed by comparing the number of institu-
tions in DBIR to the number of eligible institutions known by the Dutch Health and 
Youth Care Inspectorate (IGJ). In the first full registration year (2016), the participation 
rate was 95% for hospitals and 78% for private clinics.
In chapter 7, we provide an overview of early outcomes and experiences of the DBIR 
registry. Between 2015 and 2017, a total of 15,049 patients and 30,541 breast implants 
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were included. A minimum incidence rate of 1 implant per 1,691 women in 2017 could 
be determined. The majority of devices was inserted for a cosmetic indication 26,036 
(85.2%), and 4,505 (14,8%) for a breast reconstruction. In general, patient, device and 
surgery characteristics differed per indication group. Patients who underwent cosmetic 
breast augmentation were younger than breast reconstruction patients (31,5 versus 
49,7 years of age). Between 2016 and 2017, a decrease in the use of textured implants 
was seen in both indication groups. Furthermore, in the reconstructive group, an in-
crease of the use of round implants and silicone filled implants was found, with appears 
to coincide with the critical issue of breast implant-associated ALCL.
Another preliminary finding is the differences between hospitals in the use of four 
selected perioperative infection control measures (all ranged 0-100%). Overall, 
an increased use was shown of prophylactic intravenous antibiotics, gloves change 
before the insertion, and in the rinse of a breast implant with an antiseptic solution. 
The use of drains decreased in reconstructive procedures but increased in cosmetic 
augmentations. Long-term clinical data will eventually reveal the actual health effects 
of intraoperative techniques and antiseptic precautions.
In the final part of this thesis, chapter 8, we have outlined the process undertaken by 
the International Collaboration of Breast Registry Activities (ICOBRA). ICOBRA is an 
international multidisciplinary group with expertise in breast device registries including 
consumer representatives, national regulators, and biostatisticians, and were gathered 
to develop a standardized global minimum dataset for breast implant registries. Data 
points from the six up and running national breast implant registries were compared. 
Secondly, a modified Delphi approach was used, with surveys requiring the panellists 
to rate the importance of each data point to be included in the global minimum data 
set. After four survey rounds, a consensus was reached on a list of 32 data points to be 
included in the global core dataset. Data points for which consensus was not achieved 
(16 data points), were not voted into the core set and became the optional dataset. 
Consensus on definitions for all data points was achieved using the definitions of the 
Australian dataset as the starting point. The ICOBRA core- and optional dataset is 
almost completely integrated into the DBIR dataset. It is expected that the global 
dataset will be adopted by currently operating breast device registries within two years 






Austria, Canada, France, Germany, Ireland, Italy, the Netherlands, New Zealand, South 
Africa, the United Kingdom, and the United States). The ICOBRA global dataset will 
allow pooling data from breast implant registries in order to evaluate active surveil-
lance and comparative outcomes. This will safeguard the health of recipients of breast 
implants by preventing implantation of under-performing devices.
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There are several reasons why national clinical quality audits can and should help us in 
the provision of good quality of care:
1. Quality Assurance and Patient Safety: Participation in quality improvement initia-
tives, with continuous quality measurement and benchmarked feedback of data, 
reveals opportunities to improve health care, decreases unintended variation and 
eventually might improve the value of healthcare delivery.1,2
2. Scientific importance: The outcomes of ‘real world’ medical practice data are 
becoming of increasing practical and scientific importance.3 By using nationwide 
clinical data, the actual applicability of important findings of biomedical and clinical 
research can be evaluated according to daily practice.
3. Shared decision making: Patients want to know the quality of care they are about to 
receive. And, shared decision making is becoming increasingly important in achiev-
ing patient-centered care. Dynamic clinical data mining can be used to provide 
real-time decision support.4
4. Cost-effectiveness: Health care systems costs in developed countries are rising, 
in part due to the introduction of advanced medical technology, pharmaceutical 
disbursement as well as growing cancer burden.5 Clinical audits can function as 
a quality instrument to increase the efficiency of care, and therefore as a tool to 
reduce costs.6
Quality assurance in breast cancer care
The main purpose of a national clinical quality audit is to provide healthcare providers 
with reliable, benchmarked information on structure, process and outcome parameters. 
We have shown that the NABON Breast Cancer Audit (NBCA) has reached that goal 
and is continuously working on exploring this purpose even more.7 In five years’ time, 
all hospitals reached the predefined standards for the management of breast cancer 
in the Netherlands; e.g. ‘more than 90% of patients being discussed in the multidis-
ciplinary meetings’, ‘more than 90% of patients with a standard defined pathology 
report’, and ‘less than 15% of patients with involved margins for invasive breast cancer’. 
This demonstrates that guideline adherence has been improved and a multidisciplinary 
approach is widely adopted in the Netherlands.
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Producing meaningful quality indicators that inform clinicians is essential in the support 
of benchmarked feedback. The current quality indicator set of the NBCA predominantly 
consists of quality process indicators, covering different aspects of the multidisciplinary 
care path for breast cancer patients, from diagnostic work-up to different treatment op-
tions. Two types of quality process indicators can be distinguished: I. Quality indicators 
that measure compliance with clinical guidelines with the aim to improve adherence 
to guidelines and reduce variation in delivered care II. Quality indicators that monitor 
the implementation of new treatment modalities and techniques, where variation is 
expected.
Figure 1 shows examples of different quality process indicators and their trends in 
time, indicating the relevance of a particular indicator for quality improvement. An 
increase or decrease on a nationwide level on a quality indicator represents its adop-
tion as a component in the multimodality care of breast cancer. In addition, decreasing 
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Examples of Type I indicators are a. ‘the use of a Magnetic Resonance Imaging scan 
(MRI) before the start of Neoadjuvant Chemotherapy (NAC)’ and b. ‘the omission of 
a completion axillary lymph node dissection (ALND) in clinical early-stage sentinel 
node-positive breast cancer patients’. Both these indicators are based on clear recom-
mendations in the Dutch guideline. An upward (1A), respectively downward (1B) trend 
in combination with decreasing variation is shown, representing an improvement of 
guideline compliance for both the use of MRI before NAC as well as the omission of 
ALND in patients with a positive sentinel node.
In figure 1 c and d, ‘the use of NAC’ and ‘the use of immediate breast reconstruction 
(IBR) after mastectomy’ in invasive breast cancer –are depicted as examples of Type II 
indicators; as evidence from research studies has not yet been included in the national 
guideline. Despite an upward trend on a nationwide level, the routine of application of 
these modalities remains different between hospitals; as being shown by a persisting 
wide variation.
Although the general trend in breast cancer treatment in the Netherlands shows 
an improvement of the quality of care and a rapid adaptation of new study results, 
transparency on inter-hospital variation may increase the exposure to new approaches, 
in particular for treatment modalities without a set standard (yet). Where national 
guidelines are rigid, feedback from clinical audits could be interpreted as a ‘dynamic 
guideline’ that provides new insights and reduces unintended clinical practice gaps.
Today, the challenge of the NBCA is to move beyond a national benchmark mainly 
centered on process information to a national breast cancer audit centered on out-
comes, including composite measures and patient-reported outcomes (PROMs), that 
visualizes the actual results of care. This approach is complex, and can only occur with 
continuous evaluation of the given quality indicators, and to redefine and test potential 
new quality indicators with the support of data over time. In the meantime, quality 




Furthermore, a national clinical quality audit provides complete information on clinical 
care and outcomes, with the inclusion of patients that do not fit within the inclusion 
criteria of clinical trials. The database of the NBCA consists of an amount of data and 
any person or hospital who is involved in the NBCA audit can submit a research ques-
tion. This has led to a scale of scientific research, of which the most important studies 
are shown in table 1. In particular, nationwide studies on the use of MRI, the use of 
neoadjuvant systemic treatment, surgical management of the breast, axillary lymph-
node management, the prognostic value of the 70-gene signature (70-GS) and the use 
of boost irradiation have been conducted.
This thesis includes the results of one of the largest nationwide studies demonstrat-
ing a trend of more breast-conserving surgery (BCS) after NAC (chapter 5). Moreover, 
this study confirms that clinicians in the Netherlands are increasingly able to perform 
‘BCS after NAC’ while maintaining good surgical outcomes (including margins and 
re-excision rates), compared to primary BCS.
Another notable finding in this thesis is the downward trend in the use of an axillary 
lymph node dissection (ALND) in cT3-4N0M0 sentinel node-positive breast cancer pa-
tients (chapter 6). While no randomized trials have been published before to justify less 
extensive axillary surgery in this group of patients, this study reflects the confidence 
of clinicians in the concept that not every positive axillary sentinel lymph node will 
develop into clinical detectable axillary disease.
Though these are promising results, however, the reliability of this developmental 
data is limited by the retrospective nature and missing data on follow-up. Therefore, 
we recommend that future research should include epidemiological sound data and 
patient-reported outcomes (e.g. quality of life, functional and cosmetic outcomes), in 









Table 1. Studies on trends and causes of inter-hospital variation, supported by NBCA data (2015-2018)
Discipline Publications
Radiology 1 M.B.I. Lobbes. Breast MRI increases the number of mastectomies for ductal cancers but 
decreases them for lobular cancers.
2 I.J.H. Vriens. Breast MRI use in patients undergoing NAC is associated with fewer 
mastectomies in large ductal cancers but not in lobular cancers.
Surgery 3 P.E.R. Spronk. Breast-conserving therapy after neoadjuvant chemotherapy; data from the 
Dutch Breast Cancer Audit.
  4 I.G.M. Poodt. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients 
Treated Between 2011 and 2015. A Dutch Population-based Study in the ACOSOG-Z0011 
and AMAROS Era.
Plastic Surgery 5 A.C.M. van Bommel. Large variation between hospitals in immediate breast reconstruction 
(IBR) rates after mastectomy for breast cancer in the Netherlands.
  6 K. Schreuder. Hospital organizational factors affect the use of IBR after mastectomy for 
breast cancer in the Netherlands.
  7 K. de Ligt. The effect of being informed on receiving IBR in breast cancer patients.
  8 A.C.M. van Bommel. Discrepancies between surgical oncologists and plastic Surgeons in 
patient information provision and personal opinions towards IBR.
Radiotherapy 9 K. Schreuder. Variation in the use of boost irradiation in breast-conserving therapy in the 
Netherlands: The effect of a national guideline and confounding factors.
Systemic 10 A. Kuijer. Using a gene expression signature when controversy exists regarding the 
indication for adjuvant systemic treatment reduces the proportion of patients receiving 
adjuvant chemotherapy.
treatment 11 A. Kuijer. Factors Associated with the Use of gene-expression profiling (GEP) in Estrogen 
Receptor-Positive Early-Stage Breast Cancer Patients.
12 K. Schreuder. Impact of GEP in patients with early breast cancer, when applied outside the 
guideline, directed indication area.
13 P.E.R. Spronk. Variation in the use of neoadjuvant chemotherapy in patients with stage III 
breast cancer: results of the Dutch Breast Cancer Audit.
  14 P.E.R. Spronk. Current decisions on neoadjuvant chemotherapy for early breast cancer: 
Experts’ experiences in the Netherlands.
15 I.G.M. Poodt. The administration of adjuvant chemo(-immuno) therapy (AC) in the post 
ACOSOG-Z0011 era; a population-based study.




Multiple determinants might attribute to unintended inter-hospital variation;
· patients’ preferences
· clinicians’ preferences
· the organizational context
An example of a treatment modality without a predefined standard is the use of 
neoadjuvant chemotherapy (NAC) for breast cancer. Despite an international trend of 
increasing implementation for NAC, considerable variation in the use of NAC remains 
between hospitals [this thesis].
Patients’ preference
Where in earlier years the patient was happy with a doctor who decided the best treat-
ment plan; nowadays, patients’ preference and the level of shared decision-making are 
important factors in clinical decision making, especially in breast cancer care. There 
are multiple factors affecting patients’ considerations, including information related 
to treatment efficacy and toxicity, prior experience with the treatment, quality of life 
during or after treatment, opinion of their care provider and of partner or family prefer-
ence.13 However, as described in chapter 4, the results of our study revealed that the 
need to make a treatment decision on NAC was found to be made explicit in only a 
small number of patients, and there remains room for improvement in the delivery of 
shared-decision making.
Clinicians’ opinions exert one of the most powerful influences over patients’ prefer-
ences.14 In order to meet the needs of patients with cancer and their families, the 
system should be oriented to the provision of ‘patient-centered care’. As defined by 
the Institute of Medicine: “Patient-centeredness is providing care that is responsive 
to individual patient preferences, needs, and values and ensuring that patient values 
guide all clinical decisions” 15. As a component of patient-centered care, structured 
decision aids have been advocated to help patients become active participants in mak-
ing treatment choices.16 In the future, NBCA data may contribute to providing more 










Whether a patient is a candidate for chemotherapy (NAC or AC) depends on mul-
tiple factors; e.g. our ability to preoperatively estimate the change on a pathological 
complete response. The results of our survey among specialists confirm that clinicians’ 
considerations on NAC differ significantly (chapter 3). In particular opinions on the 
surgical management following NAC were inconclusive. The restraint to perform 
BCS after NAC may arise from the challenge for surgeons to determine the extent 
and original location of the residual lesion after NAC. Another possible contributing 
aspect is the concept of accessibility and proximity.8 Similar to other choices made 
with equivocal information, clinicians may satisfice by choosing an advice source who 
is known. Again, this highlights the importance of continuous up-to-date feedback on 
new treatment modalities.
The organizational context
Non-clinical influences may play an important role either in the adoption of new treat-
ment modalities; such as the interaction within a professional community and features 
of clinical practice such as local management policies. Clinicians are more likely to be 
early adopters if they are actively involved in the medical community.9,10 It creates more 
awareness among physicians and it narrows the gap between the best available evi-
dence and current practice. Of notice, we observed a significantly higher use of NAC 
in hospitals participating in neoadjuvant clinical studies [this thesis]. Also, companies 
can influence physicians in certain ways; for example by arranging interaction with a 
pharmaceutical representative, funding physicians for travel or attending educational 
symposia as well as providing research funding.11,12
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Quality assurance and patient safety in breast implant surgery
Breast implants are routinely used for breast augmentation. In the Netherlands, an 
estimated of more than 11.000 implants are annually inserted for cosmetic reasons.17 
Moreover, improved outcomes of breast cancer have resulted in a growing number of 
breast cancer survivors, who choose for reconstructive surgery of the breast following 
mastectomy.18,19 Implant-based breast reconstruction is the most commons means 
of reconstructive surgery. Compared to a reconstruction with autologous tissue, the 
advantages of and implant-based breast reconstruction are the short operative time, 
lack of donor-site morbidity, and quicker return to normal life activities.20 According to 
the NBCA audit, an estimate of 10% of patients with invasive breast cancer received 
a mastectomy followed by an immediate breast implant reconstruction in the Nether-
lands in 2016.21
Despite the increase in implant procedures, there are currently no reliable or epidemio-
logically sound data to measure implant performance. Therefore, the main purpose of 
the Dutch Breast Implant Registry (DBIR), founded in 2015, is to provide sufficient data 
on breast implant surgery, to address potentially serious complications such as implant 
removal, reoperation, and rupture or deflation of the implant. Moreover, the registry 
can be used as a track-and-trace system in case of an implant recall. Patients with 
the implant(s) of interest can be identified and hospitals can be addressed to prevent 
further implantation of faulty devices. An example of this is the recent withdrawal from 
the market of Silimed implants after German health officials found that the surfaces 
of some devices were contaminated with unknown particles.22 In general, a medical 
device cannot be marketed in Europe without carrying a certificate of conformity. 
After this report became known, within a few hours the number of Silimed implants in 
the Dutch Breast Implant Registry could be determined, thereby providing clarity for 
patients and institutions.
Scientific importance
In addition, in the absence of high-quality, randomized controlled trials to assess the 
effect of various intraoperative techniques on surgical and cosmetic outcomes, data 
of the national DBIR registry provide a pragmatic alternative source of evidence. For 
example, previous studies suggest that the risk of capsular contracture is reduced when 









used instead of an areolar incision.23,24 However, most of these studies are biased due 
to treatment by indication, loss of follow-up and lack information on potential risk fac-
tors as the effect of the implant itself. Simultaneously, unexplained variation between 
hospitals in the use of antiseptic precautions (antibiotics, antiseptic rinse, glove change 
prior to implant handling and the use drains) has been observed. [this thesis].
Most importantly, epidemiologically data will reveal the actual health effects of breast 
implants in relation to breast implant-associated Anaplastic Large Cell Lymphoma 
(BIA-ALCL) and/or potential other long-term adverse outcomes. BIA-ALCL is a rare 
cancer of the immune system believed to be causally associated with textured breast 
implants.25,26 So far, various, not mutually exclusive causal factors have been suggested. 
Specifically, a local inflammatory response, elicited by silicone derived products or 
specific bacterial species adherent to the prosthesis surface (biofilm). In our DBIR data, 
between 2016 and 2017, a significant decrease in the use of textured implants and an 
increase in the use of smooth implants was observed already, that appears to coincide 
with the critical issue of BIA-ALCL [this thesis].
International collaborations
It is important that quality improvement initiatives are aligned as much as possible. 
Harmonization of indicator sets, data points, and data definitions is key to eventually 
pool and compare data from different clinical audits. The process undertaken by the 
International Collaboration of Breast Registry Activities (ICOBRA) in which they devel-
oped a standardized global minimum dataset for breast implant surgery, is an attempt 
in achieving this goal [this thesis]. Importantly, the use of large pooled international 
datasets is the only way we can address adverse events with a low incidence. In addi-
tion, an international approach can help in the exchange of information on practical 
hurdles that will be faced when starting a clinical quality audit; including (1) funding, 
(2) medical ethical issues, (3) privacy and legal issues (4) compliance (5) dataset and 




The NABON Breast Cancer Audit has been useful by serving as a platform for initiatives 
of quality improvement in breast cancer care in the Netherlands. The Dutch Breast 
Implant Registry (DBIR) is one of the first up-and-running breast implant registries 
worldwide, and the result of an international collaborative and conjoint effort by the 
ICOBRA network. Now that a sound foundation for quality assurance in breast cancer 
care and breast implant surgery has been laid, further national and global initiatives 
should be taken towards a common interconnecting registration system for multiple 
purposes.
Interconnecting data systems
Access to a vast volume of data, to identify and collect identifiable information on 
best practices, will contribute to individualized strategies for diagnostic or therapeutic 
decision-making. However, several challenges with data in healthcare have yet to be 
addressed; the technical expertise required to pool data, a lack of robust integrated 
security surrounding it, and a joint venture between facilitating companies in the field 
of health care monitoring. A. A patient-centered system will not be able without the 
involvement of all disciplines in the multidisciplinary pathway of care. B. A connection 
of clinical audits to other data systems is fundamental in order to move beyond a linear 
data structure to a multidimensional model. It would not only create an enormous 
resource for outcome research, but it may also support prescriptive modeling in order 
to more effective diagnosis and treatment.32,33
Patient-centered care
The use of Patient-Reported Outcome Measures (PROMs); reports and ratings pro-
vided by patients or their proxies about their health, functioning, health behaviors and 
quality of care, is set to rise in clinical and research setting.29 It can be used for screen-
ing early symptoms or side effects of treatments, monitoring outcomes meaningful 
to patients, and most importantly, improves communication at the individual level. 
Their use in clinical practice helps to ensure the patient ‘voice’ is present during the 
consultation and evaluation of treatment, and may help in better patient-physician 
dialogues. In 2016, a global standard set of value-based patient-centered outcomes 









Measurement (ICHOM), a multidisciplinary international working group comprised of 
patient advocates and health care providers, including members of the Dutch Institute 
for Clinical Auditing (DICA) and NBCA scientific committee.30 This standard breast 
cancer set consists of outcomes of almost a full cycle of breast cancer care, with an 
emphasis on patient-reported outcomes.
In-hospital health care programs
Health care providers are increasingly incorporating clinical auditing into daily practice, 
and that is changing perspectives into how to make care more efficient and valuable. 
An example of a quality improvement program is the ‘Santeon Value-Based Health 
Care Program’, a conjoint effort of seven teaching hospitals across the Netherlands that 
use benchmarked information on the process, outcomes, and costs, including the use 
of the ICHOM breast cancer set.31 The strength of this collaboration lies in its set-up 
in which a ‘quality improvement team’ is assigned per hospital (consisting of a project 
manager, data manager, data analyst). As a result, expertise on clinical auditing is not 
limited to a national audit board, but an in-hospital clinical team creates a sustainable 
base for continued implementation of quality culture improvement activities. In addi-
tion, the implementation of the ‘Codman dashboard’, an application from DICA that 
provides dynamic feedback on process and outcomes of data per hospital, will increase 
the use of clinical audits in daily practice even more.35
Cost-effectiveness
Beyond the scope of this thesis, a national clinical quality audit can also function as 
a tool to reduce costs.6 Medical innovation has delivered significant improvements 
in clinical care, but the changes in healthcare are also reflected by the expenditure 
in healthcare costs.36 And, the fact is that we are faced with an aging population and 
the demand for care will only increase. As raised by Michael E. Porter, the overall goal 
in healthcare should be maximizing value for patients.37 An opportunity to improve 
insight in the efficiency and value of healthcare is the introduction of more accurate 
cost calculations when evaluating care processes. As seen in the study of Govaert et al. 
in which they investigate whether improvements in surgical colorectal cancer care leads 
to a reduction of hospital costs, the reduction of complications or other undesired 
outcomes is undoubtedly beneficial to patients and reduces costs.38
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CONCLUSION
The results of this thesis show that clinical audits as The NABON Breast Cancer Audit 
(NBCA) and The Dutch Breast Implant Registry (DBIR) have the potential to provide 
quality assurance and further extensive outcome research. Several important nation-
wide trends on breast cancer treatments and breast implant surgery are described, 
what no randomized trials have been published before. Furthermore, data from clinical 
audits can be used for clinical  decision-support systems and may support broader 
health care effectiveness research. Future quality initiatives should focus on (interna-
tional) collaborations and sharing data, which may help to improve the quality of care 
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Landelijke kwaliteitsaudits dienen ter ondersteuning van kwaliteitsverbetering van zorg 
in Nederland. In dit proefschrift worden de resultaten beschreven van twee belangrijke 
landelijke kwaliteitsaudits op het gebied van borstkankerzorg (de NBCA) en borstim-
plantaatchirurgie (de DBIR).
Het meten en evalueren van de kwaliteit van geleverde zorg is van cruciaal belang 
om zorg te kunnen verbeteren. Deze kwaliteitsinformatie wordt tevens gebruikt ter 
ondersteuning van beleidsvorming in de gezondheidszorg en voor zorginkoop door 
zorgverzekeraars. Er zijn diverse instrumenten ontwikkeld om de kwaliteit van zorg 
meetbaar te maken; o.a. enquêtes onder consumenten, inspecties vanuit de overheid, 
interne audits, en dus zogenaamde landelijke ‘kwaliteitsaudits’.1 Een kwaliteitsaudit is 
een systematische methode, waarbij het proces en de uitkomsten van zorg op landelijk 
niveau worden geëvalueerd aan de hand van vooraf vastgestelde standaarden (kwa-
liteitsindicatoren), welke voornamelijk zijn gebaseerd op ‘evidence-based medicine’.2 
In het algemeen is het doel van een kwaliteitsaudit om expertise samen te brengen en 
hierdoor kennis over ziekten en behandelingen te vergroten.
Middels financiering vanuit het Nederlandse Ministerie van Gezondheidzorg (VWS), 
werd door de Nederlandse Verenging van Heelkunde (NvvH) in 2009 de eerste lande-
lijke kwaliteitsaudit ontwikkeld: the Dutch Surgical Colorectal Audit (DSCA).3 In 2011 
werd ‘the Dutch Institute of Clinical Auditing’ (DICA) opgericht om de oprichting van 
nieuwe landelijke kwaliteitsaudits in Nederland te kunnen blijven faciliteren.4 In deze 
periode werd tevens een alarmerend rapport gepubliceerd vanuit de Inspectie van 
de Gezondheidszorg over de verschillen in borstkankerzorg in Nederland.5 Vanuit het 
Nationaal Borstkanker Overleg Nederland (NABON) werd een werkgroep geformeerd 
en nog in hetzelfde jaar werd de NABON Breast Cancer Audit (NBCA) opgericht.6 
Inmiddels zijn er gegevens van meer dan 100.000 borstkankerpatiënten geregistreerd, 
kwaliteitsindicatoren geëvalueerd en doorontwikkeld, en kwaliteit-verbeterinitiatieven 
in ziekenhuizen ondersteund middels de data uit de NBCA. Ook andere landelijke 
kwaliteitsaudits voor uiteenlopende oncologische en niet-oncologische ziektebeelden 
ontwikkelen zich in snel tempo (vandaag de dag telt DICA 22 kwaliteitsaudits, inclusief 
de Dutch Breast Implant Registry).7
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Deel I: Kwaliteitsborging borstkankerzorg; de NABON Breast 
Cancer Audit (NBCA)
Borstkanker is de meest voorkomende oorzaak van kanker bij vrouwen. In Nederland 
krijgen elk jaar meer dan 15.000 vrouwen de diagnose borstkanker.8 Er hebben in de 
afgelopen decennia enorme ontwikkelingen plaatsgevonden op het gebied van de 
behandeling van borstkanker. Om de kwaliteit van de geleverde borstkankerzorg te 
kunnen blijven bewaken, werd door een groep vertegenwoordigers van verschillende 
disciplines betrokken binnen de behandeling van borstkanker de NBCA-audit opge-
richt.
In hoofdstuk 2 hebben we ons gericht op trends in het gebruik van Neoadjuvante 
Chemotherapie (NAC) binnen de behandeling van borstkanker in Nederland. Chemo-
therapie kan zowel vóór als na de operatie worden toegepast, respectievelijk Neoad-
juvant (NAC) of Adjuvant (AC), beide leidend tot vergelijkbare cijfers betreft ziektevrije 
en totale overleving.10,11 Het doel van chemotherapie is om mogelijke nog bestaande 
micro-metastasen te elimineren en hierdoor de kans op een recidief te verminderen.9
Echter, het toepassen van NAC (chemotherapie voorafgaand aan de operatie) heeft 
voordelen ten opzichte van AC. Ten eerste leidt het gebruik van NAC tot zogenaamde 
‘downstaging’; het verkleinen van de tumor. Hierdoor kan uiteindelijk vaak borstspa-
rend geopereerd worden, terwijl in eerste instantie een mastectomie (het verwijderen 
van de gehele borst) zou zijn geïndiceerd.12,13 Een ander voordeel van NAC is ‘down-
staging’ van mogelijke uitzaaiingen naar de lymfklieren in de oksel.14,15 Bovendien is er 
aangetoond dat NAC, in vergelijking tot AC, de ziektevrije overleving kan verbeteren 
voor bepaalde subtypen van borstkanker (respectievelijk triple-negatieve en/of HER2-
positieve borstkanker), mits er een pathologische complete respons na NAC wordt 
bereikt.16 Een ander potentieel voordeel van NAC is de mogelijkheid om de tumor-
biologie ‘in vitro’ te onderzoeken. De respons op chemotherapie kan hierdoor worden 
geanalyseerd en het chemotherapieschema kan worden aangepast indien er sprake is 
van een suboptimale respons.
Volgens de Nederlandse richtlijn voor borstkanker is NAC geïndiceerd bij patiënten 





uitzaaiingen naar de lymfeklieren in de oksel). Dit is conform de aanbevelingen van 
internationale richtlijnen.
Het landelijke gemiddelde aan NAC voor stadium III borstkanker is van 2011 tot 2015 
in Nederland nauwelijks veranderd, met een consistent percentage van gemiddeld 
77%. Echter, een aanzienlijke variatie in de toepassing hiervan tussen ziekenhuizen [van 
0 tot 100%] suggereert dat er sprake is van een onderbenutting van NAC in Nederland. 
Factoren die samenhingen met het krijgen van deze behandeling waren: een jonge 
leeftijd, de tumorgrootte, het aantal positieve lymflieren en de (negatieve) hormoonre-
ceptorstatus. Ook een multidisciplinaire preoperatieve samenwerking tussen zorgver-
leners en deelname aan klinische trials bleken het gebruik van NAC te beïnvloeden. 
Grote verschillen tussen ziekenhuizen bleven echter aanwezig na correctie van deze 
case-mix. De conclusie luidt dan ook dat slechts een deel van de aangetroffen variatie 
tussen ziekenhuizen in Nederland in het toepassen van NAC is toe te schrijven aan 
patiënt- of tumorkenmerken.
Om beter inzicht te krijgen in de achterliggende oorzaken van variatie en om de 
bewustwording bij specialisten en patiënten te verhogen, werd er vervolgonderzoek 
geïnitieerd, zoals beschreven in hoofdstuk 3 en 4. In hoofdstuk 3 onderzochten we 
de mening van chirurgen en medisch oncologen ten aanzien van NAC. In totaal waren 
er 138 specialisten (70 chirurgen en 68 medisch oncologen) die een online survey 
voltooiden, met vragen die betrekking hadden op de invloed van patiënt-, ziekte- en 
managementgerelateerde factoren op de besluitvorming ten aanzien van NAC. Vrijwel 
elke deelnemer (94%) was het eens met de Nederlandse richtlijn; NAC is geïndiceerd 
voor stadium III borstkanker. Ondanks dat ook het merendeel (75%) het voordeel van 
‘downstaging’ beaamde, adviseert 64% van de artsen NAC op stelselmatige basis 
wanneer chemotherapie geïndiceerd is op basis van preoperatief vastgestelde facto-
ren. Redenen om NAC niet aan te bevelen zijn: co morbiditeit, een leeftijd >70 jaar 
en een WHO-prestatiestatus ≥2. Ook werden de volgende risico’s ten aanzien van de 
chirurgie onderstreept door enkele specialisten; NAC zou het risico verhogen op: een 
niet-radicale resectie (21%), chirurgische complicaties (9%) en een recidief (5%).
In hoofdstuk 4 hebben we onderzocht in hoeverre patiënten zich betrokken voelden 
in de besluitvorming over de timing van chemotherapie; die respectievelijk vóór (NAC) 
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als na de operatie (AC) toegepast kan worden. Alle 394 vrouwelijke respondenten 
waren >18 jaar en tussen 2013 en 2014 behandeld met NAC of AC vanwege stadium 
II of stadium III borstkanker. De 35 vragen hadden o.a. betrekking op de mate van 
informatieoverdracht, of de mogelijke keuze tussen beide opties was besproken en of 
de patiënt zich betrokken had gevoeld in de uiteindelijke besluitvorming. Slechts met 
een kleine groep respondenten die behandeld waren met AC was de mogelijkheid 
van NAC besproken. Dit was met name in de groep respondenten met stadium II 
borstkanker. Minder dan de helft van alle respondenten heeft het gevoel gehad ‘dat zij 
de keuze over de timing van chemotherapie zelf hebben gemaakt’.
In hoofdstuk 5 hebben we de trends in het gebruik van NAC onderzocht voor alle 
stadia van borstkanker en daarbij met name gekeken naar de impact van NAC op de 
chirurgische uitkomsten (zowel het percentage aan positieve resectiemarges als het 
aantal her-operaties). Het algehele gebruik van NAC is toegenomen in Nederland, 
met een landelijk gemiddelde van 9% in 2011 naar 18% in 2016. Tevens konden we 
aantonen dat NAC de mogelijkheid tot borstsparende chirurgie (BCS) voor alle stadia 
van borstkanker aanzienlijk heeft verhoogd; van 43% in 2011 tot 57% in 2016. Het 
percentage positieve resectiemarges voor ‘BCS na NAC’ bedroeg in onze studie 6,9%, 
in vergelijking tot 3,3% voor ‘primair BCS’. Bovendien bevestigt onze studie dat ‘BCS 
na NAC’ in vergelijking tot ‘primair BCS’ resulteerde in gelijke chirurgische uitkomsten 
voor cT2 tumoren (tumorgrootte 2-5cm), en zelfs betere chirurgische uitkomsten voor 
cT3 tumoren (tumorgrootte >5cm).
Deze resultaten zijn veelbelovend gezien de tendens naar de-escalatie van de chirur-
gische behandeling; het minder invasief opereren of zelfs - in de toekomst - niet meer 
opereren indien een complete pathologische respons kan worden bereikt middels 
NAC. Het bevestigt dat chirurgen steeds beter in staat zijn een resectie uit te voeren 
na NAC.
In hoofdstuk 6 onderzochten we trends in de behandeling van lymfeklierpositieve 
borstkanker, een stadium van borstkanker waarbij er uitzaaiingen naar de oksel (axilla) 
zijn geconstateerd. De behandeling van lymfeklierpositieve borstkanker is in de af-
gelopen decennia drastisch veranderd. Voorheen was het uitvoeren van een axillaire 





Echter, een ALND is geassocieerd met een significant risico op complicaties zoals lym-
foedeem (zwelling van de arm door stapeling van lymfevocht), pijn, beperkte mobiliteit 
en sensorische disfunctie in de onderarm.17,18 In het begin van de jaren ‘90 werd de 
schildwachtklierprocedure (SLNB) geïntroduceerd. Dit is een nauwkeurige en minder 
invasieve axillaire stadiëringsprocedure waardoor er geen noodzaak meer is voor een 
ALND in patiënten met een negatieve schildwachtklier.
Sinds de publicatie van twee belangrijke studies op het gebied lymfeklierpositieve 
borstkanker, de ACOSOG-Z0011- en AMAROS- trial, wordt het weglaten van een 
ALND geadviseerd in een geselecteerde groep aan patiënten waarbij de schildwacht-
klier desondanks positief is.19,20
De tienjaarresultaten van de ACOSOG-Z0011-studie (1999-2004, gepubliceerd in 
2011) toonden aan dat er geen significant verschil was in locoregionale recidiefvrije 
overleving voor cT1-2 borstkankerpatiënten (tumorgrootte <5cm) met 1-2 positieve 
schildwachtklier(en), indien zij behandeld waren met BCS gevolgd door radiotherapie 
of indien zij behandeld waren met een ALND.21 De AMAROS-studie (2001-2010, ge-
publiceerd in 2014) bevestigde dat voor cT1-2 borstkankerpatiënten met 1≤ positieve 
schildwachtklier de regionale controle vergelijkbaar is tussen een ALND en axillaire 
bestralingstherapie. Tevens gaat axillaire radiotherapie gepaard met aanzienlijk minder 
morbiditeit.20 Naar aanleiding van deze resultaten adviseert de huidige Nederlandse 
borstkankerrichtlijn dat een ALND achterwege gelaten kan worden indien er sprake is 
van cT1-2 borstkanker met 1-2 positieve schildwachtklier(en) en de behandeling be-
staat uit borstsparende chirurgie, radiotherapie en adjuvante systemische therapie.22
Het gebruik van een schildwachtklierprocedure als definitieve axillaire stadiëring is 
toegenomen van 92% in 2011 naar 98% in 2015, voor alle borstkankerpatiënten in Ne-
derland. Het gebruik van een ALND als definitieve axillaire stadiëring daalde van 24% 
naar 6%. Deze afnemende trend in het aantal ALND’s voor alle stadia van borstkanker 
is een weerspiegeling van de snelle implementatie in Nederland van deze belangrijke 
studieresultaten en een groeiende kennis en ervaring onder specialisten, waardoor de 
oksel steeds minder invasief wordt behandeld.
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Deel II: Kwaliteitsborging borstimplantaatchirurgie; the Dutch 
Breast Implant Registry (DBIR)
Een borstvergroting is de meest uitgevoerde chirurgische ingreep binnen de plastische 
chirurgie, veelal uitgevoerd vanwege cosmetische redenen of vanwege de wens tot 
een borstreconstructie na bijvoorbeeld de behandeling van borstkanker. In Nederland 
heeft ongeveer 3,3% van alle volwassen vrouwen borstimplantaten.23
Hoewel het gebruik van borstimplantaten over het algemeen als veilig wordt be-
schouwd, is borstimplantaatchirurgie geassocieerd met het risico op complicaties; 
zoals infecties, deflatie of ruptuur van het implantaat, seroomvorming en kapsel-
contracturen.24,25,26 Met name het schandaal rondom de gescheurde ‘Dow-Corning 
borstimplantaten’ in de jaren tachtig en de ophef rondom de omstreden Poly Implants 
Prothèses (PIP), heeft het publieke bewustzijn rondom de veiligheid van borstim-
plantaten verhoogd.27 Tevens is uit recent onderzoek gebleken dat vrouwen met 
borstimplantaten een verhoogd risico lopen op het ontwikkelen van een anaplastisch 
grootcellig lymfoom (ALCL).28,29 Ook wordt gesuggereerd dat er een verband bestaat 
tussen auto-immuniteit en de blootstelling aan siliconen, wat zou kunnen resulteren in 
het ASIA-syndroom (autoimmune/inflammatory syndrome induced by adjuvants) en 
verschillende auto-immuunziekten.30,31,32
Vanwege de onopgeloste veiligheidsvraagstukken zijn verschillende landen gestart 
met het opzetten van borstimplantaat-registraties. Momenteel hebben zes landen 
een actieve registratie: Australië (ABDR),33 Zweden (BRIMP),34 Oostenrijk (ABIR),35 
England (BCIR),36 Amerika (NBIR).37 In 2015 werd de DBIR opgericht ten behoeve van 
borstimplantaat-gerelateerde uitkomstmaten in Nederland.38 Een uniek concept van 
de DBIR is het ‘opt-out systeem’, wat betekent dat de patiënt geïncludeerd is mits 
er voorafgaand expliciet géén toestemming is verleend. De landelijke dekking van 
de DBIR kan worden gecontroleerd middels gegevens vanuit de Inspectie voor de 
Gezondheidszorg. In het eerste volledige registratiejaar (2016) bedroeg de participatie 
95% voor ziekenhuizen en 78% voor privéklinieken.
In hoofdstuk 7 geven we een overzicht van de eerste uitkomsten van de DBIR-registra-
tie. Van 2015 tot 2017 zijn 15.049 patiënten en 30.541 borstimplantaten geregistreerd. 





implantaat per 1691 vrouwen. Het merendeel van de implantaten (85.2%) zijn geïm-
planteerd vanwege cosmetische reden en 14,8% vanwege een borstreconstructie. 
Zowel de patiënt- als implantaatkenmerken verschillen significant per indicatiegroep. 
Patiënten die kiezen voor een borstvergroting zijn aanzienlijk jonger dan patiënten met 
een wens tot een borstreconstructie (31,5 versus 49,7 jaar). Voor beide indicaties was 
er in een jaar tijd (2016-2017) een duidelijke afname zichtbaar in het gebruik van ge-
textureerde implantaten. Verder is in de reconstructieve groep een duidelijk toename 
in het gebruik van ronde en met siliconen gevulde implantaten opmerkelijk. Deze trend 
lijkt samen te vallen met de recente ophef rondom ALCL.
Een andere opvallende bevinding is de variatie tussen ziekenhuizen in de getroffen 
maatregelen ter infectiebestrijding. In het algemeen wordt een toename gezien in 
het gebruik van profylactisch intraveneus antibiotica, het aantal handschoenwissels 
vóór het inbrengen van het implantaat en in het spoelen van het implantaat met een 
antiseptische oplossing. Het gebruik van drains daalde in de reconstructieve groep 
maar nam toe in de cosmetische groep. Gegevens op langer termijn zullen antwoord 
gaan geven op de vraag of deze antiseptische voorzorgsmaatregelen en andere intra-
operatieve technieken daadwerkelijke effect hebben op het risico op complicaties.
In het laatste hoofdstuk van dit proefschrift, hoofdstuk 8, beschrijven we een van de 
projecten uitgevoerd door ‘the International Collaboration of Breast Registry Activities 
(ICOBRA)’. ICOBRA is een internationale multidisciplinaire werkgroep met expertise 
op het gebied van borstimplantaat-registraties. Zowel plastisch chirurgen, chirurgen, 
patiëntenverenigingen, regelgevende instanties en statistici zijn in deze werkgroep 
betrokken. Het doel van het project was om een  gestandaardiseerde minimale dataset 
te definiëren ten behoeve van kwaliteitsmonitoring van borstimplantaatchirurgie 
wereldwijd. Als uitgangspunt werden de datasets van de huidige zes registraties ver-
geleken. Vervolgens werd een Delphi-procedure gestart waarbij elk panellid verplicht 
het belang van elk datapunt beoordeelde. Na vier delphi-rondes werd er consensus 
bereikt over een lijst van 32 datapunten. Datapunten waarover geen consensus werd 
bereikt (N=16), werden niet in de minimale dataset opgenomen en als ‘optionele data-
set’ bestempeld. Ook werd er consensus bereikt over de definities van alle datapunten, 
waarbij de definities van de Australische dataset als uitgangspunt zijn gehanteerd. De 
ICOBRA-dataset is vrijwel volledig geïntegreerd in de DBIR-dataset. Naar verwachting 
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zal binnen twee jaar de set in alle huidige (en nog op te starten) borstimplantaatregis-
traties worden gebruikt binnen het ICOBRA-netwerk (Australië, Oostenrijk, Canada, 
Frankrijk, Duitsland, Ierland, Italië, Nederland, Nieuw-Zeeland, Zuid-Afrika, het Ver-
enigd Koninkrijk en de Verenigde Staten). Het doel van deze gestandaardiseerde set is 
dat gegevens over borstimplantaten wereldwijd kunnen worden gekoppeld, waardoor 
er een actieve surveillance ontstaat. Problemen rondom implantaten komen zo snel-
ler aan het licht. Ook kunnen de gegevens gebruikt worden voor een internationale 
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